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ABSTRACT
The aim of the project was to investigate the role of LCPTP (Leucocyte 
phosphotyrosine phosphatase) in T cell signalling and activation.
The investigation was divided into three parts. In the first part, biochemical 
studies were used to identify possible LCPTP substrates/interacting proteins. 
Antibodies specific for LCPTP were used to characterise potential interactions of 
endogenous LCPTP protein in cells. Recombinant LCPTP proteins, including 
wildtype and a substrate-trap protein were also generated. These were used to show 
that LCPTP interacts with members of the MAP kinase family, specifically ERK1 and 
ERK2, suggesting that these proteins are major LCPTP substrates.
In the second part, the effect of overexpressing LCPTP on T cell function was 
investigated. The Jurkat T cell line was transfected to produce stable cell lines 
expressing wildtype and mutant forms of LCPTP. LCPTP transfected cells were 
stimulated via the TCR and CD28 and monitored for cytokine production, surface 
marker expression and cell proliferation. It was shown that LCPTP inhibited IL-2 
production and expression of the surface IL-2 receptor, CD25. LCPTP also protected 
cells from TCR induced cell death and promoted homotypic aggregation.
Following on from the observations made in the Jurkat T cell line, the final 
part of the project was aimed at looking at the effects of LCPTP in primary T cells. 
LCPTP adenovirus constructs were made and used to infect both naive T cells as well 
as antigen differentiated Thl and Th2 populations. Overexpressed LCPTP substrate- 
trap protein lead to increased levels of cellular phosphoERK. Increased levels of 
LCPTP resulted in changes in cytokine production in TCR stimulated cells relative to 
control cells. Cells overexpressing LCPTP had a higher basal level of proliferation.
The results obtained support a role for LCPTP in regulating the early stages of 
T cell activation by changing MAP kinase activity.
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CHAPTER ONE: INTRODUCTION
1.1 The immune system
The immune system has evolved to enable the human body to survive in an 
environment in which it is constantly being exposed to a range of pathogens eg 
bacteria, viruses, allergens, protozoa. The immune system includes a number of 
specialised cells such as phagocytic cells, natural killer cells, B and T cells and 
antigen presenting cells, which act in coordination to eliminate the invading foreign 
agents. The study of the science of immunology dates back to 1796 when Edward 
Jenner successfully vaccinated people against smallpox (Jenner, 1798).
There are two main immune mechanisms implicated in the elimination of 
foreign antigens: the innate response and acquired response. The innate response, or 
natural immunity, includes physical barriers provided by skin and mucous 
membranes, as the first line of defence and physiological factors such as PH 
environment and temperature to limit microbial growth. Cells involved in innate 
immunity include phagocytic cells, neutrophils and macrophages. These recognise 
pathogen associated motif patterns (PAMPS) expressed on the surface of invading 
organisms via receptors including the Toll family and CD 14 (Fearon and Locksley, 
1996); (Madzhitov et al., 1997); (Hirschfeld et al., 1999); (Hemmi et al., 2000); 
(Akira et al., 2001). Natural killer cells recognise abnormal cells that have lost the 
MHC class I molecule ; often a result of a microbial infection or a malignant 
transformation. Natural killer cells eliminate target cells by releasing perforin and 
granzymes, which mediate cell lysis and activate apoptotic pathways (Abbas et al., 
1994); (Delves and Roitt, 2000a). Soluble mediators, including cytokines, such as IL- 
12, released by cells involved in natural immunity, activate and direct the antigen- 
specific adaptive immune response (Vasselon and Detmers, 2002).
The acquired immunological response is antigen specific which distinguishes 
it from innate immunity. A first encounter with a foreign agent triggers the 
differentiation of effector cells as well as establishing immunological memory. 
Further encounters with the same foreign pathogen will stimulate the immune system 
to mount a quicker, more effective response leading to the elimination of the invading
16
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agent. Acquired immunity is subdivided into two types dependent on the components 
of the response: humoral immunity and cellular immunity. Humoral immunity is 
mediated by proteins, termed antibodies, which are antigen specific. Antibodies are 
produced by B lymphocytes. Cellular immunity is mediated by T lymphocytes 
(Abbas et al., 1994).
B lymphocytes mature in the bone marrow and recognise native antigen 
exposed on the surface of invading organisms via specific receptors on the B cell 
surface. Upon antigen recognition, B cells clonally expand and some cells will 
differentiate to become plasma cells, which secrete high affinity antibodies to 
neutralise the antigen. The function and activity of B lymphocytes is dependent on 
the help of specialised T lymphocytes: helper T cells (Abbas et al., 1994).
T lymphocytes can be subdivided into helper T cells, cytotoxic T cells and 
regulatory T cells. T cells are derived from the bone marrow but undergo maturation 
in the thymus. In the thymus, T cells are subjected to both positive and negative 
selection, which means that cells with the potential for self reactivity are eliminated or 
rendered anergic (Sebzda et al., 1999); (Viret and Janeway, 1999); (Anderson et al., 
1999); (Starr et al., 2003). T cells recognise peptide antigens bound non-covalently to 
proteins, which form part of the major histocompatibility complex (MHC). This 
MHC complex is subdivided into two classes: class 1 and II. Antigen peptides derived 
from extracellular proteins (bacterial or fungal products and allergens) bind to class II 
proteins in the endosomal compartment in cells. MHC class II proteins are mainly 
expressed on B lymphocytes, macrophages and on dendritic cells. Peptides bound to 
MHC class II proteins are presented to CD4+ T lymphocytes (Delves and Roitt, 
2000b). CD4+ effector T cells, or helper T cells, can be divided into Thl and Th2 
subsets. Thl cells secrete IL-2 and interferon-y and promote inflammatory responses, 
for example, by activating macrophages. Th2 cells secrete IL-4, IL-5 and IL-13 and 
promote humoral immunity by stimulating B cell growth and differentiation leading 
to antibody production.
A third population of CD4+ T cells characterised as CD25+hl8h have been 
recently identified and they function as regulatory T cells. This specialised
17
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population of T cells controls the activation of helper T cells by suppressing the 
proliferation and cytokine induction of T cells receiving weak TCR signals although 
permitting the immune response of T cells in contact with a strong TCR signal 
together with a co-stimulatory signal (see section 1.3 for more details) (Thornton and 
Shevach, 1998); (Jonuleit et al., 2001); (Dieckmann et al., 2001); (Baecher-Allan et 
al., 2001).
Endogenously synthesised peptides (for example, viral products, intracellular 
parasites, tumour antigens) bind to class I molecules in the cytosol. MHC class I 
molecules are expressed on the surface of the majority of nucleated cells and the 
peptide they present is recognised by CD8+ cytotoxic T cells, which can destroy 
infected cells (Delves and Roitt, 2000b).
CD8+ cells, or cytotoxic T cells (CTL), destroy target cells by one of a number 
of different mechanisms. These include the release of perforin and cytolysin causing 
cell lysis and ligation of Fas, which activates signalling pathways, inducing cell 
apoptosis (Harty et al., 2000); (Wong and Pamer, 2003). CD8+ T cells also release 
cytokines, specifically, interferon-y and tumour necrosis factor (TNF), which induce 
macrophage activation (Harty et al., 2000); (Wong et al., 2003). CD8+ T cell lysis is 
antigen specific and requires cell contact (Harty et al., 2000); (Delves and Roitt, 
2000b); (Wong et al., 2003).
Antigen presenting cells (APCs) include macrophages, dendritic cells (DCs) 
and B cells. These cells take up foreign agents and enzymatically process them into 
small peptides. These peptides are then presented on the surface of the APC in 
association with MHC II proteins (Abbas et al., 1994). Dendritic cells are regarded 
as the professional antigen presenting cells and are located in strategical sites such as 
in the skin and in the mucosal epithelia. Immature dendritic cells are highly adept at 
antigen capture and processing. Once they have captured antigen, immature DCs 
migrate to T cell rich areas in lymphoid tissue where they undergo maturation, 
upregulating a number of costimulatory and adhesion molecules. This enables the 
DCs to effectively activate both naive and memory T cells (Austyn et al., 1988);
18
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(Hauss et al., 1995); (McLellan et al., 1996); (Banchereau and Steinman, 1998); 
(Woodhead et al., 2000).
1.2 T cell receptor signalling complex
The CD4 glycoprotein expressed on a subset of T cells, facilitates the 
interaction between the T cell and the APC and it is often referred to as a coreceptor. 
CD4 binds to the invariable domain of the MHC class II molecule helping to stabilise 
the interaction between the T cell and APC (Abbas et al., 1994); (Guermonprez et al., 
2002). CD4 via its associated) LCK kinase also plays a key role in initiating signal 
transduction in the T cell (Qian et al., 1993). Other molecules on the surface of the T 
cell, including CD2 and LFA-1, act as adhesion molecules and provide further 
interactions via ligands on the APC, which help to maintain a close contact between T 
cell and APC. The major T lymphocyte surface molecules and their respective 
ligands on the APC are shown in Figure 1 (Abbas et al., 1994).
The T cell receptor (TCR) is composed of the a  and p chains. This 
heterodimer recognises and binds to foreign peptide and the self MHC class II 
molecule. Associated non covalently with the TCR is the CD3 complex composed of 
the y, 6 and the e chains and the zeta homodimer (Abbas et al., 1994). Each member 
of the CD3 complex possesses an extracellular domain, with glycosylation sites on the 
y and 6 chains, and an intracellular domain, which contains an immunoreceptor 
tyrosine-based activation motif (ITAM) (tyr-X-X-leu sequence found twice in a 
stretch of 17 amino acid residues) (Cambier, 1995). Each £ chain has a very short 
extracellular domain and a long cytoplasmic tail, which contains three ITAMs. The 
ITAMS are important for initiating signal transduction in the T cell (Weissman,
1994).
Ligation of the TCR alone is insufficient to lead to full T cell activation. A 
second signal is provided by the binding of a costimulatory molecule to its ligand on 
the APC (Weiss, 1991). One of the most important costimulatory molecules for naive 
T cell activation is CD28. Cognate ligands of CD28 include B7.1 (CD28) and B7.2 
(CD86) (Aruffo and Seed, 1987); (June et al., 1990). The signal through CD28 is 
essential for optimal production of IL-2, expression of IL-2 receptor on the surface of
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the cell and progression of the cell cycle (Jenkins et al., 1991); (Harding et al., 1992). 
The signalling pathway via CD28 enhances the TCR signal. Helper T cells are more 
dependent on the second signal for activation than cytotoxic T cells (Lenschow et al., 
1996); (Whitmire and Ahmed, 2000). Another costimulatory molecule named ICOS 
(inducible costimulatory molecule) is upregulated 24—48 hrs following T cell 
activation and therefore, is not present on naive T cells (Hutloff et al., 1999). ICOS 
binds to ICOSL and its stimulation enhances the production of effector cytokines: 
IFN-y, TNF-a, IL-4, IL-5 and IL-10. Hence ICOS plays a key role in memory and 
effector cell function (Hutloff et al., 1999); (Coyle and Gutierrez-Ramos, 2001); 
(Frauwirth and Thompson, 2002).
T cell proliferation is regulated by signals from molecules, which provide a 
negative signal into cells. CTLA-4 (cytotoxic T lymphocyte antigen 4) binds to the 
same ligands as CD28 but with a higher affinity (Brunet et al., 1987). Like ICOS, 
CTLA-4 is induced during activation but upon ligation it inhibits T cell proliferation 
and IL-2 synthesis (Thompson and Allison, 1997). It is likely that a balance between 
the activation and inhibition signals given by the costimulatory molecules sets the 
threshold for lymphocyte activation (Frauwirth and Thompson, 2002).
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Figure 1.1: T lymphocyte surface molecules and their ligands involved in 
antigen recognition and T cell activation
Figure from Abbas et al., 1994. A. Interactions between a CD4+ T cell and an 
antigen-presenting (APC). B. Interactions between a CD8+ cytolytic T lymphocyte 
(CTL) and an antigen-presenting (APC) (Abbas et al., 1994).
1.3 The T cell receptor signalling pathway
1.3.1 Initiation of T cell signalling
Following contact with an APC, T cells can respond functionally in three 
ways: 1) by undergoing apoptosis 2) by proliferating or 3) by becoming anergic. The 
outcome will depend on the context in which the T cell is stimulated. If a T cell 
encounters a strong signal, in the absence of costimulation, apoptosis will occur. 
Alternatively, TCR ligation in the absence of costimulation can drive cells into a state 
of anergy. Anergy is a state in which cells become functionally unresponsive to 
further stimulation with the same antigen and may be one mechanism by which cells 
become self tolerant (Abbas et al., 1994); (Lechler et al., 2001); (Walker and Abbas, 
2002); (Nel, 2002); (Nel and Slaughter, 2002); (Schwartz, 2003). TCR ligation and
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appropriate costimulation results in transcription of the IL-2 gene. IL-2 acts as an 
autocrine growth factor driving G1 to S cell cycle progression and T cell proliferation.
Following T cell activation, one of the earliest events detectable includes an 
increase of protein tyrosine phosphorylation. This is mediated by increased activity 
of kinases. The phosphorylation of a tyrosine residue on a protein can have two 
major consequences. Firstly, phosphorylated proteins containing specific tyrosine 
phosphate binding sites provide binding sites for other proteins via their SH2 
domains. For example, TCR zeta phosphorylation results in the recruitment and 
binding of zeta associated protein (ZAP-70) via its two tandem SH2 domains and this, 
in turn, provides further binding sites allowing recruitment of other signalling 
molecules to the complex (Koch et al., 1991). Secondly, numerous enzymes can be 
activated via tyrosine phosphorylation and perpetuate the signal; eg ZAP-70, once 
bound to zeta, becomes tyrosine phosphorylated at residues 492-493 by Lck and as a 
result of this, its kinase activity increases (Mege et al., 1996).
1.3.4 The molecules and structures involved in TCR signalling pathways
1.3.4.1 Kinases
Binding of an antigen to the T cell receptor leads to activation of kinases, 
which induces a rapid increase in protein tyrosine phosphorylation. This initiates 
signalling pathways which control the activation, proliferation and differentiation of 
the T cell. Four classes of nonreceptor protein tyrosine kinases have been identified: 
Src (Lck, Fyn), Syk/Zap-70, Tec (Itk, Rlk) and the Csk family. Apart from 
possessing a catalytic domain, the kinase protein structures include additional 
conserved domains which enables them to associate with specific targets and to 
localise to distinct parts of the cell (Chow and Veillette, 1995); (Chu et al., 1998); 
(Latour and Veillette, 2001); (Lewis et al., 2001).
1.3.4.2 Phosphatases
The activity of kinases in cells is regulated by the activity of phosphatases. 
The phosphotyrosine phosphatases implicated in the immunological signalling are 
categorised in two groups: transmembrane phosphatases and cytoplasmic
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phosphatases. Details on the main phosphatases, which play a role in T cell signalling 
are given in section 1.4.
1.3.4.3 Adaptors
Adaptors can be phosphorylated on key residues, which act as docking sites 
for other proteins and they act to provide a scaffold enabling the assembly of large 
signalling complexes. They do not have any enzymatic or transcriptional activity but 
their role in protein-protein or lipid-protein interaction is important for directing 
signalling pathways (Leo et al., 2002). Two groups of adaptors are found in cells: 
transmembrane adaptor proteins (LAT, TRIM, SIT and PAG/Cbg) and cytosolic 
adaptor proteins (Grb2, Gads and SLP-76) (Cantrell, 2002); (Leo et al., 2002).
1.3.4.4 Lipid raft microdomains
The lipid raft microdomains are regions in the plasma membrane with a 
unique protein and lipid composition. The concentration of signalling proteins in 
membrane rafts is higher than elsewhere on the cell membrane and it is proposed that 
they play an important role in amplifying signalling pathways (Ahmed et al., 1997); 
(Zajchowski and Robbins, 2002). Upon TCR activation, TCR complexes become 
concentrated into lipid rafts leading to activation of signalling cascades (Montixi et 
al., 1998); (Janes et al., 2000); (Viola, 2001).
1.3.5 Immunological synapse
The immunological synapse is a physical structure formed when a T cell 
receptor interacts with an MHC class II-peptide complex initiating an immunological 
response (Creusot et al., 2001); (Bromley et al., 2001). This physiological interaction 
can be divided mainly into four stages: T cell polarisation, T cell:APC adhesion, T 
cell signalling complex formation (see section 1.3.6 for more details), leading finally 
to sustained signalling required for activating transcription factors required for cell 
proliferation and differentiation (Grakoui et al., 1999). Following chemokine 
exposure, T cell polarisation occurs by migration of the TCR to the site of contact 
with the MHC class II-peptide complex (Kupfer and Singer, 1988). This migration is 
orchestrated by the rearrangement of cytosketetal proteins, including actin and tubulin 
(Lanzavecchia, 1997); (Viola and Lanzavecchia, 1999); (Dustin and Cooper, 2000);
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(Peterson et al., 2001). The adhesion site can be subdivided into two areas named the 
supramolecular acivation clusters (SMACs). The central core SMAC is enriched in 
TCR and CD28 molecules and the peripheral SMAC contains mainly large adhesion 
molecules like LFA-1 and ICAM-1 and smaller receptors like CD2 and CD58 which 
maintain a close contact between T cell and APC (Monks et al., 1998); (Bromley et 
al., 2001); (Dustin, 2002). The formation of an immunological synapse occurs within 
minutes following the first contact between T cell and antigen-presenting cell and its 
duration may last for hours, leading to secretion of diverse cytokines and 
differentiation of the T cell into specialised effector subsets (see section 1.3.7) (Iezzi 
et al., 1998).
1.3.6 Activation of T cell signalling pathways
The reorganisation of the surface molecules during the immunological synapse 
induces changes in the cellular status quo. The CD45 molecule, a transmembrane 
phosphotyrosine phosphatase of 180-220 kDa, situated near the TCR, 
dephosphorylates the autoinhibitory site of two major T cell Src kinases: Lck and 
Fyn (Shiroo et al., 1992); (McFarland et al., 1993). Lck is non-covalently associated 
with the cytoplasmic tail of the CD4 molecule (Glaichenhaus et al., 1991) and Fyn is 
non covalently associated with the CD3 e chain (Osman et al., 1995). Both kinases 
are maintained in an inactive state by Csk kinase which phosphorylates a tyrosine 
residue at the C-terminal end of the protein inhibiting kinase activity (Bergman et al., 
1992); (MacAuley et al., 1993). Dephosphorylation by CD45 of this inhibitory site 
enables autophosphorylation of the Src kinases, increasing their kinase activity 
(Biffen et al., 1994); (Stone et al., 1997); (Thomas and Brown, 1999).
Once dephosphorylated by CD45, Lck and Fyn can then phosphorylate the 
tyrosine residues within the ITAMs of the £ and the CD3 molecules (Alberola-Ila et 
al., 1997); (Qian and Weiss, 1997) (see Figure 2). This leads to the recruitment of 
ZAP-70 and Syk kinases (Chu et al., 1998). A fraction of the phosphorylated zeta 
chain is located in the lipid rafts and this puts ZAP-70 in close proximity to one of its 
substrates, LAT (linker of T cell activation) (Kosugi et al., 1999). ZAP-70 
phosphorylates LAT and this allows the binding of other adaptor proteins including 
Grb2, Cbl and SLP-76 and the proteins Sos and Vav which are a guanine nucleotide
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exchange factor. Each of these becomes phosphorylated enabling the activation of the 
Ras-Raf pathway and subsequently the phosphorylation and increased activity of the 
mitogen-activated protein (MAP) kinases, ERK1-ERK2, permitting the induction of 
AP-1 and NFAT transcription factors (Weiss and Littman, 1994); (Cantrell, 1996); 
(Zhang et al., 1998); (Finco et al., 1998); (Zhang et al., 1999). Another action 
mediated by LAT phosphorylation is the recruitment of PLCy-1 to the plasma 
membrane and hence access to its substrates. Phosphorylation and activation of 
PLCy-1 allows the formation of the secondary messengers, inositol triphosphosphate 
(IP3) and diacylglycerol (DAG). These, in turn, drive the elevation of intracellular 
calcium and the regulation of serine kinases including PKC ending in the activation of 
NF-kB and NFAT transcription factors (Sieh et al., 1994); (Winkler et al., 1993); (van 
Leeuwe and Samelson, 1999); (Kane et al., 2000). Other ZAP-70 substrates include 
SLP-76 and Vav which form a complex and initiate activation of the Rac/Cdc42 
pathw ay leading to the activation of the c-jun kinases (JNK) and the 
induction/activation of the AP-1 transcription factor (Coso et al., 1995); (Crespo et 
al., 1996); (Teramoto et al., 1996). Depending on the signals received by the T cell, 
different combinations of transcription factors are induced. This promotes differential 
gene transcription which determines cell fate (Rao et al., 1997); (Foletta et al., 1998); 
(Powell et al., 1998); (Medena and Borst, 1999).
T Cell Receptor Signalling
Joseph Lin and Arthur Weiss
Cell Science
ER
Adapter protein* . 0^
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Figure 1.2: T cell signalling pathways
Figure from Lin and Weiss, 2001. See text for more details (Lin and Weiss, 2001).
1.3.7 T cell fate: Thl and Th2 subsets
In the late eighties, Mosmann and Coffman characterised two different 
functional subsets of Th cell, which regulated distinct immune responses. Following 
activation, naive helper T cells clonally expand and produce IL-2. They can further 
differentiate into Thl or Th2 cells, each subset expressing a distinct pattern of genes 
and they can be distinguished by cytokines they express (Mosmann et al., 1986); 
(Mosmann and Coffman, 1989); (O'Garra and Arai, 2000). Differentiation into Thl 
or Th2 cells is dependent on a number of factors, including the nature and the 
concentration of antigen, the affinity of the interaction between the TCR and the APC, 
the type of APC as well as strength and nature of co-stimulation signals received. For 
example, ligation of LFA-1 on the T cell by its reciprocal ligand, ICAM-1 on an APC 
has been shown to inhibit Th2 development (Constant et al., 1995); (Constant and 
Bottomly, 1997); (Salomon and Bluestone, 1998); (Luksch et al., 1999). Badou et al. 
(2001) suggested that a weak TCR signal triggers Th2 differentiation while stronger 
TCR stimulation induces MAP kinases controlling Thl differentiation (Badou et al., 
2001). Thl and Th2 cytokines each inhibit the production of the reciprocal subset’s 
cytokines (Mosmann et al., 1986); (O'Garra, 1998); (O'Garra and Arai, 2000).
1.3.7.1 Thl
Thl cells are implicated in the elimination of intracellular pathogens (bacteria, 
parasites, yeasts, viruses). Thl cells produce IL-2 and interferon-y. These cytokines 
are important for macrophage activation and the growth and maintenance of natural 
killer cells and CD8+ cells. Thl cells also regulate the production of complement- 
fixing antibodies of the lgG2a isotype, characteristic of cellular immunity (Mosmann 
et al., 1986); (O'Garra, 1998); (O'Garra and Arai, 2000). IL-12 enhances Thl 
commitment by inducing the activation of the transcription factor STAT4 (Trinchieri,
1995); (Murphy et al., 1999); (Murphy and Reiner, 2002). Another transcription 
factor selectively induced in Thl cells is T-bet (Szabo et al., 2000). The introduction 
of T-bet into differentiated Th2 cells has been shown to revert the phenotype to that of
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a T hl cell (Szabo et al., 2000). The MAP kinase p38 pathway is selectively engaged 
in T h l cells (Rincon et al., 1998).
1.3.7.2 Th2
Th2 cells are known to have a role in the humoral immune response by 
producing 1L-4, IL-5, IL-9, IL-10 and IL-13 cytokines which regulate B cell 
proliferation as well as antibody class-switching, activation of mast cells and 
eosinophils. Th2 cells are involved in the elimination of helminths and other 
extracellular parasites (Mosmann et al., 1986); (Sher and Coffman, 1992); (Urban et 
al., 1992). The presence of IL-4 during the differentiation process will favour the Th2 
differentiation by activating the STAT6 transcription factor (Paul and Seder, 1994); 
(Swain et al., 1990). Other transcription factors reported to direct the Th2 subset 
include Gata-3 and c-Maf. Similar to T-bet in Th2 cells, the introduction of Gata-3 
into T hl cells mediates a reversal of the phenotype to that of a Th2 cell (Ouyang et 
al., 2000); (Lee et al., 2000); (Ho et al., 19%); (Zheng and Flavell, 1997); (Feber,
1999); (Murphy and Reiner, 2002).
Figure 1.3: T cell fate: Thl and Th2 differentiation.
Figure from (Murphy and Reiner, 2002). See text for more details.
1.4 Protein phosphatases
Cell signalling pathways, which mediate a variety of cellular functions such as 
cell proliferation, differentiation and metabolism are regulated by the addition or the
GATA3
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removal of a phosphate group, which is achieved by the coordinated actions of 
kinases and phosphatases. The role of protein kinases in cells have been well 
documented. The important role of the phosphatases in signalling pathways has been 
appreciated relatively recently with the first phosphatase being cloned in 1990. 
Phosphatases play both positive and negative roles in T cell signalling, switching on 
as well as terminating kinase activity (Mustelin et al., 2002).
1.4.1 Different families of phosphatases
There are two kinds of phosphatases in cells; they are categorised by their 
substrate specificity. Firstly, the phosphoserine/threonine phosphatase group, which 
can be subdivided into phosphoprotein phosphatases (PPP) and phosphoprotein 
magnesium dependent phosphatases (PPM) and secondly, the phosphotyrosine 
phosphatase (PTP) group. The first group of phosphatases act by removing a 
phosphate group from serine and/or threonine residues only. They are implicated in 
several processes, including stress activated signalling pathways, mitosis and cell 
cycle progression. The phosphotyrosine phosphatase family of phosphatases remove 
phosphate groups from tyrosine residues. The PTPs can be further subdivided into 
three classes: the specific PTP, the dual specificity phosphatases and the low 
molecular weight PTP.
1.4.2 Phosphotyrosine phosphatases
The specific PTP or standard PTP, are restricted by their ability to remove a 
phosphate group from tyrosine residues only. The dual specificity phosphatases 
hydrolyse preferentially phosphotyrosine residues but can also remove phosphate 
groups from serine/threonine residues at a rate 40 to 500 fold slower than for tyrosine 
residues (Zhang, 1995). The low molecular weight PTP proteins are distinguished 
from the first two classes of PTPs by possession of a short specific motif CX3R 
instead of the [I/V]HCXAGXXR[S/T]G phosphotyrosine activation site (where X 
represents a random amino acid in the single-letter amino acid code) (Streuli et al., 
1990); (Guan and Dixon, 1991); (Barford et al., 1994).
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1.4.2.1 Standard phosphotyrosine phosphatase
Standard PTP can be further subdivided into two families based on their 
location in the cell: the transmembrane PTP and the cytoplasmic PTP. The 
transmembrane PTP are also called receptor-like PTP. Transmembrane phosphatases 
contain an extracellular domain of variable length and composition, a single 
transmembrane sequence and usually two duplicated cytoplasmic PTP domains (Guan 
and Dixon, 1991). The reason why these PTP have two distinct PTP domains is still 
unclear (Streuli et al., 1990). There is a consensus sequence (HCSAGVGR) in the 1st 
catalytic domain of transmembrane PTP, which has enzymatic activity. Pulido et al 
(1995) have proposed a protein-protein interaction function, for the second domain 
(Pulido et al., 1995). The extracellular domains have the potential to serve as a 
receptor for a specific ligand.
The cytoplasmic family proteins contain a single catalytic domain (Guan and 
Dixon, 1991). They have a consensus sequence common to all cytoplasmic PTP: 
HCSAGIGR (Streuli et al., 1990). In some PTP, other domains for protein-protein 
interactions, such as SH2 domains, can be present. All PTPs possess a unique 
characterised motif for the active site in the catalytic domain containing essential 
cysteine and arginine residues: [I/V]HCXAGXXR[S/T] (Streuli et al., 1990); ( Guan 
and Dixon, 1991); (Barford et al., 1994). The PTP family has the characteristic of 
requiring another amino acid to close the active site cleft during the catalysis. This is 
an aspartic acid residue, which is located approximately 30 to 40 amino acids 
upstream from the signature motif (Zhang et al., 1994); (Hengge et al., 1995); 
(Fauman and Saper, 1996). The PTP do not require any ion or cofactor for their 
function but they are inhibited by vanadate and by hydrogen peroxide (H20 2) (Heffetz 
et al., 1990); (Secrist et al., 1993). Vanadate will bind to the enzymatic centre acting, 
as a phosphate analogue and inhibits the release of substrate from the phosphatase 
(Gresser and Tracey, 1990). H20 2 oxidises the thiolate anion of a cysteine residue in 
the PTP-reactive center, blocking the formation of a phosphorylcysteine intermediate, 
which is a critical step in dephosphorylation (Jin et al., 1998).
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1.4.2.2 Dephosphorylation mechanism
The conserved cysteine residue, which sits at the bottom of a deep catalytic 
pocket in the phosphatase is essential for the hydrolysis of the phosphate group on the 
tyrosine. This cysteine is positioned in such manner that it can make a nucleophilic 
attack on the phosphorus atom, creating a covalent thiol phosphate bond between the 
phosphotyrosine of the substrate and the cysteine (Guan and Dixon, 1991); (Barford et 
al., 1994); (Stuckey et al., 1994). The cysteine attack is followed by a transfer of 
charges, mediated by the upstream invariant aspartic acid. The arginine acts to 
I position the phosphate residue in the pocket (Zhang, 1998). Thus, the substrate 
| binding to the PTP allows a conformational change of a surface loop, creating a 
phosphotyrosine recognition pocket and inducing a catalytically competent form of the 
enzyme (Jia et al., 1995). The depth of the pocket controls the phosphatase specificity 
(Pannifer et al., 1998)
1.5 T cell signalling: the role of phosphatases
1.5.1 Transmembrane phosphotyrosine phosphatases
1.5.1.1 CD45
The role of CD45 in early T cell signalling has been outlined in section 1.3.5. 
CD45 is expressed on the surface of all nucleated hematopoietic cells and represents 
up to 5-10% of the cell surface membrane proteins (Thomas, 1989). The extracellular 
domain of CD45 is very long and can vary by alternative splicing of exons 4, 5 and 6 
(Thomas, 1989). The cytoplasmic domain of CD45 contains two PTP domains. The 
domain closest to the membrane accounts for most of the PTP enzymatic activity but 
it is possible that the two domains have independent activities, which could be 
differentially regulated (Neel, 1997). Cells lacking the CD45 molecule fail to respond 
to stimulation by antigen or mitogenic antibodies (Pingel and Thomas, 1989).
The best described role for CD45 is its activation of Src-family kinases (Lck 
and Fyn) (Shiroo et al., 1992); (McFarland et al., 1993). The kinases will then 
activate different components of the signalling pathway, leading to the 
phosphorylation of TCR CD3-8, Slp-76, Vav, PLCyl, Cbl and HS1, all of which 
are positive regulators of T cell signalling (Biffen et al., 1994); (Stone et al., 1997); 
(Thomas and Brown, 1999).
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Other substrates reported for CD45 include TCR £ (Furukawa et al., 1994). It 
would be predicted that dephosphorylation of TCR £ ITAMs would have a negative 
influence on signalling which is an opposite effect of the previous actions described 
above for CD45 in T cell signalling. It has been shown that when the MHC 
molecules present peptide to T cells, the CD45 protein is excluded from the T 
cell/APC contact zone within which TCRs polarise and thus CD45 is unable to 
complete the dephosphorylation of the TCR £ ITAMs (Thomas, 1994); (Thomas and 
Brown, 1999); (He et al., 2002). Under these conditions, Lck and Fyn gain exclusive 
access and are able to fully phosphorylate ITAMs on CD3 and zeta. Termination of 
TCR signalling could be achieved by CD45 regaining proximal contact with zeta 
thereby returning it to an unphosphorylated form (Furukawa et al., 1994); (Alberola- 
Ila et al., 1997); (Qian and Weiss, 1997); (Mustelin et al., 1999). A recent report 
states that the Jak kinases could also be a physiological substrate for CD45, 
abrogating the Jak-Stat pathway necessary for cytokine production (Irie-Sasaki et al.,
2001).
CD45 is located at the same chromosomal location as LCPTP (see section 
1.6), another PTP, suggesting that there could have been a duplication of an ancestral 
gene encoding the PTP domain to generate two distinct phosphatases (Adachi et al., 
1994a).
1.5.1.2 CD 148
The PTPase CD 148 is also called HPTPr]/DEP-l (density-enhanced protein 
tyrosine phosphatase-1). It is found in all hematopoietic lineages but is expressed 
more abundantly on monocytes, B cells, NK cells and memory T lymphocytes with 
lower levels on CD4+ T cells (Tangye et al., 1998). The protein has a molecular 
weight of 180-250 kDa and has one catalytic phosphatase domain in the intracellular 
region (Schraven et al., 1997). Crosslinking of CD148 induces tyrosine 
phosphorylation of PLC-yl, which has also been reported for CD45. However, unlike 
CD45, crosslinking of CD 148 has been shown to induce an increase of [Ca2+]j (de la 
Fuente-Garcia et al., 1998). Overexpression of CD148 in Jurkat T cells, resulted in 
inhibition of ZAP-70 tyrosine phosphorylation (Tangye et al., 1998). CD 148 would
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thus appear to be a PTPase involved in down-regulation of T-cell activation. A recent 
study using an inducible system expressing CD 148 protein, reports that CD 148 
inhibits many events following TCR activation, such as CD69 upregulation, ERK 
phosphorylation and calcium mobilisation by the specific inhibition of LAT and PLC- 
yl phosphorylation (Baker et al., 2001).
1.5.2 Cytoplasmic phosphotyrosine phosphatases
1.5.2.1 PEP
PEP phosphatase is expressed only in hematopoietic cells where it is reported 
to associate with Csk (Matthews et al., 1992); (Cloutier and Veillette, 1996). This 
phosphatase is a member of the PEST PTPases which contain an N-terminal PTPase 
domain and a C-terminal with several proline, glutamic acid, serine and threonine-rich 
motifs (Mustelin et al., 2002). The interaction of PEP with Csk is interesting because 
Csk leads to a negative regulation of the Lck kinase, which is phosphorylated by Csk 
on the inhibitory activation site (Bergman et al., 1992) suppressing TCR signalling 
(Chow et al., 1993). Gjorloff-Wingren (1999) and Cloutier (1996) suggested that PEP 
could have a role in the dephosphorylation of the Src or Syk kinases family members 
(Gjorloff-Wingren et al., 1999); (Cloutier and Veillette, 1999). This phosphatase is 
mainly localised in the cellular membrane, in the cytosol and a tiny amount is found 
in the nucleus. Deletions in PEP and confocal microscopy data suggest that the C- 
terminal domain is necessary for cellular membrane associations and the N-terminal 
domain is necessary for the presence of PEP in the nucleus (Davidson et al., 1997); 
(Gjorloff-Wingren et al., 1999).
1.5.2.2 LYP
LYP PTP is expressed predominantly in lymphoid cells (both immature and 
mature B and T cells) and has a molecular weight of 85-105kDa (Cohen et al., 1999). 
The name LYP is derived from lymphoid phosphatase. The gene is located on the 
human chromosome lp l3 , a common site for chromosomal rearrangement in 
hematopoietic cancers (Lion et al., 1992). LYP protein shares 70% homology with 
PEP. When resting peripheral T cells were stimulated with anti-CD3 or PHA, Cohen 
et al (1999) observed a significant increase in the expression of LYP protein (Cohen 
et al., 1999). The messenger RNA of LYP undergoes an alternative splicing at the C-
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terminal end and produces two forms of LYP: LYP1 and LYP2. LYP2 is mainly 
detected in fetal liver tissue and has only one SH3 domain (this domain possibly 
interacts with proline rich proteins) compared to four SH3 domains in LYP1 
expressed in both the early and the late stage of T cell development. The creation of 
C-terminal changes by alternative RNA splicing appears to be a widely used 
mechanism for generating functional diversity in phosphatases (Reddy and Swarup, 
1995); (Cohen et al., 1999). Overexpression of LYP showed a constitutive interaction 
with c-Cbl, an adaptor protein (Cohen et al., 1999). c-Cbl is heavily tyrosine 
phosphorylated after T cell stimulation (Ota and Samelson, 1997) and has been shown 
to associate with the kinases, Syk and ZAP-70, negatively regulating their functions 
(Lupher et al., 1999). When phosphatases are inhibited by vanadate, c-Cbl becomes 
hyperphosphorylated (Ota and Samelson, 1997). Cohen et al. (1999) suggested that 
LYP could maintain c-Cbl in a basally dephosphorylated state and could function to 
negatively regulate c-Cbl and associated proteins in the TCR signalling pathway 
(Cohen et al., 1999). Another negative function has recently been discovered for 
LYP. Hill and collaborators (2002) showed in 293T cells that LYP coprecipitated 
with the adaptor molecule, Grb2 under conditions when both proteins were 
overexpressed (Hill et al., 2002). Overexpression of wild-type LYP or a substrate- 
trap (D195A) mutant inhibits anti-CD3/anti-CD28 transcriptional activity in Jurkat T 
cells confirming the negative regulatory role of LYP in T cell signalling (Hill et al.,
2002).
1.5.2.3 SHP-1
The name SHP-1 is derived from SH2 domain containing protein tyrosine 
phosphatase. SHP-1 is mainly expressed in cells of hematopoietic origin (Mustelin et 
al., 1999). The enzyme binds through its two SH2 domains to receptors that have an 
intracellular immunoreceptor tyrosine-based inhibitory motif (ITIM). Studies in 
motheaten mice which have a loss-of-function mutation in the SHP-1 protein, have 
shown SHP-1 to be a negative regulator of signalling through the TCR. These mice 
have enhanced and prolonged tyrosine phosphorylation of TCR zeta and CD3 and 
also prolonged MAP kinase activation following TCR stimulation (Pani et al., 1996). 
However, the IL-2 response to TCR stimulation is unchanged in motheaten mice 
(Lorenz et al., 1996). In HTLM-1 transformed T cells, SHP-1 dephosphorylates the
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75kDa subunit of the interleukin-2 receptor and the associated tyrosine kinases JAK1 
and JAK3. By this action, SHP-1 downregulates the IL-2 induced signalling response 
in T cells (Migone et al., 1998). Lorenz et al (1996) found that SHP-1 can inactivate 
Lck and Fyn kinases and Plas et al (1996) suggested that ZAP-70 is a direct target for 
the phosphatase (Lorenz et al., 1996); (Plas et al., 1996); (Brockdorff et al., 1999). 
Furthermore, SHP-1 dephosphorylates c-Src from JurkatT cells indicating that SHP-1 
is implicated in the activation of this kinase (Somani et al., 1997). Gjorloff-Wingren 
et al. (2000) have shown that SHP-1 is evenly distributed in the cytosol of Jurkat T 
cells. Activation of Jurkat T cells by anti-CD3 antibody did not change SHP-1 
location (Gjorloff-Wingren et al., 2000).
1.5.2.4 SHP-2
The SHP-2 phosphatase is closely related to SHP-1 protein and is expressed 
ubiquitously in all cell types (Mustelin et al., 1999). In contrast to its homologue 
SHP-1, SHP-2 appears to have a positive role in the regulation of TCR signalling 
following receptor ligation (Mustelin et al., 1999). Phosphorylation of SHP-2 in its 
C-terminal end enhances the recruitment of Grb2 to the membrane and the 
translocation of Sos and activation of Ras (Bennett et al., 1994); (Li et al., 1994). 
Tailor et al. (1996) have shown that after stimulation, SHP-2 becomes tyrosine 
phosphorylated and then associates with Grb2, c-Cbl and PI3K (Tailor et al., 1996). 
In addition, a 110 kDa protein homologue of Dos (Daughter-of-Sevenless), 
coprecipitates with SHP-2 and the dephosphorylation of this protein is involved in the 
regulation of the MAP kinase signalling pathway (Adachi et al., 1997). SHP-2 
activity has been reported to increase MAP kinase activation in T cells following 
observations that overexpression of a SHP-2 substrate-trap results in inhibition of 
TCR-stimulated ERK-2 phosphorylation (Frearson and Alexander, 1998). A negative 
role for SHP-2 has also been suggested by virtue of its association with the inhibitory 
CTLA-4 receptor in mice (Marengere et al., 1996). Like SHP-1, experiments using 
confocal microscopy have shown that SHP-2 is equally distributed throughout the 
cytosol in transfected Jurkat T cells and stimulation with anti-CD3 did not change its 
location (Gjorloff-Wingren et al., 2000).
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1.6 The role of phosphotyrosine phosphatase LCPTP in T cell signalling
The nomenclature regarding this hematopoietic restricted phosphatase differs 
in the literature. After an explanation o f the differences between the two proteins, the 
term LCPTP will be used throughout the manuscript.
HePTP (accession number M64322) also known as LCPTP (accession number 
D11327) was first identified in 1992. The name HePTP comes from hematopoietic 
phosphotyrosine phosphatase and the name LCPTP is derived from leucocyte 
phosphotyrosine phosphatase (Zanke et al., 1992); (Adachi et al., 1992b). Zanke’s 
group used a tyrosine phosphatase consensus sequence-specific degenerate 
oligonucleotide in a PCR using cDNA from pokeweed mitogen (PWM)-stimulated 
human peripheral T lymphocytes to find HePTP (Zanke et al., 1992). They 
characterised the protein and found that HePTP includes I only one phosphatase 
domain. Murine HePTP mRNAtaanscriptionwas shown to be increased up to 10-15 
fold, following anti-CD3, PHA, LPS or Con A stimulation. Increased HePTP mRNA 
was noticeable at 24 hrs with a maxima^ increase at 72 hrs post-stimulation while 
the protein level increased only moderately. In vivo expression was seen in BALB/c 
murine T and B lymphocytes but not in murine non-hematopoietic tissues (brain, 
liver, kidney and ovary) (Zanke et al., 1992). Seven months later, Adachi et al., 
published the chromosomal mapping of LCPTP from the PCR product B-PTP-4, 
which was obtained from total RNA of pre-B cells NALM-6 (Adachi et al., 1992a) 
from a PEER cDNA library. Their observations corroborate Zanke’s findings with 
the addition to identifying the chromosomal locus occupied by LCPTP: lq32.1 where 
a deletion is observed in non-Hodgkin’s lymphomas (NHL) and chronic 
lymphoproliferative disorders (CLD) (Mitelman et al., 1990). They also found that 
LCPTP has a consensus sequence for a nontransmembrane PTP and that the human 
mRNA is expressed in two transcriptional sizes: 4.0 kilobases and 2.9 kilobases 
(Adachi et al., 1992a). The main difference between the two proteins is the location 
of the presumptive translation initiation codon. LCPTP has 21 more amino acids in 
the N-terminal end compared to HePTP caused by a missing cytosine in the HePTP 
sequence. Other differences are located within the coding sequence at (R-234 Q L T,
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LCPTP)-(R G V T, HePTP) and (T-336 D E, LCPTP)-(T A E, HePTP) (Adachi et al., 
1992a); (Swieter et al., 1995); (Mustelin et al., 1998).
Zanke et al. (1994) looked at the expression of LCPTP in diverse murine and 
human cell lines. LCPTP was found to be expressed at high levels in myeloid (HL- 
60, M07E, OCI AML 1 through 4), B and T lymphoid (Jurkat, CTLL, Molt-4, Molt- 
3, P30/OKUBO, Raji, HPB-ALL) and myeloma (OCI My-4, OCI My-5) cells (Zanke 
et al., 1994). By fluorescent in situ chromosomal hybridisation (FISH), the gene was 
mapped to chromosome lq32.1 (Adachi et al., 1992a). The analysis of patients with 
myelodysplastic syndrome (myeloid hypoplasia and monocytosis) showed triplication 
of the LCPTP gene (Zanke et al., 1994). The overexpression of LCPTP in NIH 3T3 
fibroblasts caused altered morphology, disorganised growth, anchorage independent 
colony formation and subtle differences in the pattern of tyrosine phosphoproteins. It 
was concluded that unbalanced LCPTP activity may contribute to non-regulated 
growth and establishment of clonal dominance of cells and it was suggested that 
LCPTP plays a role in the regulation of cell proliferation, survival or differentiation 
(Zanke et al., 1994).
The rat homolog of LCPTP was discovered by Swieter et al. (1995). It shares 
92% identity with the human sequence. They showed a tyrosine phosphorylation of 
LCPTP upon FceRI aggregation in the RBL-2H3 cell lines. This post-translational 
modification seems to be calcium dependent and it was suggested that LCPTP played 
a role in IgE receptor aggregation (Swieter et al., 1995). By immunofluorescence 
microscopy, in RBL mast cells, LCPTP was shown to be localised into discrete 
compartments in the cytoplasm, was absent from the nucleus and could not be 
detected associated with the cell surface membrane (Swieter et al., 1995). It was 
shown in a more recent study that LCPTP was localised in the cytoplasm, with a clear 
enrichment near the plasma membrane. This location did not seem to change upon T 
cell activation (Gjorloff-Wingren et al., 2000). LCPTP has been labelled as an early 
response gene. This follows studies in which the IL-2-dependent cell line ILT-Mat 
(Adachi et al., 1994b) or the I.L-3-dependent pro-B cell BAF-B03 F7 clones 
expressing IL-2R|3 and IL-2Ra (Adachi et al., 1995) were stimulated with IL-2. A 
rapid increase in LCPTP mRNA and LCPTP protein, peaking at 6 and 8 hours
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respectively was seen after IL-2 stimulation (Adachi et al., 1994b); (Adachi et al., 
1995). In the IL-3-dependent cell lines, the increase in LCPTP mRNA was abolished 
by the presence of tyrosine kinase inhibitors and promoted by the overexpression of 
activated-Lck or activated-Raf-1 kinases suggesting an involvement of these kinases 
in the LCPTP mRNA induction (Adachi et al., 1995).
Recent studies have implicated the phosphatase as playing a role in TCR 
signalling (Saxena et al., 1998); (Saxena et al., 1999a); (Oh-hora et al., 1999); 
(Saxena et al., 1999b); (Pettiford and Herbst, 2000). IL-2 gene transcription activity 
was measured following cotransfection of the reporter gene NFAT/AP-1 luciferase 
(derived from the 5’ IL-2 gene promotor) and another plasmid containing HA-LCPTP 
wild-type in J-TAg and JCaMl cell lines. It was found that when LCPTP is 
transiently overexpressed in anti-CD3 activated cells, the activity of the reporter 
NFAT/AP-1 luciferase was greatly diminished. In contrast, a catalytically inactive 
mutant (C270S) had no effect (Saxena et al., 1998). When the two proteins, LCPTP 
and MAPK ERK2 were transfected simultaneously, a reduction of MAPK kinase 
activity was observed, but the same experiment with JNK kinase overexpression did 
not change the kinase activity (Saxena et al., 1998). Thus a specific role for LCPTP 
in dephosphorylating the MAPK and not the JNK members was identified. LCPTP 
and MAPK family members: ERK1, ERK2 and p38 were overexpressed in Jurkat 
and JCaMl cell lines and a constitutive association, mediated via the N-terminus of 
LCPTP, was reported between the wild-type and the catalytically inactive mutant 
LCPTP and MAPK family members (Saxena et al., 1999a). A ratio of 1:1 between 
the phosphatase and the kinase was put forward for the dephosphorylation action of 
the recombinant LCPTP (Saxena et al., 1999a). Oh-hora et al. (1999) demonstrated 
the same constitutive association between LCPTP and the MAPK family members 
ERK1, ERK2 and p38, in the 293 T cell line along with the importance of the N- 
terminal extremity of LCPTP for the binding, named KIM motif (kinase interacting 
motif: GLQERRGSNVSLTLDM) (Pulido et al., 1998); (Oh-hora et al., 1999). Two 
other phosphatases, which also possess KIM motifs, are STEP and PTP-SL. STEP 
and PTP-SL are found primarily in neuronal cells and have been shown to be 
associated with ERK1 and ERK2, when using overexpressed proteins (Pulido et al.,
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1998). In addition, other phosphatases: PTP-ER (Karim and Rubin, 1999), MKP-3 
(Zhou et al., 2001) and the yeast Ptp3 (Zhan and K.L., 1999) contain the KIM motif.
Further studies by Saxena et al. have demonstrated a potential crosstalk 
between the cAMP system and the MAPK cascade (Saxena et al., 1999b). Treatment 
of radiolabelled Jurkat T cells with 32P, with a membrane-permeable cAMP analogue 
(8-CTP-cAMP) induced serine phosphorylation on overexpressed LCPTP, 
implicating activity downstream of cAMP kinase action. An in vitro experiment in 
which PKA, a kinase activated by cAMP, and LCPTP proteins were added together, 
showed that PKA can phosphorylate Ser23 on LCPTP, within the KIM motif. GST 
pull-downs of this phosphorylated form of LCPTP have a reduced association with 
overexpressed MAPK family members. Treatment of a Jurkat T cell line with cAMP 
caused a small activation of the MAPK family members sufficient to induce further 
events such as c-fos transcription (Saxena et al., 1999b). Pettiford and Herbst (2000) 
showed that in the human chronic myelogenous leukemic cell line, K562, ERK2 is the 
only substrate for LCPTP. ERK2 interacted with the catalytically inactive 
phosphatase but not with the wild-type protein. The substrate, ERK2, needed to be 
phosphorylated for the interaction to occur and the weak interaction between LCPTP 
and p38 only occurred under mild immunoprecipitation conditions (Pettiford and 
Herbst, 2000).
A genetically modified mouse lacking the LCPTP gene has been generated 
(Gronda et al., 2001). The mild phenotype observed included an enhanced activation 
of ERK1 and ERK2 following PMA or anti-CD3 stimulation. All other physiological 
measurements made failed to show any differences compared to the control. This 
included looking at the distribution of hematopoietic lineages in bone marrow and 
peripheral blood, in vitro proliferation of bone marrow progenitors, IL-2 production, 
Th2 differentiation and surface expression of activation markers on lymphoid cells 
(Gronda et al., 2001). It was concluded that LCPTP is a regulator of the MAPK 
family members but its deletion in the mouse is compensated by an alternative 
signalling protein, or proteins (Gronda et al., 2001).
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Saxena’s model is illustrated in Figure 4. This data is based on use of 
recombinant LCPTP protein.
Table 1.1 summarises data available on the phosphatases implicated in T cell 
signalling with regard to their substrates, localisation in the cell and the roie ihey play 
in regulating TCR signalling.
PTKs
Cytoplasm Ras 
Raf
Ligand
PTKs
cAMP
Cytoplasm Ras
4
Mek
4
Erkl— HePTP
Nucleus
Ser-23
HePTP
Nucleus
Figure 1.4: Model for LCPTP (HePTP) in T cells signalling
Figure from Saxena et al., 1999. “A. In the absence of external stimuli, the classical 
pathway of MAP kinase activation (originating at a receptor, R l) through Ras, Raf 
and Mek has a low basal activity, which is counteracted by HePTP. B. Stimulation 
of receptors (R2) that couple to adenylate cyclase (AC) turn on the new pathway that 
involves phosphorylation of HePTP at Ser 23 by PKA, leading to dissociation of ERK 
from HePTP. This release from inhibition results in MAP-kinase activation and 
subsequent c-fos induction.” (Saxena et al., 1999a).
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Table 1.1: Main phosphatases implicated in T cell signalling
Phosphatase Proposed substrate Localisation Action in TCR 
signalling
CD45 Lck, Fyn, Zeta (?) Membrane Positive
CD 148 ZAP-70 (?) Membrane Negative
PEP Src, Syk kinases Cytosol, nucleus Negative (?)
LYP c-Cbl Cytosol Negative (?)
SHP-1 ZAP-70, Lck, Fyn, 
75kDa protein
Cytosol Negative
SHP-2 Grb2, c-Cbl, PI3K, 
110 kDa protein (?)
Cytosol Positive
LCPTP MAPK Cytosol Negative
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AIMS
The major aims of this study are:
=> To investigate the role of LCPTP in T cell signalling and activation.
=>To propose a model for the involvement of LCPTP in T cell signalling and 
activation.
41
CHAPTER TWO: MATERIALS AND METHODS
2.1 Molecular Biology
2.1.1 Bacterial strains
Escherichia coli strain DH5a (supE44 A/aclI169 laczAM\5 h sd R ll recAX endA\ 
gyrA96 thi-1 relAl) was used as general transforming bacteria for plasmid expansion 
(Grant et al., 1990). Escherichia coli strain DH10B Admid294, containing a low 
copy plasmid with a full-length adenoviral genome, lacZatttTn7::El and an inefficient 
E3 gene (El E 3), supplemented with a mini-Tn7 element plasmid (Richards et al.,
2000) was used for the adenoviral expression system. Cells were cultured in Luria 
Bertani medium (LB - 10 g/1 bacto-tryptone, 5 g/1 bacto-yeast extract, 5 g/1 NaCl) or 
on solid medium (LB + 1.5% (w/v) agar) with specific antibiotic added for each 
plasmid used at a concentration of 100 p<g/ml for ampicillin or kanamycin, 15 ^ig/ml 
tetracycline, 20 p-g/ml chloramphenicol, 300 p-g/ml Bluo-Gal (Life Technologies, 
UK) and 40 p-g/ml isopropylthio-p-galactoside (IPTG) (Sigma, UK). Cells were 
stored at -80°C in 30% (v/v) glycerol in LB.
2.1.2 Preparation of competent DH10B Admid294 cells
Single colonies of DH10B Admid294 were grown in LB supplemented with 
tetracycline and chloramphenicol for 18 hours at 37°C in a shaking incubator. A total 
of 200 ml of 2YT (16 g/1 bacto-tryptone, 10 g/1 bacto-yeast extract, 5 g/1 NaCl) was 
cultured and grown until an absorbance of A590 = 0.375 was obtained. Cells were then 
centrifuged in a Sorvall rotor SS-34, for 12 min at 5000 rpm at 4°C. Cells were 
resuspended in cold 60mM CaCl2/15% glycerol. Cells were centrifuged for 10 min at 
3000 rpm at 4°C, resuspended in 60mM CaCl2/15% glycerol and incubated on ice for 
90 min. Cells were centrifuged for 10 min at 2500 rpm at 4°C and cell pellets were 
resuspended in 4 ml of 60mM CaCl2/15% glycerol, aliquoted in 0.150 ml volumes 
into eppendorf tubes and stored at -80°C.
2.1.3 Transformation of DNA into competent cells
Competent DH5a cells were obtained following the protocol described in Sambrook 
et al. (1990) (Sambrook et al., 1989). 50 ng DNA was mixed with 0.2 ml of the
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competent cell suspension. After 30 min incubation on ice, cells were heat-shocked 
for 45 sec at 42°C and immediately transferred back onto ice. After 2 min, 0.8 ml LB 
was added and samples were incubated for 1 h at 37°C. 0.2 ml aliquot was spread on 
LB agar plates 1.5% (w/v) agar) containing the appropriate antibiotic. Plates were 
incubated at 37°C overnight, or until colonies were observed.
2.1.4 Preparation of Plasmid DNA
A 5 ml (Mini-prep kit) or 400 ml (Maxi-prep kit) culture of DH5a containing the 
plasmid of interest was grown up overnight with aeration in a 37°C shaking incubator. 
Cells were harvested by centrifugation for 3 min at 13 000 rpm (Mini-prep) 
(Eppendorf minicentrifuge) or 15 min at 6 000 rpm (Maxi-prep)(Sorvall centrifuge). 
Plasmid DNA was isolated using the Qiagen plasmid purification kit (Mini-prep or 
Maxi kit), according to the manufacturer’s protocol. The DNA pellets obtained were 
air-dried, resuspended in 0.1 ml or 0.5 ml TE buffer (10 mM Tris-HCl pH. 8.0, 1 mM 
EDTA) and stored at -20°C.
2.1.5 Cloning of LCPTP from a cDNA library
The human LCPTP gene (accession number: D11327) was amplified by PCR from an 
H9 library. The H9 cDNA library was donated by M. Suda of GlaxoNippon, Japan. 
The cDNA was generated from poly (A+) RNA extracted from a mixture of non­
activated and 12-O-tetradecanoylphorbol-13-acetate-activated H9 T-cells and 
synthesised using an oligo(dT) primer and random primers. The primers used were 
LCPTP-1 (CGCGTGGATCCATGGTCCAGCCCATGGGGGGCGCTC) and 
LCPTP-2 (CGCGTGGAICCGCAGGGGCTGGGTTCCTCAGGCAGC) bearing 
BamHI restriction sites (underlined). This yielded an 1120-bp fragment flanked with 
a BamHI site of each side.
2.1.6 Cloning of LCPTP into pcDNA3.1 plasmid
The PCR product LCPTP was digested with Bam H I and then subcloned into the 
pcDNA3.1 (Invitrogen, UK) containing N-terminal cmyc-tag (CAGCC ATG GAG 
CAA AAG CTC ATT TCT GAA GAG GAC TTG TTG) kindly provided by Dr Janet 
Smith (GlaxoSmithKline, UK).
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2.1.7 Site directed mutagenesis
Site directed mutagenesis was performed using a QuickChange Site-Directed 
Mutagenesis Kit following the manufacturer’s protocol (Stratagene, UK) to generate 
the substrate-trap mutant phosphatase (called Trap) D257A-C291A and the null 
mutant phosphatase (called Null) R297M. The primers used were LCPTP-9 
( C G G C T G G C C A G C C C A T C A G A C A C C )  a n d  L C P T P - 10 
(GGTGTCTGATGGGCTGGCCAGGCCG) for D257A and LC PTP-11 
(C TA TC G TA G TC C A C TC C A G TG C A G G G A TTG G ) and L C P T P -12 
(CCAATCCCTGCACTGGAGTGGACTACGATAG) for C291S, LCPTP-15 
(C AGTGCAGGGATTGGCATG ACGGGCTGCTTCATC) and LC PTP-16 
(G A TG A A G CA G C CC G TC A IG C CA A TCC CTG CA C TG ) fo r R297M . 
Amplification of these plasmids was done using the transformation and DNA 
isolation protocols described above (sections 2.1.3 and 2.1.4).
2.1.8 Cloning of LCPTP into pGFP plasmid
The green fluorescent vector (GFP) construct was obtained from Clontech (GenBank 
accession #: U19280, UK). Cloning of LCPTP into the GFP vector was performed 
using constructs from plasmids pcDNA 3.1 myc-wt-LCPTP; pcDNA 3.1 myc-C291S- 
D257A-LCPTP; pcDNA 3.1 myc-R297M-LCPTP provided by Dr Angela Boyhan 
(GlaxoSmithKline, UK). GFP vector was linearised by cutting in the multi-cloning 
site with BamHI (New England Biolab, UK). The different LCPTP genes (wt, 
C291S-D257A and R297M) were cut from the pcDNA 3.1 cmyc plasmid using 
BamHI enzyme (New England Biolab, UK). The LCPTP inserts were religated into 
the GFP vector to create: GFP-LCPTP wt, GFP-LCPTP C291S/D257A and GFP- 
LCPTP R297M constructs.
2.1.9 Cloning of LCPTP into pCR259 plasmid
The plasmid pCD259 was obtained from Dr Nigel Sharp (GlaxoSmithKline, UK). 
Cloning of LCPTP into the pCR259 vector was performed using constructs from 
plasmids pcDNA 3.1 myc-wt-LCPTP; pcDNA 3.1 myc-C291S-D257A-LCPTP 
provided by Dr Angela Boyhan (GlaxoSmithKline, UK). pCR259 vector was 
linearised by cutting in the multi-cloning site with Nhel and Notl (New England 
Biolab, UK). The 5’polymerase Klenow (New England Biolab, UK) was used to fill
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in ends. The different LCPTP genes (wt and C291S-D257A) were cut from the 
pcDNA 3.1 cmyc plasmid using BamHI enzyme (New England Biolab, UK) and the 
ends were filled by the 5 ’polymerase Klenow (New England Biolab, UK). The 
LCPTP inserts were ligated into the pCR259 vector to create: pCR259-LCPTP wt 
and pCR259-LCPTP C291S/D257A.
2.1.10 Insertion of pCR259-LCPTP into the homing vector pCR249,
selection of pCR249-LCPTP
Transformation of pCR259-LCPTP was performed as described in section 2.1.3 in 
DH10B Admid294 and plated on LB medium supplemented with ampicillin, 
chloramphenicol, tetracycline, Bluo-Gal and IPTG. After 18 hours, white colonies 
were picked and grown in LB broth supplemented with chloramphenicol. Mini-preps 
were performed following the Qiagen protocol (section 2.1.4). Once the DNA was 
obtained, transformation into DH5a was performed and cells were plated on LB 
medium supplemented with chloramphenicol, Bluo-Gal and IPTG. After a further 18 
hours, white colonies were picked and transferred to replicate plates each containing 
one of the different antibiotics (ampicillin, tetracyclin or chloramphenicol). Cells 
growing on LB with chloramphenicol only were selected for bulk preparation.
2.1.11 Agarose gel electrophoresis
Gels containing 0.7-1.2% (w/v) agarose in TAE buffer (0.04 M Tris-acetate, 0.001 M 
EDTA) were prepared using the Bio-Rad Wide Mini-Sub cell system. 1/6 volume 
agarose gel loading buffer (6x) (50 mM Tris-HCl (pH 8.0), 50% (v/v) glycerol, 0.2% 
(w/v) bromophenol blue) was added to DNA samples and gels were run in TAE 
buffer at 100 mV. Following electrophoresis, DNA was visualised under short-wave 
UV light.
2.1.12 DNA concentration determination
DNA concentrations were determined by measuring the optical density (OD) at 260 
nm, using a quartz cuvette and a Pharmacia Ultrospec 2000 spectrophotometer. 
Calculations were based on the assumption that an OD260= 1 (measured in a cuvette 
with a 1 cm pathlength) is equivalent to 50 pg/ml dsDNA.
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2.1.13 Solvent extraction of DNA
Samples were mixed thoroughly with an equal volume phenol/chloroform (50:50) and 
the two phases (organic and aqueous) separated by low speed centrifugation at 5000 
rpm for 5 minutes. The aqueous phase was retained for further processing.
2.1.14 Ethanol precipitation of DNA
DNA samples were diluted 1/10 with 3 M sodium acetate (pH 5.2) followed by the 
addition of 2.5 volumes ethanol (ice-cold). After 15 min at -80°C, or 2 hr at -20°C, 
precipitated DNA was pelleted by centrifugation (13 000 rpm, 15 min, 4°C). DNA 
pellets were washed with 70% (v/v) ethanol (ice-cold), air dried and resuspended in 
TE buffer.
2.1.15 Production of transfection stock of adenovirus in HEK293 cells
A total amount of 2.5 ng of pCR249-LCPTP was digested with PacI restriction 
enzyme, purified with phenol/chloroform (as described in section 2.1.13) and 
precipitated with ethanol (described in section 2.1.14). The digested DNA was mixed 
with lipofectamine (Sigma, UK) and added to HEK293 cells growing at 80% 
confluency in 6 well plates. After 24 hours incubation, the transfection mix was 
removed and replaced with DMEM medium supplemented with 2% FCS and 
incubated for 5-7 days. Cells were harvested and freeze/thawed three times before 
centrifuging at 2000 rpm for 15 min at 4°C to remove cellular debris. Glycerol was 
added at a final concentration of 10% and the transfection stock was then aliquoted 
and stored at -80°C or used for master seed stock infection.
2.1.16 Production of master seed stock of adenovirus in HEK293 cells
Five T175 flasks of HEK293 cells grown to 75% confluency were taken, medium 
removed and replaced with 2 ml of transfection stock adenovirus diluted in 10 ml 
total of DMEM/2% FCS. Flasks were incubated at 37°C for 5 days or until cell lysis 
was apparent. Cells and medium were then harvested and freeze/thawed twice before 
centrifugation at 2000 rpm for 15 min at 4°C. Clarified medium was aliquoted and 
stored at -80°C or used for seed stock infection.
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2.1.17 Titration of adenovirus
Fibroblast HER911 cells were plated at a concentration of 1 x 104 cells/well in flat 
bottomed 96 well plates in 50 pi of DMEM/2% FCS/Pen/Strep. Log and half-log 
dilutions of virus (range from IQf45 to 10'12) were prepared in DMEM/2% FCS. A 
total of 50 pi of each virus dilution was added to the wells; 7 wells were plated per 
dilution. Plates were incubated for 7 days at 37°C. After incubation, cell growth was 
visualised in each well using a light microscope set on low magnification. Wells in 
which cell lysis had occurred were scored. The titration of the virus measured in 
m.o.i. (multiplicity of infection) was calculated as half the TCID50 (dilution of virus 
at which there is a 50% probability of an infectious particle being present). The 
TCID50 value was calculated as Log TCID50 = Highest dilution giving 100% lysis 
formation + (difference in log between dilution * 0.5) -  (difference in log between 
dilution) * (total number of wells with lysis formation (including last row in which 
cell lysis occurred in wells))/number of wells per row.
2.1.18 Production of seed stock of adenovirus in HEK293 cells
Twenty T175 flasks of HEK293 cells grown at 75% confluency were taken, medium 
was removed and replaced with master seed stock adenovirus at a m.o.i. of 0.01 
diluted in 10 ml total of DMEM/2% FCS per flask. Flasks were incubated at 37°C for 
5 days or until cell lysis was apparent. Cells and medium were then harvested and 
freeze/thawed twice before centrifugation at 2000 rpm for 15 min at 4°C. Clarified 
medium was aliquoted and stored at -80°C or used for batch stock infection.
2.1.19 Production of batch stock of adenovirus in HEK293 cells
Forty T175 flasks of HEK293 cells grown at 75% confluency were taken, medium 
removed and replaced with master seed stock adenovirus at a m.o.i. of 10 diluted in 
10 ml total of DMEM/2% FCS per flask. Flasks were incubated at 37°C for 3 days or 
until cell lysis was apparent. Cells and medium were then harvested and 
freeze/thawed twice before centrifugation at 2000 rpm for 15 min at 4°C. Clarified 
medium was aliquoted and stored at -80°C or purified using caesium chloride density 
gradients.
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2.1.20 Caesium chloride purification; step gradient
A solution of CsCl 1.4 (265 g CsCl + 4.35 ml 1 M Tris-HCl pH 7.9 + 430.65 ml H20 ) 
was layered in SW28 ultra-clear tubes (Beckman, UK) followed by a solution of CsCl
1.2 (134 g CsCl + 4.6 ml 1 M Tris-HCl pH 7.9 + 455.4 ml H20). The virus 
suspension was iayered on top of the caesium chloride. A total of 6 tubes were 
centrifuged using a Beckman centrifuge rotor SW28 at 23 000 rpm for 90 min at 4°C, 
with the brake set at 0. After centrifugation, the concentrated band of intact virus was 
removed with an 18G syringe needle and virus was mixed with an equal volume of 10 
mM Tris-HCl pH 7.9, ready to transfer onto the continuous gradient.
2.1.21 Caesium chloride purification; continuous gradient
Using a mixer gradient former (Bethesda Research Laboratories, USA), a gradient 
was poured using CsCl 1.4 solution and CsCl 1.2 solution. The virus Tris-HCl mix 
was then layered on top of the gradient. Tubes were centrifuged for 16-20 hrs at 
23000 rpm at 4°C, with the brake set at 0. The concentrated band of virus was 
extracted using an 18G syringe needle. The virus stock was added to a dialysis 
cassette (Pierce, USA) and dialysed three times against a solution of 10 mM Tris-HCl 
pH 8.0, 2 mM MgCl2, 5% sucrose. The virus was stored at -80°C.
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Table o f antibodies used
Antibody Source Type Application Dilution/amount
Mouse IgG Sigma Polyclonal Cell activation 10 iAg/ml
Mouse Sigma Polyclonal Western blot 1 :100000
Rabbit Sigma Polyclonal Western blot 1 :10000
DR Becton Dickinson Polyclonal Cell separation 100 nl/2.5 x 107 
cells
CD3 human 
(OKT3)
A.T.C.C. Monoclonal Cell activation 10 p-g/ml
CD2-FITC Becton Dickinson Polyclonal FACS 1 :1000
CD3 mouse Pharm ingen Monoclonal Cell activation 1 (ig/ml
CD3-FITC Becton Dickinson Polyclonal FACS 1 :1000
CD3-FITC Becton Dickinson Polyclonal FACS 1 :1000
CD8 Becton Dickinson Polyclonal Cell separation 50 nl/2.5 x 107 
cells
CD1 la-FITC Becton Dickinson Polyclonal FACS 1 :1000
CD14 Becton Dickinson Polyclonal Cell separation 100 (j.1/2.5 x 107 
cells
CD18-FITC Becton Dickinson Polyclonal FACS 1 :1000
CD20 Becton Dickinson Polyclonal Cell separation 100 (xl/2.5 x 107 
cells
CD25-PE Becton Dickinson Polyclonal FACS 1 .1000
CD28 human In house Monoclonal Cell activation 10 [ig/ml
CD28 mouse Pharmingen Monoclonal Cell activation 1 p.g/ml
CD28-PE Becton Dickinson Polyclonal FACS 1 :1000
CD56 Becton Dickinson Polyclonal Cell separation 100 nl/2.5 x 107 
cells
CD62L-PE Becton Dickinson Polyclonal FACS 1 :1000
CD69-FITC Becton Dickinson Polyclonal FACS 1 :1000
CD152-PE Becton Dickinson Polyclonal FACS 1 :1000
CD154-FITC Becton Dickinson Polyclonal FACS 1 :1000
cmyc Santa Cruz Polyclonal Western blot, IP 1 :500
LCPTP In house Polyclonal Western blot, IP 1 :1000
Phospho-tyrosine Upstate Biotech Monoclonal Western blot 1 :2000
Active MAPK Promega Polyclonal Western blot 1 :1000
Phospho-LCK Upstate Biotech Polyclonal Western blot 1 :1000
IL-4 R&D System Polyclonal Cell activation 5 |Lig/ml, 10 
ng/ml
IL-12 R&D System Polyclonal Cell activation 5 |ag/ml
IFN-y R&D System Polyclonal Cell activation 1 |xg/ml
Fas-PE Becton Dickinson Polyclonal FACS 1 :1000
FasL-FITC Becton Dickinson Polyclonal FACS 1 :1000
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2.1.22 Table of vectors/plasmids used
Vector Insert Tag Constructed by
pcDNA3.1cmyc - cmyc Dr. Janet Smith
pcDNA3.1 cmyc LCPTP wt cmyc Nikol Heinrichs
pcDNA3.1 cmyc LCPTPTrap cmyc Nikol Heinrichs
pcDNA3.1 cmyc LCPTP Null cmyc Nikol Heinrichs
pMBP LCPTP wt Maltose Dr Angela Boyhan
pGEX - GST Pharmacia
pGEX LCPTP wt GST Dr Angela Boyhan
pGEX LCPTPTrap GST Dr Angela Boyhan
pGFP - GFP Clontech
pGFP LCPTP wt GFP Isabelle Brodeur
pGFP LCPTPTrap GFP Isabelle Brodeur
pGFP LCPTP Null GFP Isabelle Brodeur
pCR259 - - Cynthia Richard
pCR259 LCPTP wt - Isabelle Brodeur
pCR259 LCPTPTrap - Isabelle Brodeur
pCR259 LCPTP anti-sense - Isabelle Brodeur
pCR249 - - Cynthia Richard
pCR249 LCPTP wt - Isabelle Brodeur
pCR249 LCPTPTrap - Isabelle Brodeur
pCR249 LCPTP anti-sense - Isabelle Brodeur
pCR249 Gata3 - Dr Nigel Sharp
2.2 Protein chemistry techniques
2.2.1 Isolation of GST-fused protein on beads
E. coli D H 5a containing the plasmid GST-LCPTP wild-type or substrate-trap (kindly 
given by Dr Angela Boyhan, GlaxoSmithKline, UK) was inoculated in 5 ml LB broth 
containing ampicillin at 100 ng/ml for 18 hours. The 5 ml culture was inoculated into 
500 ml of LB/Ampicillin broth and incubated at 37°C with aeration until an 0 0 ^  = 
0.75 was obtained. GST-LCPTP production was induced by the addition of 0.1 mM 
IPTG for 4 hours at 30°C. After growth expansion, cells were harvested by
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centrifugation at 7500 rpm for 7 min at 4°C (Sorvall, SS-34). Peliets were 
resuspended in buffer A (10 mM Tris-HCl pH 7.5, 50 mM NaCl, 0.1 mM EDTA, 
ImM DTT, 1 mM PMSF). Cells were sonicated on ice and centrifuged at 15 000 rpm 
for 1 hour at 4°C (Sorvall, SS-34). Supernatant was mixed end-over-end with 
Glutathione Sepharose 4B beads (Amersham Pharmacia Biotech, UK). Beads were 
recovered by centrifugation at 3000 rpm for 5 min at 4°C and washed with buffer A. 
Beads coupled with GST-LCPTP fusion proteins were stored at 4°C in PBS/0.05% 
sodium azide. In order to generate polyclonal antisera against LCPTP, recombinant 
GST-LCPTP protein was eluted from the beads using 5 mM glutathione in buffer A 
pH 8.0.
2.2.2 Isolation of MBP-LCPTP beads
E. coli transformed with plasmid containing the MBP-LCPTP gene (kindly provided 
by Dr Angela Boyhan, GlaxoSmithKline, UK) were induced with 0.1 mM IPTG as 
described in section 2.3.1. Cells were lysed by sonication (section 2.3.1) and cell 
lysate was incubated with amylose resin (Amersham Pharmacia Biotech, UK) packed 
in a 10 ml Bio-Rad column. The column was washed with buffer A to remove 
unbound material and MBP-LCPTP protein was eluted from the beads with 10 mM 
maltose in buffer A. Beads were stored at 4°C in lOmM Tris-HCL pH 7.6/0.05% 
sodium azide.
2.2.3 Purification of LCPTP antibody
Serum from rabbits immunised with GST-LCPTP protein was diluted 1:5 with 10 
mM Tris-HCL pH 7.6 and loaded onto a column containing 1.4 ml MBP-LCPTP- 
amylose resin (New England BioLab, UK) at a flow rate of 1 ml/min. The column 
was washed with 10 mM Tris-HCl pH 7.6 to remove unbound material, and the 
antibody was eluted with 100 mM Glycine pH 2.5 and collected into fractions. 
Fractions containing antibody were neutralised with 1/10 volume 1 M Tris-HCl pH 8. 
Antibody was concentrated using a Centricon column (Amicon, USA), following the 
manufacturer’s instructions.
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2.2.4 Coupling LCPTP Ab to Aminolink gel
Aminolink coupling gel (Pierce, USA) was washed in PBS and purified antibody was 
added at a concentration of 1 mg antibody/0.5 ml gel. 5 M sodium borohydrate was 
added and the gel and antibody were mixed end-over-end for 18 hours, at 4°C. The 
antibody coupled beads were isolated from the supernatant by centrifugation (13 000 
rpm, 30 sec). The concentration of antibody bound to the beads was determined by 
measuring the absorbance of the protein remaining in the supernatant at 280 nM using 
a Pharmacia Ultrospec 2000 spectrophotometer. The amount of antibody bound = 
[solution Ab start] -  [solution Ab end])/[solution Ab start]. Beads were washed in 
Tris-HCl pH 7.4 to block any remaining free amino groups and mixed for a further 30 
min. Finally, the beads were washed with 1 M NaCl and stored in PBS/ 0.05% 
sodium azide.
2.2.5 Evaluation of antibody concentration
The absorbance of antibody solutions at 280 nm was measured using a Pharmacia 
Ultrospec 2000 spectrophotometer. Antibody concentration was calculated using the 
equation: 1.4 : lmg Ab/ml.
2.2.6 Evaluation of protein concentration (Bradford)
The Bradford assay ((Bradford, 1976)) was used to determine the concentration of the 
protein solution of interest. Samples were diluted to a volume of 0.8 ml in H20  and 
mixed with 0.2 ml of protein assay dye reagent concentrate (Bio-Rad, UK). The 
colour was allowed to develop for 5 min at 20°C. The absorbance at 595 nm was 
measured, using a Pharmacia Ultrospec 2000 spectrophotometer, and unknown 
protein concentrations read against a standard curve obtained with known 
concentrations of BSA.
2.2.7 Cell activation
To activate the Jurkat cells for immunoprecipitations or Western blotting, cells were 
resuspended in 30 mM Hepes-buffered RPMI and prewarmed at 37°C for 10 min. 
Anti-Mouse IgG (Sigma, UK) was added at a final concentration of 10 pg/ml and 
incubated with the cells for 2 min (time 0). The anti-CD3 antibody (Clone OKT3, 
A.T.C.C.) was added at a final concentration of 10 pg/ml and reactions stopped at
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suitable intervals by addition of SDS-sample loading buffer [125 mM Tris pH 6.8, 4 
% (w/v) SDS, 20 % (w/v) glycerol, 0.2 M DTT, 0.013 % bromophenol blue (Sigma, 
UK)]. For immunoprecipitations, samples were snap frozen in liquid nitrogen instead 
of adding SDS-sample loading buffer.
2.2.8 Immunoprecipitations
Jurkat T cells (1 x 108) were activated as described above for 1 min in the presence of 
anti-CD3. Cells were snap frozen in liquid nitrogen and then lysed in 1 % n-octyl 
glucoside, 10 mM Tris-HCl pH 8.0, 50 mM NaCl, 10 mM iodacetamide, 10 mM 
sodium orthovanadate, 2 mM EDTA, 0.076 TIU/ml aprotinin, 10 pg/ml pepstatin, 10 
pg/ml leupeptin and 10 pg/ml 4-(2-aminoethyl)benzenesulfonyl fluoride (AEBSF) 
(Sigma, UK). The lysate was separated from insoluble material by centrifugation for 
5 min at 13000 rpm. LCPTP protein was immunoprecipitated using 3 pg anti-LCPTP 
antibody coupled to Aminolink Plus Coupling Gel (Pierce, UK) per sample. 
Following a 1 hour incubation at room temperature with constant mixing, the 
immunoprecipitates were washed with lysis buffer five times. Bound proteins were 
eluted by heating the Coupling gel in the presence of SDS-sample loading buffer for 5 
min at 100°C. To control for nonspecific binding, lysate was incubated with 
Coupling gel in the absence of antibody. The MAPK members (ERK1, ERK2 and 
p38) were immunoprecipitated by mixing 3 pg of monoclonal antibody to ERK1 
(Affinity Research Products, UK), ERK2 (Upstate Biotechnology, USA) or p38 
(Upstate Biotechnology, USA)) with 40 pi 10% suspension of Protein A Sepharose 
(Sigma, UK) added to the cell lysate. Protein complexes were separated by 4-20% 
gradient SDS PAGE and proteins identified by Western blotting (See section 2.3.9).
2.2.9 Total cell lysates
Jurkat T cells or LCPTP stable cell lines (1 x 106) were taken and snap frozen in 
liquid nitrogen and then lysed in 1 % n-octyl glucoside, 10 mM Tris pH 8.0, 50 mM 
NaCl, 10 mM iodacetamide, 10 mM sodium orthovanadate, 2 mM EDTA, 0.076 
TIU/ml aprotinin, 10 pg/ml pepstatin, 10 pg/ml leupeptin and 10 pg/ml 4-(2- 
aminoethyl)benzenesulfonyl fluoride (AEBSF) (Sigma, UK). The lysate was 
separated from insoluble material by centrifugation for 5 min at 13 000 rpm. The
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lysate was mixed with SDS sample loading buffer and heated for 5 min at 100°C. 
Samples were separated on a 4-20 % gradient SDS-PAGE (Novex-Pharmacia, UK).
2.2.10 GST pull-downs
Pull-downs with recombinant proteins were done by mixing either 3 ^g of the GST 
fused protein (LCPTP wild-type or substrate-trap (C291S, D257A)) or the GST 
protein alone, coupled to Glutathione Sepharose 4B beads with the cell lysate. The 
pull-downs were performed and processed as described for the immunoprecipitations.
2.2.11 Western blots
Proteins were transferred from gels to PVDF (Millipore, UK) membrane using a 
semi-dry blotter (Amcos, Netherlands). Gels and 3MM filter paper were soaked in 
transfer buffer (5.8 g Tris, 2.95 g Glycine, 3.7 ml SDS 10%, 200 ml methanol), 
PVDF membrane was activated by immersion in methanol. To blot for cmyc or 
LCPTP, membranes were blocked in 3 % milk in PBS (Sigma, UK) and probed with 
cmyc rabbit polyclonal antibody (Santa Cruz, USA) or LCPTP rabbit polyclonal 
antibody (GlaxoSmithKline, UK), followed by goat anti-rabbit horseradish 
peroxidase-conjugated antibody (Sigma, UK) and then exposure to enhanced 
chemiluminescence (ECL) reagents (Amersham, UK). Phosphotyrosine proteins 
were detected using the 4G10 mouse mAb (Upstate Biotechnology, USA) followed 
by goat anti-mouse horseradish peroxidase-conjugated antibody (Sigma, UK). Active 
MAPK proteins were detected using the rabbit polyclonal anti-active MAPK antibody 
(Promega, UK) followed by goat anti-rabbit horseradish peroxidase-conjugated 
antibody (Sigma, UK) using I-Block buffer (0.2% I-Block (Tropix, USA), 0.1% 
Tween-20 (Sigma, UK) in PBS). Phosphorylated-Lck proteins were detected using 
the rabbit polyclonal anti-phospho-Lck antibody (Upstate Biotechnology, USA) 
followed by goat anti-rabbit horseradish peroxidase-conjugated antibody (Sigma, 
UK) using 3% milk in PBS. To verify that equal amounts of protein were loaded per 
track, gels were stained with Coomassie blue (0.1% Coomassie blue (R-250 Fluka, 
UK), 45% methanol, 45% acetic acid) and then destained in 20% methanol, 7% acetic 
acid solution. Semi-quantitation of differences in band intensities weas measured by 
densitometry using a Bio-Rad GS-710 calibrated imaging densitometer (Bio-Rad, 
UK).
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2.2.12 Protein Sequencing
Immunoprecipitations using 1 x 109 cells were performed as described in section 2.3.7 
with an additional step. A preclean step was performed: aminolink coupling gel 
aione, not bound to any antibody was mixed with the cell lysate for an hour. For 1 x 
109 cells, approximately 15 pg of antibody was used for the immunoprecipitation. 
Proteins were separated on a 4-20% gradient SDS-PAGE (Novex, UK) and stained 
with Colloidal Blue (Novex, UK) following the manufacturer’s instructions. 
Sequencing was carried out by the Cell Map Incubator Project group 
(GlaxoSmithKline, UK) with equipment using tandem on line mass spectrometry 
techniques (Bio-Rad, UK).
2.2.13 Intracellular cAMP measurement
1 x 105 cells were stimulated in the presence, or absence of 0.05 mM forskolin for 7 
minutes (following (Kvanta et al., 1990) material and methods). After each treatment, 
cells were incubated for 2 minutes with anti-mouse IgG (lOpg/ml final concentration) 
followed by the addition of anti-CD3 (lOpg/ml final concentration) and incubated for 
1 minute at 37°C. cAMP measurements were done using a cAMP enzyme 
immunoassay* (EIA) system (Amersham Pharmacia Biotech, UK) following the 
manufacturer’s instructions.
2.3 Cell biology
2.3.1 Cell lines
The Jurkat T E6-1 cell line (A.T.C.C.) was maintained in RPMI 1640 medium (Life 
Technologies, UK) supplemented with 10% heat inactivated fetal calf serum, 2 mM 
L-glutamine, 100 IU/ml penicillin and 100 mg/ml streptomycin (Life Technologies, 
UK). Stable cell lines containing cmyc-LCPTP were maintained in the same medium 
supplemented with 1 mg/ml geneticin (Sigma, UK). Fibroblast lines HEK293 and 
HER911 (A.T.C.C.) were maintained in DMEM medium (Life Technologies, UK) 
supplemented with 10% heat inactivated fetal calf serum, 2 mM L-glutamine, 100 
IU/ml penicillin and 100 mg/ml streptomycin (Life Technologies, UK).
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2.3.2 Cell count
Viable cell counts were obtained using Trypan blue (Gibco-BRL, UK) exclusion to 
discriminate between live and dead cells. Cells were counted using a 
hematocytometer.
2.3.3 Transient transfections
2 x 107 Jurkat cells were resuspended in 0.3 ml RPMI 1640 medium (Life 
Technologies, UK), supplemented with 10% heat inactivated fetal calf serum, 2 mM 
L-glutamine, 100 IU/ml penicillin and 100 pg/ml streptomycin (Life Technologies, 
UK), in 0.4 cm electrocuvette (Bio-Rad, UK) and incubated with 30 pg of vector 
pcDNA 3.1 (Invitrogen, UK) containing cmyc tag or plasmids pcDNA 3.1 cmyc- 
LCPTP WT or pcDNA 3.1 cmyc-LCPTP C291S-D257A for 5 min. Cells were 
electroporated at 260 V, 960 pF, oo Ohms (Bio-Rad Gene Pulser, UK), washed, 
resuspended in complete RPMI medium and incubated at 37°C. 48 hours post­
transfection, LCPTP immunoprecipitations were carried out.
2.3.4 Establishment of stable cell lines
The same protocol as that used for the transient transfections (section 2.3.3) was 
followed with the exception that 48 hours post-transfection, the medium was replaced 
with selective medium (RPMI 1640 supplemented with 10% heat inactivated fetal calf 
serum, 2 mM L-glutamine, 100 IU/ml penicillin, 100 pg/ml streptomycin and 2 pg/ml 
gentamycin (Sigma, UK). Cells surviving gentamicin selection were cloned by 
limiting dilution in round bottomed 96 well plates (Costar, UK).
2.4 Cellular Immunology
2.4.1 Preparation of human CD4+ cells
Defibrinated blood was obtained from healthy human volunteers and PBMC 
(peripheral blood mononuclear cells) were isolated by density centrifugation using 
Lymphoprep (Life Technologies, Scotland). CD4+ T cells were prepared by 
immunomagnetic negative selection as follows. Cells were incubated with saturating 
concentrations of anti-CD 14, anti-DR, anti-CD20, anti-CD8 and anti-CD56 antibodies 
(Becton Dickinson, UK) for 30 min at room temperature. Cells were washed twice 
and sheep anti-mouse IgG and anti-human CD8-coated Dynal beads (Dynal, Norway)
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were added, mixed and incubated with cells for 15 min at room temperature. Cells 
were then incubated with a Dynal magnet and unbound cells harvested and counted. 
The CD4+ were expanded by stimulation with anti-CD3 (clone OKT3, A.T.C.C.) and 
anti-CD28 (clone 9.3, provided by Neil Burden, GlaxoSmithKline, UK) coated on 
plates at (1 ug/ml and 10 ug/ml respectively) and cultured in medium RPMI 1640 
(Life Technologies, UK) supplemented with 10% fetal calf serum, 2 mM L- 
glutamine, 100 IU/ml penicillin and 100 mg/ml streptomycin (Life Technologies, 
UK), containing 10 ng/ml purified recombinant IL-2 (GSK, UK).
2.4.2 Preparation of Thl and Th2 CD4+ subsets
Studies using murine T cells were done from cells isolated from the CAR-1 transgenic 
mouse strain which expresses the CAR-1 receptor on all cells, kindly provided by Dr 
James De Gregori (Leon et al., 1998). The CAR-1 transgenic mice have been bred 
with DO11.10 mice to produce the double transgenic CAR-l-DOl 1.10 mice. 
DO11.10 mice are T cell receptor transgenic having a TCR specific to ovalbumin 
(amino acids 323-339) (Murphy et al., 1990). Naive CD4+ T cells were purified using 
mouse CD4+ subset small enrichment columns (R & D Systems, UK) following the 
manufacturer’s instructions. Cells were subsequently differentiated into Thl or Th2 
type cells by culturing the cells in the presence of IAd and ICAM transfected human 
fibroblasts, which express endogenous B7.1 and B7.2. Ovalbumin peptide 
corresponding to amino acid residues 323-339 was added at 1 pM final concentration. 
For Thl cells, the medium was supplemented with anti-IL4 antibody at 5 pg/ml and 
IL-12 at 10 ng/ml final concentration. For Th2 cells, the medium was supplemented 
with anti-IL-12 antibody at 5 pg/ml, anti-IFNy at 1 pg/ml and IL-4 at 10 ng/ml final 
concentration (R & D Systems, UK). The medium for both subsets was supplemented 
with IL-2 at a final concentration of 20 ng/ml (human recombinant IL-2, 
GlaxoSmithKline, UK). Cells were harvested at day 6 for infection with adenovirus 
constructs.
2.4.3 Naive, Thl and Th2 murine cell infection with adenovirus
Cells were washed in serum free DMEM and resuspended at 1 x 107 cells/ml in serum 
free DMEM. Cells were aliquoted in 15 ml falcon tubes in 0.1 ml volumes and 0.1 ml 
virus diluted in DMEM was added to give a m.o.i. of 10. Cells were mixed with virus
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by pipetting and incubated at 37°C for 1-2 hours. Cells were washed and centrifuged 
at 1200 rpm for 5 min at 20°C. Cells were resuspended at a concentration of 1 x 106 
cells/ml in complete culture medium (RPMI 1640, L-Glu/Pen/Strep/FCS/2-|3- 
mercaptoethanol) containing 10 pg/ml IL-2 and plated in 24 well plates. Cells were 
incubated for 24 hours, washed and counted before using in experiments.
2.4.4 ELISA -  Measurement of human IL-2
Jurkat T cells were activated in flat bottomed 96 well plates coated with 1 pg/ml of 
mouse monoclonal anti-CD3 antibody (clone OKT3 A.T.C.C.) and 3 pg/ml of mouse 
monoclonal anti-CD28 antibody (clone 9.3, GlaxoSmithKline, UK). Cells were 
added at 5 x 105 cells per well in 200 pi volume, in RPMI 1640 supplemented with 
10% heat inactivated fetal calf serum, 2 mM L-glutamine, 100 IU/ml penicillin, 100 
mg/ml streptomycin. Supernatants from triplicate wells were taken at 24 hours and 
pooled. IL-2 production was measured by ELISA. ELISA plates (Nunc, UK) were 
coated overnight at 4°C, with anti-human IL-2 (Pharmingen, UK) at 2 pg/ml, diluted 
in PBS. Plates were subsequently blocked with 2% BSA (A-7030, Sigma, UK) 
diluted in PBS. Dilutions of recombinant human IL-2 standard (GlaxoSmithKline, 
UK) were added in triplicate and culture supernatants were added to the wells in 
duplicate. After incubation, plates were washed and anti-human IL-2 biotinylated 
antibody (Pharmingen, UK) was added at 1 pg/ml per well, diluted in blocking buffer. 
After incubation, wells were washed and HRP-conjugated streptavidin (Caltag, UK) 
was added at a dilution of 1:2000, in blocking buffer. Plates were incubated, washed 
and 3,3’,5,5’-tetramethylbenzidine (TMB) substrate Sigma, UK) was added to wells. 
Reactions were stopped with 0.2 M sulphuric acid (BDH, UK) and read at absorbance 
450nm using a Spectramax ELISA plate reader with Softmax Pro 3.2.1 software 
(Molecular Devices, UK).
2.4.5 ELISA -  Measurement of murine IL-2, IL-4, IL-5, IL-13 and IFN-y
Mouse IL-2, IL-4, IL-5 (Pharmingen, UK), IL-13 (R&D, UK) and IFN-y 
(Pharmingen, UK) were measured from culture supernatants using paired capture and 
detection antibodies and recombinant protein standard following the manufacturer’s 
instructions.
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2.4.6 Human T cell proliferation assay
Flat bottomed 96 well plates were coated with 0.3 pg/ml of mouse monoclonal anti- 
CD3 antibody (clone OKT3) and 1 pg/ml of mouse monoclonal anti-CD28 antibody 
(clone 9.3). Cells were added at 2 x 104 cells per well in 200 pi volume, in RPMI 
1640 supplemented with 10% heat inactivated foetal calf serum, 2 mM L-glutamine, 
100 IU/ml penicillin, 100 mg/ml streptomycin. Plates were incubated for 24, 48, 72 
and 96 hours at 37°C, 5% C 02. 1 pCi/well 3H thymidine (Amersham, UK) was added 
for the final 4 hours of culture. Plates were harvested on printed filtermats A (Wallac, 
Finland) using a semi-automatic Skatron cell harvester (Wallac, Finland). Filters 
were read using a Betaplate liquid scintillation counter (Wallac, Finland) and data 
generated in counts per minute (cpm). The mean value for triplicate wells was 
calculated. Results are expressed as a percentage of the non activated control sample 
(100%). For one set of experiments, IL-2 was added to the medium at a final 
concentration of 100 ng/ml.
2.4.7 Mouse proliferation assay
Proliferation was performed as described in section 2.4.6 with the following 
modifications: activating antibody: 1 pg/ml hamster anti-mouse CD3 (clone 2C11, 
Pharmingen, UK), 1 pg/ml hamster anti-mouse CD28 (Pharmingen, UK), 1 x 105 
cells per well.
2.4.8 Extracellular marker staining
Jurkat T cells were activated in 24 well plates coated with 1 pg/ml of mouse 
monoclonal anti-CD3 antibody (clone OKT3) and 3 pg/ml of mouse monoclonal anti- 
CD28 antibody (clone 9.3). Cells were added at 5 x 105 cells per well in 2 ml volume, 
in RPMI 1640 medium supplemented with 10% heat inactivated fetal calf serum, 2 
mM L-glutamine, 100 IU/ml penicillin, 100 pg/ml streptomycin. Cells were 
recovered at 72 hrs and washed in FACS buffer (2.5% fetal calf serum, 0.05% sodium 
azide in PBS). Anti-CD3, anti-CD28, anti-CD69 and anti-CD25 antibodies 
conjugated to FITC or PE (Becton Dickinson, UK) were added to the cells and 
incubated at 4°C for 30 min. Cells were washed and resuspended in FACS buffer. 
Data was acquired using a Becton-Dickinson FacScan with WinScan software and 
analysed using Expo32 software.
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2.4.9 Intracellular cytokine staining
2 x 106 CAR-1 Thl or Th2 cells were gently pelleted with 0.5 x 106 DAP3.ICAM 
APCs expressing IAd’B7.1 and B7.2 and 10 pM ovalbumin peptide and incubated for 
2 hours at 37°C. 10 pg/ml 2 pM Monensin was added and cells incubated for a 
further 2 hours at 37°C. Cells were centrifuged at 1200 rpm for 5 minutes and 
washed in PBS/2.5% FCS/0.5% sodium azide. Cells were washed and divided into 5 
x 105 aliquots and then fixed with 100 pi Fixation reagent (Caltag, UK) for 15 
minutes at room temperature. Cells were washed in FACS buffer and permeabilised 
with 100 pi Permeabilisation reagent (Caltag, UK) added together with the 
appropriate PE or FITC labelled anti-cytokine antibody (Pharmingen, UK). Staining 
for IL-2, IL-4 and IFN-y was used to assess the polarisation of cells to a Thl or a Th2 
phenotype. Cells were incubated with antibody for 15 minutes at room temperature, 
washed and resuspended in FACS buffer. Data was acquired using a Becton- 
Dickinson FacScan with WinScan software and analysed using Expo32 software.
2.4.10 Photomicrography of cells
Jurkat T cells were cultured in 24 well plates and photographs were taken at days 1 
and 3 following the addition of different stimuli. Cells were visualised using a Nikon 
Eclipse TS100 microscope (Nikon, UK) with 4x or lOx magnification. Photographs 
were taken using a Digital Camera Coolpix995 (Nikon, UK). Stable cell lines were 
stimulated with anti-CD28 (clone 9.3) added either in solution or coated onto plates at 
a final concentration of 10 pg/ml; anti-CD 18 (GlaxoSmithKline, UK) was added in 
solution at a final concentration of 10 pg/ml; EDTA (Sigma, UK) was added in 
solution at a final concentration of 4mM.
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CHAPTER THREE: RESULTS 
PROTEIN INTERACTIONS OF LCPTP IN JURKAT T CELLS AND HUMAN
PERIPHERAL CD4+ T CELLS
3.1 Introduction
Previous studies looking at the role of LCPTP in cell signalling have all used 
systems in which recombinant LCPTP was overexpressed at levels much higher than 
those found normally in cells (Oh-hora et al., 1999); (Saxena et al., 1999a). This 
approach does have limitations as seen in the study of Bailyes, in which recombinant 
prohormone convertase PC2 and the endogenous rat hormone have the same substrate 
specificity but their pH and calcium sensitivities are different (Bailyes et al., 1995). 
Also, if a protein is overexpressed in a cell, it is possible that it could form 
associations which are not physiologically relevant. For example, the cytoplasmic 
protein, hsp70 which when overexpressed in cells, goes into the nucleus and interacts 
with a nuclear protein (Personal communication, Dr. Jean-Yves Masson).
LCPTP has been shown in overexpression systems to constitutively form 
associations with members of the MAP kinase family (Oh-hora et al., 1999); (Saxena 
et al., 1999a). In order to address the physiological significance of the interaction 
reported with overexpressed LCPTP protein, experiments presented in this chapter 
examined protein associations of endogenous LCPTP, rather than transfected 
recombinant protein.
MAP kinase family members are found widely distributed in different cell 
types (Keyse, 1998); (Roovers and Assoian, 2000); (Chang and Karin, 2001) 
including T cells (Keyse, 1998); (Saxena and Mustelin, 2000); (Rincon et al., 2000). 
However, the distribution of LCPTP appears to be restricted to cells of hematopoietic 
origin (Zanke et al., 1992); (Adachi et al., 1992b). The Jurkat T cell line was thus 
chosen as a suitable model system in which to study the interactions of endogenous 
LCPTP in cells stimulated via the T cell receptor. Jurkats were used in the 1980s to 
produce and purify IL-2 (Smith, 1988). Since then, Jurkat cell lines, have been used 
extensively as a model system for studying TCR signal transduction (Landegren et al., 
1985); (Astoul et al., 2001). Consequently, the function of many molecules has been 
characterised, including protein tyrosine kinases, protein tyrosine phosphatases and
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adapter proteins using Jurkats (Peterson et al., 1998); (van Leeuwe and Samelson, 
1999)(Lin and Weiss, 2001). The use of Jurkat T cell lines as a good model system 
for examining T cell signalling pathways has been justified by studies in primary T 
cells where similar functions were attributed for most of the molecules looked at 
(Astoul et al., 2001).
The Jurkat T cell line available in the laboratory, namely JE6 (American Type 
Culture Collection), expresses high levels of endogenous LCPTP. In addition, the 
JE6 Jurkat T cell line expresses a functional T cell receptor and the costimulatory 
molecule, CD28. Previous studies looking at the role of LCPTP in signalling 
pathways have used pervanadate to induce phosphorylation of multiple cell proteins, 
via inactivation of endogenous phosphatases (Pettiford and Herbst, 2000). In order to 
use a more physiologically relevant stimulus and also in order to allow study of 
interactions with endogenous LCPTP without interference by pervanadate, which 
modifies irreversibly the catalytic sulfhydryl group at the active site on the 
phosphatase (Huyer et al., 1997), cells were activated via antibody to the TCR CD3 
molecule.
To date, reported substrates of LCPTP include ERK2 and p38 (Oh-hora et al., 
1999); (Saxena et al., 1999a); (Pettiford and Herbst, 2000). Therefore, in attempts to 
further elucidate the role of LCPTP in T cell signalling, experiments were designed to 
identify other potential substrates of LCPTP. These experiments made use of a 
recombinant LCPTP mutant protein which can bind irreversibly to its substrate (Flint 
et al., 1997) and thus enable isolation of LCPTP with potential substrates and their 
subsequent identification using Western blotting or protein sequencing techniques.
Jurkat T cells, as mentioned, provide a good system for examining signalling 
pathways, but nonetheless, they represent a transformed cell line. This means that 
any conclusions drawn must be interpreted with a cautionary note regarding the 
relevance of what happens in Jurkat cells compared to primary T cells. Experiments 
performed in Jurkat T cells were repeated in CD4+ T cells derived from peripheral 
blood in order to further validate the results obtained in a more physiologically 
relevant cell type.
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3.2. Results
3.2.1 Time course to determine the point of maximal tyrosine 
phosphorylation in Jurkat T cells
In order to start looking at interactions of LCPTP with other proteins, studies 
were carried out to select the optimal conditions for Jurkat T cell activation, as 
measured by an increase in tyrosine phosphorylation in response to TCR ligation. 
Maximal substrate phosphorylation is desirable with the view to maximise the amount 
of substrate available for the phosphatase to bind to its substrate. Different 
concentrations of crosslinking anti-mouse IgG and mouse anti-CD3 (OKT3) 
antibodies were tested. Anti-CD3 binds to the TCR associated molecule CD3 and is 
in turn bound by the anti-mouse IgG causing TCR clustering which has been shown 
to be necessary to drive T cell signalling pathways leading to transcription of IL-2 
(Lanzavecchia, 1997). This is illustrated in Figure 3.1.
/ \A A
A
Anti-CD3 (OKT3)
TCR TCR
+ OKT3CR
/  e y b  e Y 0 e y 6 £Y6
TCR TCR TCR TCR
Signalling
Figure 3.1: TCR clustering initiated by anti-CD3 antibody binding and
secondary crosslinking with anti-mouse IgG.
The anti-CD3 antibody binds to the extracellular domain of CD3 molecules. Anti­
mouse IgG binds to the mouse anti-CD3 antibody and effectively crosslinks the 
primary antibody, leading to TCR aggregation. This mimics the binding of peptide 
presented by an MHC class II molecule on an APC binding to the TCR, the clustering
62
CHAPTER THREE
of TCRs at the point of contact with an APC and the activation of TCR associated 
kinases, initiating TCR signalling pathways.
Different concentrations of anti-mouse IgG ranging from 1 ,3  10, 30 pg/ml 
and the same concentrations for anti-CD3 (1, 3 10, 30 pg/ml) were tested for their 
ability to give maximal protein tyrosine phosphorylation as determined by SDS- 
PAGE and Western blotting using an anti-phosphotyrosine monoclonal antibody 
(Clone 4G10). An optimal concentration of 10 pg/ml for both antibodies was used in 
all following signalling experiments (Data not shown). In order to determine the 
optimal time of activation to achieve maximal tyrosine phosphorylation, a time course 
was done. The time course shows a rapid rise in protein tyrosine phosphorylation 
peaking at 1 min (Figure 3.2A, lanes 1 to 5) and a gradual reduction of tyrosine 
phosphorylation after this time point (Figure 3.2A, lanes 5 to 10). To demonstrate 
equal protein loading, the gel was stained with Coomassie blue (Figure 3.2B). 
Resting and cells activated maximally for 1 minute (corresponding to the peak of 
protein phosphorylation) were used for subsequent immunoprecipitation experiments.
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Figure 3.2. Phosphotyrosine blot of time course of anti-CD3 antibody stimulated 
Jurkat T cells.
A. Phosphotyrosine blot of cell lysates at different times. B. Coomassie blue staining 
showing equivalent protein loading. Lanes 1 to 10 represent activation times o f 0, 
0.25, 0.5, 0.75, 1, 2, 5, 10, 20 and 30 minutes at 37°C, respectively. Each lane is the 
equivalent o f  1 x 105 cells. The data shown are representative o f  4 separate 
experiments.
3.2.3 Endogenous LCPTP immunoprecipitations in Jurkat T cells
It has been reported in the literature, that overexpressed LCPTP binds 
constitutively to MAP kinases (Oh-hora et al., 1999); (Saxena et al., 1999a). In order 
to determine whether the MAP kinases could be shown to constitutively associate 
with endogenous LCPTP, Jurkat T cells were activated for 1 minute with anti-CD3
0s 15s 30s 4 5 s 1’ 2 ’ 5 ’  10’ 2 0 ’ 3 0 ’
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antibody, cells were lysed and LCPTP complexes were isolated using a rabbit 
polyclonal anti-LCPTP antibody. Following protein separation by SDS-PAGE, 
Western blots were performed and probed with antibodies raised against ERK1, 
ERK2 and p38. As shown in Figure 3.3A, ERK1 was not detected in LCPTP 
immunoprecipitates (lanes 1 and 2), but was seen in the total cell lysate control (lane 
6), containing 100 times less total protein than the IPs. A similar pattern was seen 
when LCPTP IPs were probed for ERK2 protein and p38 (Figure 3.3B and 3.3C, 
respectively, lane 6). Some p38 was detected binding non-specifically to coupling gel 
(Figure 3.3C, lane 4). In order to confirm the presence of LCPTP in the 
immunoprecipitates, membranes were stripped and reprobed for the presence of 
LCPTP. Figure 3.3D shows one representative example. LCPTP was brought down 
by the coupled antibody and the amount was enriched in the immunoprecipitation 
compared to the total lysate (Figure 3.3D, lanes 1 and 2 and 6); LCPTP did not 
interact non-specifically with the coupling gel (lanes 3 and 4) and could be detected in 
the cell lysate (lane 6).
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Figure 3.3. LCPTP immunoprecipitates from Ju rkat T cells do not contain 
ERK1, ERK2 or p38.
LCPTP antibody immunoprecipitated complexes from Jurkat T cells were blotted for 
A. ERK1; B. ERK2; C. p38; D. LCPTP. Cell equivalents corresponding to 1 x 108 
cells for Jurkat T cells were immunoprecipitated with rabbit antisera raised against 
LCPTP protein from either unstimulated or anti-CD3 antibody-stimulated Jurkat T 
cells. Figures A, B, C, D: lane 1- LCPTP immunoprecipitations non-activated. Lane 
2- LCPTP immunoprecipitations activated 1 min with anti-CD3 antibody. Lanes 3, 4
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and 5 represent controls for non-specific binding and lane 6, soluble cell lysate 
equivalent to 1 x 106 cells.
3.2.4 Microsequencing of LCPTP IPs in Jurkat T cells
The presence of LCPTP in immunoprecipitations was confirmed by 
microsequencing using tandem on line mass spectrometry. LCPTP 
immunoprecipitations were done using 1 x 109 cells per IP and proteins separated by 
4-20% gradient SDS-PAGE. Only one band was visualised which was specific for 
LCPTP IPs, with or without anti-CD3 activation (Figure 3.4A, lanes 1 and 2) and this 
band was excised and processed for mass spectrometry protein sequencing. Results 
obtained confirmed the presence of LCPTP (Table 3.1 A and B) and demonstrated the 
specificity of the rabbit polyclonal anti sera used for immunoprecipitations. A number 
of peptides from B-amyloid precursor protein (Table 3.IB) were also present in the 
band excised. This was due to contamination during the preparation of the sample by 
the Cell Map Incubator Project Group (Personal communication, Malcolm Ward). No 
peptides corresponding to MAP kinase family members were detected even though 
ERK1 migrates on SDS-PAGE at the same molecular weight as LCPTP. A number 
of other proteins identified in the excised band were deemed to be nonspecific 
contaminants (see Table 3.1 A and B), as these proteins are commonly seen in other 
non related samples analysed by the Cell Map Incubator (Cell Map Incubator, 
personal communication).
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Figure 3.4: Microsequencing of band in LCPTP IPs.
Colloidal blue staining of LCPTP immunoprecipitations using 1 x 109 cells/IP. Cell 
equivalents corresponding to 1 x 109 cells were immunoprecipitated with rabbit 
an tisera raised against G ST -LC PTP fusion  pro tein . Lane 1- LC PTP 
immunoprecipitations non-activated. Lane 2- LCPTP immunoprecipitations activated 
1 min with anti-CD3 antibody. Lane 3 represents control for non specific binding and 
lane 4 is soluble cell lysate equivalent to 1 x 106 cells. The data shown are 
representative of two separate experiments.
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Sample 1: LCPTP IP non activated
Protein identification Peptides matches
Human keratin, type II cytoskeletal 1 34
Human keratin, type I cytoskeletal 9 19
Protein-tyrosine phosphatase LCPTP 19
Bovin trypsinogen, cationic precursor 44
Human keratin, type I cytoskeletal 10 8
AS 1-casein 2
Sample 2: LCPTP IP activated 1 min with anti-CD3
Protein identification Peptides matches
Amyloid B-protein precursor 43
Protein-tyrosine phosphatase LCPTP 18
Bovin trypsinogen cationic precursor 47
Human PTB-associated splicing factor 6
Human keratin, type II cytoskeletal I 4
IG kappa chain I (fragment) 1
KIAA1482 protein (fragment) 1
Signal peptidase I 1
Table 3.1: Identification of proteins by mass spectrometry sequence analysis.
Bands excised from the gel, were trypsinised and then applied to tandem on line mass 
spectrometry analysis. Proteins were identified by sequence homology using 
GenBank database. M icrosequencing of non-activated sample (sample 1) and 
Microsequencing of activated sample with anti-CD3 (sample 2).
3.2.5 Endogenous MAPK immunoprecipitations in Jurkat T cells
One possible explanation for the inability to demonstrate any constitutive 
interaction between endogenous LCPTP and members of the MAP kinase family was 
that the rabbit polyclonal anti-LCPTP antibody used for immunoprecipitations was 
in te rfe rin g  w ith L C PT P-M A PK  in te rac tio n s . T h e re fo re , rev e rse
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immunoprecipitations were carried out using antibodies to the different members of 
the MAP kinase family to immunoprecipitate putative MAPK-LCPTP complexes. 
LCPTP was not detected in MAPK immunoprecipitations (Figure 3.5A, lane 1-6), or 
control precipitations (Figure 3.5A, lane 7 and 8), but was seen in the total cell lysate 
(Figure 3.5A, lane 10), containing 100 times less protein than the IPs. To confirm the 
presence of appropriate kinases in the immunoprecipitations, the membranes were 
stripped and reprobed for the presence of ERK1, ERK2 and p38 protein. Figure 3.5B 
shows the presence of each MAPK fam ily m em ber in the appropriate 
immunoprecipitation and in the total cell lysate (Figure 3.5B, lane 1-6 and 10) but not 
in control precipitations (Figure 3.5B, lane 7 and 8).
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Figure 3.5: Endogenous MAPK immunoprecipitations
A. LCPTP blot of MAPK immunoprecipitates. B. MAPK blot of MAPK IPs. Cell 
equ ivalen ts corresponding  to 1 x 108 cells were im m unoprecipitated . 
Immunocomplexes were isolated using monoclonal mouse antisera raised against 
ERK1, ERK2 or p38 protein/Protein A Sepharose in unstimulated, or anti-CD3 
antibody-stimulated Jurkat T cells. Lane 1- ERK1 im munoprecipitations non­
activated. Lane 2- ERK1 immunoprecipitations activated 1 min with anti-CD3 
antibody. Lane 3 -  ERK2 immunoprecipitations non-activated. Lane 4- ERK2 
im m unoprecipitations activated 1 min with anti-CD3 antibody. Lane 5- p38 
immunoprecipitations non-activated. Lane 6- p38 immunoprecipitations activated 1
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min with anti-CD3 antibody. Lanes 7, 8 and 9 represent controls for non specific 
staining/binding. Lane 10 - Cell lysate equivalent to 1 x 106 cells.
3.2.6 Intracellular cAMP measurement in Jurkat T cells
Previous studies have suggested that cAMP may regulate LCPTP interactions 
and that increased levels resulted in the dissociation of MAP kinase and LCPTP 
complexes (Saxena et al., 1999b). High levels of cAMP in Jurkat T cells could 
therefore explain why we cannot demonstrate the interaction between endogenous 
LCPTP and MAP kinases. To address whether Jurkat T cells have elevated cAMP 
levels thus favouring release of LCPTP from MAP kinase complexes, the levels of 
cAM P in non activated and anti-CD3 stimulated cells were measured. As a positive 
control, cells were activated in the presence or absence of forskolin which induces 
raised cAM P levels (Kvanta et al., 1990). There was a five fold increase in the 
concentration of cAM P in cells activated with anti-CD3 antibody for 1 minute 
compared to resting cells. In contrast, cAMP levels were increased 10 000 fold after 
forskolin stimulation. PKA activity was not measured and so it was not possible to 
confirm whether the levels of cAMP detected, albeit very small would still be sufficient 
to activate PKA and phosphorylate LCPTP
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Figure 3.6: Intracellular cAMP measurement in Jurkat T cell
A. Intracellular cAMP from cells was measured: Unstimulated cells (blue bars) and 
cells activated 1 min with anti-CD3 antibody (pink bars). cAMP levels are compared 
between unstimulated (left) or cells stimulated (right) with 0.05 mM forskolin. The 
amount of cAMP is measured in fmol and the results are the mean of two 
experiments.
In tracellu lar cAMP in Ju rk a t T cell
9960  11150 ,9
□  non activated  
ac tivated  1 min anti-CD 3
non stimulated stimulated with 0.05 mM forskolin
C ell t r e a tm e n t
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3.2.7 Bulk-up of endogenous LCPTP immunoprecipitations in Jurkat T 
cells
In a final attempt to show an interaction between endogenous LCPTP with 
ERK by Western blotting, lysates equivalent to 5 x 108 cells from both resting and 1 
min anti-CD3 antibody activated samples were used. LCPTP immunoprecipitations 
were probed by Western blotting for the presence of ERK1 protein. Figure 3.7A 
shows the faint presence of ERK1 in LCPTP immunoprecipitations (lanes 1 and 2), 
but the level detected is much lower than compared to the cell lysate control (lane 4) 
which contains 500 times less protein than the immunoprecipitates. The presence of 
LCPTP in the same immunoprecipitations is clearly detectable (Figure 3.7B lanes 1 
and 2) and is much higher than what is found in the lysate control. In order to look 
for other potential substrates or associating proteins for LCPTP, the bulk-up 
immunoprecipitations were probed with a phosphotyrosine antibody (Figure 3.7C). 
No phosphotyrosine proteins were detected by probing blots with the 4G10 anti- 
phospho tyrosine antibody coprecipitating with LCPTP.
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Figure 3.7: Detection of ERK1 and phosphotyrosine proteins in LCPTP
immunoprecipitations using 5 x 108 cells.
Cell equivalents corresponding to 5 x 108 cells were immunoprecipitated with rabbit 
antisera raised against LCPTP protein in either unstimulated or anti-CD3 antibody- 
stimulated Jurkat T cells. Lane 1- LCPTP immunoprecipitations non-activated. Lane 
2- LCPTP immunoprecipitations activated 1 min with anti-CD3 antibody. Lane 3 
represents a control for non specific binding and lane 4 is soluble cell lysate
equivalent to 5 x 106 cells. Membrane probed with A. ERK1 antibody; B. LCPTP
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antibody; C. anti-phosphotyrosine 4G10 antibody. The data shown are representative 
of two separate experiments.
3.2.8 Immunoprecipitations of overexpressed LCPTP in Jurkat T cells
In order to ascertain that the conditions we used could maintain proteinrprotein 
interactions, we repeated the experiments published in the literature in which LCPTP 
was overexpressed in cells. Jurkat T cells were transiently transfected with cmyc, 
cmyc-LCPTP WT or cmyc-LCPTP substrate-trap mutant proteins. Unstimulated cells 
and cells activated for 1 minute by CD3 ligation were used for LCPTP 
immunoprecipitations. Immunoprecipitations were probed for the presence of the 
MAP kinase ERK1. ERK1 was not brought down when only the myc tag protein was 
overexpressed (Figure 3.8 lanes 1 and 2) but interacted constitutively with both 
LCPTP wild-type and substrate-trap proteins (Figure 3.8 lanes 3 to 6).
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Figure 3.8. ERK1 is found in immunoprecipitates of overexpressed LCPTP. 
LCPTP immunoprecipitates were blotted for A. ERK1; B. LCPTP. Cell equivalents 
corresponding to 1 x 107 cells were immunoprecipitated with rabbit antisera raised 
against LCPTP protein in either unstimulated or anti-CD3 antibody stimulated Jurkat 
T cells. Lanes 1 and 2- cells overexpressing cmyc tag. Lanes 3 and 4- cells 
overexpressing cmyc-LCPTP wild-type. Lanes 5 and 6- cells overexpressing cmyc- 
LCPTP substrate-trap protein (DBL). Lanes 1, 3 and 5- LCPTP immunoprecipitations 
non-activated. Lanes 2, 4 and 6- LCPTP immunoprecipitations activated 1 min with 
anti-CD3 antibody. Lane 7 represents soluble cell lysate equivalent to 1 x 105 cells. 
The data shown are representative of two separate experiments.
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3.2.9 GST-LCPTP substrate-trap (C291S, D257A) pull-downs in Jurkat T 
cells
To further confirm that the lysis and immunoprecipitation conditions used, 
preserved protein complexes, we looked for the presence of MAPK proteins in GST 
pull-down assays from Jurkat T cells, using a GST-LCPTP fusion substrate-trap 
protein (C291S, D257A). Pull-down complexes were separated by SDS-PAGE and 
Western blotted using monoclonal ERK1, ERK2 and p38 antibodies. As shown in 
Figure 3.9A, lanes 1 and 2, ERK1 did not interact constitutively with GST-LCPTP 
wild-type protein. When the GST-LCPTP substrate-trap protein was used to 
immunoprecipitate from cell lysates (Figure 3.9A, lanes 4 and 5), ERK1 was brought 
down from both the non-activated and anti-CD3 activated cell lysates. More ERK1 
was seen associating with the GST-LCPTP substrate-trap from lysate from activated 
cells compared to non-activated. ERK1 protein was not brought down by GST 
protein alone (lanes 7 and 8). ERK2 interacted constitutively with GST-LCPTP 
substrate-trap protein, but in contrast to ERK1, more ERK2 was captured from the 
non-activated lysate compared to the activated lysate (Figure 3.9B, lanes 4 and 5). 
The presence of p38 protein was also detected in pull-downs using GST-LCPTP 
substrate-trap protein but the amount appeared to be much less compared to that seen 
with ERK1 and ERK2 (Figure 3.9C, lanes 4 and 5). Similarly to ERK2, more p38 
bound to the phosphatase-trap when the cells were not activated. A phosphotyrosine 
protein blot revealed that there was an increase in the phosphorylation state of the 
MAPK family members following CD3 activation of cells from a basal 
phosphorylation state (Figure 3.9D, lanes 4 and 5).
In order to semi-quantitate the data obtained looking at LCPTP-MAPK 
interactions, protein bands were scanned using a densitometer. Changes in the 
association of LCPTP with the different MAPK family members, dependent on the 
state of cell activation and cell phenotype are represented graphically in Figure 3.9E. 
The lysate for each blot was used as a reference and given an arbitrary number of one. 
This enabled a comparison of the densitometric figures obtained from bands from 
immunoprecipitated samples relative to the reference.
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Figure 3.9: ERK1, ERK2 and p38 associate with a recombinant GST-LCPTP 
substrate-trap protein in Jurkat T cells
GST fusion protein pull-downs in Jurkat T cells blotted for A. ERK1; B. ERK2; C. 
p38 and D. Phosphotyrosine (4G10). Graph representing the intensity of each band
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probed for a particular member of the MAPK family measured by densitometry 
compared to the lysate control in E. Unstimulated or anti-CD3 antibody-stimulated 
Jurkat T cells corresponding to 1 x 108 cells were used in pull-down experiments 
using recombinant GST-LCPTP wild-type, substrate-trap (C291S, D257A) and GST 
proteins. GST fusion proteins in the absence of lysates were also run to control for 
non-specific protein binding. Figures A, B, C and D: lane: 1- GST-LCPTP wild-type 
protein pull-downs non-activated. 2- GST-LCPTP wild-type protein pull-downs 
activated 1 min with anti-CD3 antibody. 3- Control: recombinant GST-LCPTP 
wild-type protein. 4- GST-LCPTP substrate-trap protein (C291S, D257A) pull- 
downs from non-activated cells. 5- GST-LCPTP substrate-trap protein (C291S, 
D257A) pull-downs from cells activated 1 min with anti-CD3 antibody. 6- Control: 
recombinant GST-LCPTP substrate-trap protein (C291S D257A). 7- GST protein 
pull-downs from non-activated cells. 8- GST protein pull-downs from cells activated 
1 min with anti-CD3 antibody. 9- Control: recombinant GST protein. 10- Cell lysate 
equivalent to 1 x 106 cells. The data shown are representative of two separate 
experiments. Figure E: Non-activated samples (blue bars), activated samples (pink 
bars) and lysate control (cream bars).
3.2.10 ERK1 does not associate constitutively with endogenous LCPTP in
human peripheral CD4+ T cells
Having shown that MAP kinase family members can associate with LCPTP in 
Jurkat T cells, it was of interest to investigate whether interactions occur between 
LCPTP and MAP kinases in primary T cells. Experiments were performed to 
determine whether any constitutive interactions occur between ERK1 and endogenous 
LCPTP. ERK1 did not interact constitutively with endogenous LCPTP (Figure 
3.10A, lanes 1 and 2) although ERK1 could be detected in the lysate containing 100 
times less protein (lane 4). This result supported our findings in Jurkat T cells, 
confirming that with the experimental conditions used, LCPTP does not form 
constitutive interactions with ERK1. As in Jurkat T cells, we were able to show that 
LCPTP was brought down by the coupled LCPTP antibody from a primary human 
CD4+ T cell lysate (Figure 3.10B, lanes 1 and 2).
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Figure 3.10. LCPTP immunoprecipitates from human peripheral CD4+ T cells 
do not contain ERK1.
LCPTP complexes immunoprecipitated from peripheral CD4+cells were blotted for A. 
ERK1 and B. LCPTP. LCPTP protein was immunoprecipitated using rabbit antisera 
raised against LCPTP from 5 x 107 CD4+ T cells either unstimulated or stimulated 
with anti-CD3 antibody. Figures A and B: lane 1- LCPTP immunoprecipitations, 
non-activated. Lane 2- LCPTP immunoprecipitations, activated 1 min with anti-CD3 
antibody. Lane 3- antibody control and lane 4- lysate control. The data shown are 
representative of four separate experiments.
3.2.11 ERK1 and ERK2 from peripheral CD4+ T cells form transient
associations with LCPTP
Having determined that LCPTP and ERK1 do not associate constitutively in 
peripheral CD4+ T cells, experiments were performed to see if transient associations 
could be detected dependent on phosphatase activity, as shown to occur in Jurkat T 
cells. In contrast to what was seen in the Jurkat T cell line, both ERK1 and ERK2 
interacted more strongly with the phosphatase-trap in pull-downs from unactivated 
cell lysates compared to activated cell lysates (Figure 3 .1 1A and 3.1 IB, lanes 1 and 
2). In com parison to what was seen in Jurkat T cells, both in activated and 
unactivated cells, p38 interacted very weakly with the substrate-trap (Figure 3.11C, 
lanes 1 and 2). To semi-quantitate the data obtained, densitometry was performed on
79
CHAPTER THREE
each band. The graph in Figure 3.1 ID  shows the changes in the association of 
LCPTP with the different MAPK family members. The lysate for each blot was used 
as a reference and given an arbitrary number of one.
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Lvsate + + - + Lvsate + + - +
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Figure 3.11: ERK1, ERK2 and p38 associate differentially with a recombinant 
GST-LCPTP substrate-trap protein in peripheral CD4+ T cells dependent on the 
state of cell activation.
GST fusion protein pull-downs in peripheral CD4+ T cells blotted for A. ERK1; B. 
ERK2 and C. p38. D. Graph representing the intensity of each band probed for a 
particular member of the MAPK family measured by densitometry compared to the 
lysate control. Unstimulated or anti-CD3 antibody-stimulated peripheral CD4+ T cells 
corresponding to 5 x 107 cells were used in pull-down experiments with GST-LCPTP 
substrate-trap protein. GST fusion proteins in the absence of lysates were also run to 
control for non-specific protein binding. Figure A, B and C: lane 1- GST-LCPTP 
substrate-trap protein (C291S, D257A) pull-downs, non-activated. 2- GST-LCPTP
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substrate-trap protein (C291S, D257A) pull-downs, activated 1 min with anti-CD3 
antibody. 3- Control: recombinant GST-LCPTP substrate-trap protein (C291S 
D257A). 4- Cell lysate equivalent to 5 x 105 cells. The data shown are representative 
of three separate experiments. Figure D: non-activated samples (blue bars), activated 
samples (pink bars) and lysate control (cream bars).
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3.3. Discussion
Following recognition by the TCR of an antigenic peptide presented by MHC 
molecules, a cascade of signal transduction events occurs. The early stages of this 
cascade are represented by a dramatic but transient increase in the total protein 
tyrosine phosphorylation (Isakov et al., 1994); (Mustelin et al., 1998). The Jurkat T 
lymphocyte cell line, activated with an anti-CD3 antibody, has been used extensively 
as a model system for studying TCR signal transduction (Landegren et al., 1985). 
This provided us with a good model system for looking at LCPTP function, since 
Jurkat T cells express high levels of endogenous LCPTP. Studies were performed 
looking at time courses following cell stimulation in order to determine the point at 
which maximal tyrosine phosphorylation occurred in Jurkat T cells. Maximal total 
protein tyrosine phosphorylation occurred at one minute following anti-CD3 
stimulation and this time point was selected as the optimal time for studies looking for 
interactions of LCPTP with other proteins and potential substrates (Figure 3.2).
Previous studies have suggested a model in which members of the MAP 
kinase families (ERK1, ERK2 and p38) interact constitutively with recombinant 
LCPTP (Oh-hora et al., 1999); (Saxena et al., 1999a). Both wild-type LCPTP protein 
and an LCPTP substrate-trap (C200S) protein formed complexes with ERK1, ERK2 
and p38 (Model 1) (Oh-hora et al., 1999); (Saxena et al., 1999a). In our experiments, 
we endeavoured to demonstrate an association between endogenous LCPTP and 
members of the ERK and p38 MAP kinase families in order to support this model.
We were not able to demonstrate any constitutive interaction with endogenous
LCPTP and members of the ERK and p38 MAP kinase families in either Jurkat T
cells or in peripheral human CD4+ T cells (Figures 3.3 and 3.10). However, we were
able to show that LCPTP/MAP kinase interactions occurred when LCPTP was
overexpressed in cells (Figure 3.8) (Oh-hora et al., 1999); (Saxena et al., 1999a). We
concluded from this, that if a constitutive interaction occurs between endogenous
LCPTP and MAP kinase family members, only a very small percentage of total
LCPTP protein associates with MAP kinases. This could be demonstrated by
increasing the number of Jurkat T cells and performing immunoprecipitations (Figure
3.7). One explanation for the failure to detect the constitutive interaction of LCPTP
82
CHAPTER THREE
and MAP kinases reported previously, is that the LCPTP antibodies disrupt the 
association of LCPTP with other protein. This remains a possibility, but is thought to 
be unlikely as performing the reciprocal immunoprecipitations with antibodies to 
MAP kinase family members and probing for LCPTP also did not reveal any 
constitutive interaction between LCPTP and MAP kinases (Figure 3.5). Our data 
supports a second model proposed recently in which LCPTP interacts transiently with 
ERK2 (Model 2). This interaction could be seen only with a substrate-trap mutant 
form of LCPTP (C200S) (Pettiford and Herbst, 2000). In addition to ERK2, we 
propose that ERK1 is also an LCPTP substrate and forms a transient association with 
LCPTP. The intensity of interaction between the MAP kinases and the phosphatase- 
trap is dependent on the state of activation of the cells and the cell phenotype. Thus, 
there is an increased amount of ERK1 associating with LCPTP following anti-CD3 
cell activation in Jurkats. However, in peripheral CD4+ T cells, the situation is 
reversed, with less ERK1 associating with LCPTP following cell activation relative to 
the unstimulated cells. This discrepancy is likely to reflect the fact that Jurkat T cells 
are a transformed cell line compared to isolated resting peripheral CD4+ T cells 
(Figures 3.9 and 3.11). These results suggest that LCPTP has a role in 
dephosphorylating the MAP kinases ERK1 and ERK2 and maintaining the kinases in 
an inactive state in unstimulated CD4+ T cells.
The presence of LCPTP in anti-LCPTP immunoprecipitations has been 
demonstrated by Western blotting but to further confirm the presence of LCPTP in 
immunoprecipitations, studies were done using mass spectrometry to obtain protein 
sequence data. The only clear band to be found uniquely in LCPTP IPs was shown to 
be LCPTP protein (Figure 3.4). There was a notable absence of the MAP kinase, 
ERK1, in the sequence analysis, despite the fact that ERK1 has a molecular weight of 
| 44 kDa ie. equivalent to LCPTP and would therefore, be expected to comigrate on a 
SDS-PAGE (Table 3.1).
There are two models in the literature which suggest two alternative 
interactions which could occur between LCPTP and protein kinases. If the kinases 
act as substrates for LCPTP, the interaction will occur transiently, and LCPTP will 
inactivate the target by dephosphorylating phosphotyrosine residues of the MAP
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kinase (Haneda et al., 1999). Alternatively, more stable constitutive interactions may 
occur if the protein which interacts with LCPTP is not solely a substrate for the 
phosphatase but contains other specific protein/protein interaction sites as suggested 
by Oh-hora et al. (1999). Examples include recombinant PTPBR7 which forms stable 
complexes with ERK1 and ERK2 both in its wild-type or substrate-trap conformation 
(Ogata et al., 1999); (Blanco-Aparicio et al., 1999). This is also the case for PTP-SL, 
STEP protein phosphatase and the Drosophila PTP-ER protein phosphatase, which 
have all been shown in overexpression systems to interact with MAP kinases via their 
respective KIM motifs (Blanco-Aparicio et al., 1999); (Karim and Rubin, 1999).
One possible explanation for our inability to detect a specific interaction 
between LCPTP and the MAP kinase family members ERK1, ERK2 and p38, is 
insufficient sensitivity of detection. However, the amount of total protein present in 
each immunoprecipitation was 100 times higher compared to protein visualised by 
blotting (LCPTP or MAP kinase) in the total lysate. Since the MAP kinase members 
in the total cell lysate are still clearly detectable, the experimental system should 
therefore detect even weak interactions between LCPTP and MAP kinases.
There is a report indicating that elevated intracellular cAMP levels inhibit the 
interaction of LCPTP with ERK, by increasing the phosphorylation of LCPTP on Ser- 
34 and thereby releasing ERK from its association with the phosphatase (Saxena et 
al., 1999b). We therefore, measured the amount of intracellular cAMP in the Jurkat T 
cells used for immunoprecipitating LCPTP to see if the absence of interaction could 
be explained by the fact that the cells contained high levels of cAMP preventing this 
association. The amount of 8-CPT-cAMP added in the aforementioned study, to 
measure the release of ERK from recombinant LCPTP, was 1 mM (Saxena et al., 
1999b). The amount of cAMP detected in our system was in the range of 1 fmol of 
cAMP per 105 cells (Figure 3.6). Adjusting the amount of cAMP for 108 cells, 
immunoprecipitations were performed in the presence of 1 pmol of cAMP per IP. 
This is 109 times less cAMP per IP than in the experiments described in the literature 
(Saxena et al., 1999b). The amount of cAMP is therefore, unlikely to be a significant 
factor inhibiting endogenous LCPTP from interacting with ERK in the cell.
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An alternative explanation for the negative results obtained could be differences in 
lysis conditions. However, endogenous LCPTP immunoprecipitations using the same 
experimental conditions as in previous studies (Oh-hora et al., 1999) did not reveal 
any MAP kinase association. Thus our results cannot be explained by differences in 
lysis conditions. Furthermore, the lysis conditions used in this study did allow the 
interaction of ERK1, ERK2 and p38 proteins with a recombinant GST-LCPTP 
substrate-trap protein in Jurkat T cells and peripheral CD4+ T cells.
We conclude that in our conditions, endogenous LCPTP does not interact 
constitutively with ERK1, ERK2 and p38. However, MAP kinase family members, 
ERK1 and ERK2 can interact constitutively with LCPTP as phosphatase substrates in 
Jurkat T cells. We have extended these studies to include peripheral CD4+ T cells in 
which both ERK1 and ERK2 can act as substrates. In both Jurkat T cells and CD4+ T 
cells there is a weak interaction detected with p38, but this appears insignificant when 
compared to levels of p38 in the total cell lysate. The association of ERK1 and ERK2 
with LCPTP in CD4+ T cells is reduced following cell activation with anti-CD3 
antibody suggesting that LCPTP activity is regulated by signalling via the T cell 
receptor. Finally, our study provides a cautionary note to the interpretation of 
protein/protein interactions seen under conditions where one partner is expressed at 
levels many times higher than is normally present. Such interactions have been 
documented for many other proteins, including other phosphatases such as the 
D rosophila  PTP-ER protein phosphatase (Karim and Rubin, 1999). More 
sophisticated approaches which allow measurement of such interactions under more 
physiological conditions will be important in determining the contribution of such 
interactions to the regulation of cellular activity in vivo}
1 Part of the work described in this chapter has been published in Brodeur, I., Boyhan,
A., Heinrichs, N., Plumpton, C., Chain, B., and Rowan, W. C. (2002). LCPTP - MAP 
kinase interaction: permanent partners or transient association? Mol Immunol 1188, 
1-9.
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CHAPTER FOUR: RESULTS 
Effect of overexpressing LCPTP on MAP kinase activation and T cell 
function in the human leukaemic Jurkat T cell line
4.1 Introduction
Several approaches have been used in studies to evaluate the function of 
phosphatases in cells (Fauman and Saper, 1996); (Conroy et al., 1997) (Frearson and 
Alexander, 1997); (Mustelin et al., 1998); (Mustelin et al., 1999). One approach is to 
stably overexpress the protein of interest in cells and look for phenotypic changes 
(Cohen et al., 1999); (Baker et al., 2001). As well as overexpressing wild-type 
phosphatase protein, phosphatases have been mutated to remove phosphatase activity. 
Two forms of phosphatase inactive protein can be generated: firstly one that binds 
irreversibly to its substrate (catalytically inactive phosphatase able to trap the substrate 
j in the phosphatase pocket) and secondly, a mutant form which forms transient 
| associations with its substrate but can not dephosphorylate it (inactive phosphatase)
| (called here null) (Flint et al., 1997); (Hoff et al., 2000). In addition to their 
* phosphatase activity, phosphatases include domains via which they can interact with 
other proteins independently of their enzyme activity. For example, SHP-1 contains 
two tandem SH homology (SH2) domains by which it can interact with proteins, 
including ZAP-70 (Jin et al., 1999). Overexpressing the different mutant forms of 
phosphatases can give an indication of when a phosphatase is involved in signalling 
I pathways, possibly acting as an adaptor protein (Peterson et al., 1998); (Bosselut et al.,
I 1999); (Bruhns et al., 2000). Thus, it is possible for a phosphatase to influence 
| signalling pathways independent of intrinsic enzyme activity.
This approach has been performed with two hematopoietic phosphatases: 
CD148 and Lyp. Baker et al. showed that CD148 inhibited IP3 production, calcium 
mobilisation and phosphorylation of the MAPK family member, ERK1. They 
observed no upregulation of the CD69 marker and the pattern of protein tyrosine 
phosphorylation in response to anti-TCR MAb C305 (Baker et al., 2001) was not 
grossly affected. These phenotypes were restricted to the CD 148 wild-type form. 
Overexpressing the catalytically inactive form had no effect on cell phenotype (Baker 
et al., 2001). In contrast, overexpression of both the wild-type and substrate-trap D/A 
Lyp phosphatase inhibited IL-2 promoter activity using a luciferase readout in a
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transcriptional reporter assay. However, the substrate-trap C/S protein or the null 
phosphatase did not inhibit 1L-2 promotor activity (Hill et al., 2002).
In order to investigate the role of LCPTP in T cells, stable cell lines expressing 
either wild-type, a substrate-trap (D257A-C291S) or a null mutant (R297M) form of 
LCPTP were established. For the purpose of these experiments, the human Jurkat T 
cell line was used as it is readily amenable to transfection (Tangye et al., 1998); (Plyte 
et al., 2000); (Denny et al., 2000) and because Jurkat cells were used successfully to 
detect interactions of LCPTP with members of the MAP kinase family (Brodeur et al., 
2002). MAP kinase activation occurs within minutes of TCR ligation (Isakov et al., 
1994); (Mustelin et al., 1998) and its association with LCPTP suggested that the 
phosphatase could have a key role in regulating kinase activity controlling 
downstream events such as IL-2 transcription (Li et al., 1999b). The effect of 
overexpressing LCPTP was monitored by following the responses of cells to TCR 
ligation and CD28 costimulation. Stable cell lines overexpressing the different forms 
of LCPTP were used to determine the effect of the phosphatase on MAP kinase 
activation, IL-2 production, expression of T cell surface activation markers, including 
CD25 and CD69 and cell proliferation.
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4.2 Results
4.2.1 Establishment of stable cell lines overexpressing LCPTP
In order to investigate the role of LCPTP in T cell signalling, LCPTP 
constructs were made incorporating GFP with the view to be able to readily isolate 
transfected cells using a FACS Cell Sorter. Following transfection and antibiotic 
selection, stable cell lines were established. However, flow cytometric analysis 
revealed the expression of the GFP to be very weak. After two to three weeks in 
culture, clones began to die suggesting that the transfected protein was toxic to cell 
growth. As LCPTP is endogenously expressed in Jurkat T cells, expression of foreign 
GFP could be a possible cause of cell death.
In a second attempt to make stable cell lines overexpressing LCPTP protein, 
constructs were redesigned to replace the GFP tag with cmyc. cmyc-LCPTP vectors 
were transfected into Jurkat cells and clones were obtained for each of the different 
forms of LCPTP protein. These included cmyc-LCPTP wild-type, cmyc-LCPTP 
substrate-trap (D257A-C291S) (Trap) and cmyc-LCPTP null mutant phosphatase 
(R297M) (Null). The cell lines were probed for the presence of recombinant cmyc- 
LCPTP using a cmyc antibody (Figure 4.1 A) and also with an LCPTP antibody, 
which detects endogenous LCPTP at a slightly lower molecular weight compared to 
the recombinant protein (Figure 4 .IB). No protein was detected using the anti-cmyc 
antibody in untransfected Jurkat cells (Figure 4.1 A lane 1) but recombinant cmyc- 
LCPTP wild-type protein was shown to be strongly expressed in four independent 
stable clones (Figure 4.1A lanes 2-5). Similarly, cmyc-LCPTP substrate-trap and null 
mutant proteins were shown to be expressed in Jurkat T cell clones (Figure 4.1 A lanes 
6 and 7 respectively). The densitometry of the cmyc-LCPTP protein taken from the 
cmyc antibody western blot is shown in Fig. 4.1C and is expressed as arbitrary units. 
cmyc-LCPTP substrate-trap protein was expressed at approximately the same level as 
the endogenous LCPTP (Figure 4 .IB lane 6) and was at a much lower level compared 
to the levels of both cmyc-LCPTP wild-type and c-myc-LCPTP null mutant 
recombinant proteins.
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Figure 4.1. Establishment of stable cell lines overexpressing LCPTP.
Western blot of cell lysate of each stable cell line, probed with A. anti-cmyc antibody.
B. anti-LCPTP antibody. Lane 1 represents the Jurkat control cell line transfected 
with cmyc vector alone. Lanes 2 to 5 show protein expression in stable cell lines 
overexpressing cmyc-LCPTP wild-type. Lane 6 is the stable cell line containing 
cmyc-LCPTP substrate-trap and lane 7 is a stable cell line containing cmyc-LCPTP 
null mutant phosphatase. Each lane is the equivalent of 1 x 105 cells C. Graph 
representing the intensity of each band probed with cmyc antibody, measured by 
densitometry and expressed as arbitrary units. The data shown are representative of 3 
separate experiments.
4.2.2 The effect of overexpressing LCPTP on cell division
Jurkat T cells are a transformed cell line and are not dependent on exogenous 
factors for cell division and growth. In order to determine whether overexpression of
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LCPTP phosphatase affects cell division, the different stable Jurkat cell lines were 
monitored for a period of five days and counted daily. Cells were plated at a starting 
concentration of 1.5 x 105 cells per ml. Figure 4.2 shows the progression in cell 
growth over five days. The doubling time was the same for the control cmyc cell 
lines, the cell lines overexpressing LCPTP wild-type, substrate-trap or null mutant.
cells/ml Cell progression
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Figure 4.2. Cell division of stable cell lines overexpressing LCPTP.
Cells were seeded at a starting concentration of 1.5 x 105 cells per ml in 6 well plates 
and cell growth was monitored for 5 days by counting the number of viable cells. The 
graph shows the total cell numbers in cultures at each time point for control cell lines, 
cm ycl and cmyc3 (red diamonds and yellow squares), LCPTP wild-type (green 
triangles, light blue crosses, dark blue crosses), substrate-trap (pink circles) and null 
mutant (grey squares) cells.
4.2.3 Phosphorylation of active MAPK family members is dependent on 
LCPTP
The only identified LCPTP substrates to date are the MAP kinase family 
members, ERK1, ERK2 and p38 (Brodeur et al., 2002). In order to determine 
whether the recombinant cmyc-LCPTP was active in Jurkat T cells, we investigated 
the phosphorylation levels of MAPK following TCR activation with anti-CD3/CD28 
antibodies. Cells were activated for 5 minutes. Cell lysates were probed with an 
antibody recognising the phosphorylated forms of ERK1 and ERK2. Control cell lines 
expressing only the cmyc tag showed the normal levels of MAPK phosphorylation 
following anti-CD3/CD28 stimulation (Figure 4.3A, lanes 1 and 2). Following 
expression of cmyc-LCPTP wild-type, a sharp decrease in ERK 1/2 phosphorylation
cmycl
WT2
WT10
WT12
Day 1 Day 2 Day 3 Day 4 Day 5
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was observed (Figure 4.3A lanes 3-5). The reduction of phosphorylation seen was 
not due to differences in total protein loading as protein loaded in each lane was 
equivalent as determined by Coomassie blue staining (Figure 4.3B). Consistent with 
the inability of cmyc-LCPTP substrate-trap and null mutants to dephosphorylate their 
target substrates, an increase of MAPK phosphorylation was observed in cell lysates 
expressing these proteins (Figure 4.3A, lanes 6 and 7 respectively). The MAPK 
phosphorylation is assumed to increase because of a competition occurring between 
the overexpressed cmyc-LCPTP substrate-trap or null mutant proteins, which are 
unable to dephosphorylate the MAPK and the endogenous LCPTP. The variation of 
total MAPK phosphorylation (ERK1 and ERK2) assessed by densitometry is shown 
in Figure 4.3C.
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Figure 4.3. Stable expression of wild-type but not catalytically inactive mutants 
of LCPTP reduces levels of phosphorylated MAP kinase in Jurkat T cells.
A. Western blot of cell lysate of each stable cell line, activated with anti-CD3 for 5 
minutes and probed with anti-active MAPK antibody. B. Coomassie stain of SDS- 
PAGE gel controlling for equal protein loading. Lanes 1 and 2 represent the cmyc 
control cell lines. Lanes 3 to 5 represent stable cell lines overexpressing cmyc- 
LCPTP wild-type. Lane 5 is cmyc-LCPTP substrate-trap and lane 6 is cmyc-LCPTP 
null mutant phosphatase. Each lane represents the equivalent of 1 x 105 cells. C. 
Graph represents the intensity of total MAPK phosphorylation for each cell line 
measured by densitometry and is expressed as arbitrary units. The data shown is 
representative of 5 separate experiments.
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4.2.4. Overexpressing LCPTP does not have gross effects on total protein 
tyrosine phosphorylation or LCK phosphorylation in Jurkat T cells
As mentioned in the section above, to date, the only substrates identified for 
LCPTP include members of the MAP kinase family. This does not exclude the 
possibility that LCPTP can dephosphorylate other proteins. To investigate whether 
LCPTP has a general effect on tyrosine phosphorylation, lysates from cells 
overexpressing the different forms of LCPTP and activated with anti-CD3 were 
probed with an anti-phosphotyrosine antibody (4G10). Similar levels of tyrosine 
phosphorylation were observed in cmyc control (Figure 4.4A lanes 1 and 2), cmyc- 
LCPTP wild-type (lanes 3-5), cmyc-LCPTP substrate-trap (lane 6) and cmyc-LCPTP 
null mutant cell lines (lane 7). The effect was not time dependent as the same pattern 
of phosphorylation was seen at other other time points and supports the findings that 
LCPTP has a limited number of substrates and that LCPTP is not affecting the 
activity of kinases, such as Lck, involved in TCR proximal signalling.
It has been reported in the literature that ERK can phosphorylate Lck on serine 
residues leading to changes in Lck activity (Kesavan et al., 2002). Lck activation is 
believed to be one of the earliest events to occur following TCR ligation and the 
increase in Lck kinase activity is largely responsible for activating downstream 
kinases, including ZAP-70, which in turn phosphorylate a number of proteins and 
give rise to the characteristic patterns of tyrosine phosphorylation which can be seen 
in Figure 4.4A (Hall et al., 1999); (Brodeur et al., 2002). It was of interest to 
determine whether overexpressing LCPTP influenced MAP kinase activity and the 
subsequent serine phosphorylation of Lck. The results are shown in Figure 4.4B. No 
changes in serine phosphorylation were observed when the same blot used for looking 
at patterns of protein tyrosine phosphorylation was stripped and reprobed with a 
phospho-Lck antibody (Figure 4.4B). Equal protein loading in each track is shown in 
Figure 4.4C by Coomassie staining.
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Figure 4.4. The effect of overexpressing LCPTP does not affect total protein 
tyrosine phosphorylation or LCK phosphorylation in Jurkat T cells.
A. Western blot of cell lysate of the different LCPTP cell lines, activated with anti- 
CD3 for 1 minute and probed with anti-phosphotyrosine antibody 4 G 10. B. Western 
blot probed with anti-phospho-serine Lck antibody. C. Coomassie staining of SDS- 
PAGE gel showing equal protein loading. Lanes 1 and 2 represent the cmyc control, 
lanes 3 to 5 represent cmyc-LCPTP wild-type cell lines, lane 6 is the cmyc-LCPTP 
substrate-trap and lane 7 is the cmyc-LCPTP null mutant phosphatase cell line. Each 
lane represents the equivalent of 1 x 105 cells. The data shown are representative of 3 
separate experiments.
4.2.5. LCPTP regulates IL-2 production
The production of interleukin-2 is used as a measure to characterise the
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proliferation state of the cell and its ability to respond to stimulation. Following 
stimulation via CD3 and CD28, the Jurkat cell line is stimulated to release IL-2. Anti- 
CD3 and CD28 antibodies were titrated to determine the optimal concentration for 
stimulating IL-2 release and accordingly 1 pg/ml anti-CD3 and 3 pg/ml anti-CD28 
were selected for experiments. The optimal time point for detecting IL-2 release was 
determined to be 24 hours post-stimulation. Unlike in primary T cells, IL-2 appeared 
to accumulate in the medium and was not consumed by Jurkat T cells (Figure 4.5A). 
A significant reduction in IL-2 release was observed in all cmyc-LCPTP expressing 
cell lines, including wild-type, substrate-trap and null mutant compared to the c-myc 
controls (Figure 4.5B).
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Figure 4.5. LCPTP regulates IL-2 expression.
Production of IL-2 following anti-CD3 and anti-CD28 stimulation was measured and 
compared to the control cell lines. A. IL-2 production was measured at: 24 (cream
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bars), 48 (pink bars), 72 (purple bars) and 96 (blue bars) hrs post-stimulation. B. 
IL-2 production of all cell lines 24 hrs post-stimulation with error bars. Graphs show 
the mean values of 5 independent experiments.
4.2.6. LCPTP regulates cell growth following anti-CD3/anti-CD28 
stimulation
As a consequence of T cell receptor ligation, both in the presence, or absence 
of CD28 costimulation, Jurkat T cells undergo growth inhibition. It was of interest to 
determine the consequences of LCPTP overexpression on this effect. Cell 
proliferation was monitored by measuring 3H-thymidine incorporation into cells over 
a time course up to 96 hours following stimulation with anti-CD3 and anti-CD28. 
The optimal concentrations of antibodies for inducing growth inhibition were 0.3 
p,g/ml anti-CD3 and 1 p.g/ml anti-CD28. Results are plotted as a percentage of the 
growth of each stimulated cell line at a given time relative to the unstimulated growth 
at the same time point (Figure 4.6A). In contrast to the control cell lines, when cmyc- 
LCPTP wild-type was overexpressed in the Jurkat cells, the CD3/CD28 mediated 
growth inhibition effect was reduced. This reduction in growth inhibition was also 
seen in the cell line overexpressing the cmyc-LCPTP substrate-trap. However, the 
cmyc-LCPTP null mutant cell line behaved similarly to the cmyc control cell lines.
One explanation for the loss of sensitivity of cell lines overexpressing LCPTP 
to anti-CD3/CD28 mediated growth inhibition is that dependent on the state of cell 
activation, IL-2 can render cells more sensitive to activation-induced death (Wang et 
al., 1996). Thus, a reduction in IL-2 production as a consequence of overexpressing 
LCPTP might favour Jurkat cell survival. To investigate whether the Jurkat cells 
were responsive to the effects of IL-2, the experiment was repeated with the addition 
of exogenous IL-2 into cultures. Addition of IL-2 had no effect on cell growth of 
either the cmyc control cell lines, or cell lines overexpressing LCPTP indicating that 
although the cells are capable of producing IL-2, they are not responsive to it (Figure 
4.6B).
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Figure 4.6. LCPTP regulates Tceflf |rcm iftCttotlc)w]ng anti-CD3/anti-CD28 
stimulation.
The growth of the different cell lines in response to anti-CD3/CD28 stimulation was 
monitored over a period of 96 hours by measuring (Koch et a l. 1991) thymidine 
incorporation (cpm),added during the last 4 hours of culture. Cpm are expressed as a 
percentage of the non activated control sample (100%). A. Growth curves for each 
cell line following anti-CD3/CD28 stimulation: cmycl (red squares), cmyc3 (yellow 
squares), WT2 (green triangles), WTIO (light blue triangles), WT12 (dark blue 
triangles), Trap (pink circles), Null (grey diamonds). B. Growth curves for each cell 
line following anti-CD3/CD28 stimulation in the presence of 100 ng/ml IL-2: cmycl 
(red squares), cmyc3 (yellow squares), WT2 (green triangles), Trap (pink circles), 
Null (grey diamonds). Results are the mean of 6 independent experiments.
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4.2.7. Effect of LCPTP on surface marker expression in unstimulated and anti- 
CD3/CD28 stimulated cells
Following T cell activation, the TCR is downregulated and there is an increase 
in expression of so-called activation markers, including the IL-2 receptor (CD25) and 
CD69 (Reem et al., 1985); (Ashwell et al., 1986); (Kabouridis and Tsoukas, 1990); 
(Cerdan et al., 1995); (V illalba et al., 2000). Experiments were performed to 
determine whether overexpressing LCPTP had any effect on expression of selected 
surface markers, both in unstimulated and anti-CD3/anti-CD28 stimulated cells. CD3 
was expressed in all cell lines and was downregulated following stimulation (Figure 
4.7A). CD28 was expressed on all cell lines at an equivalent level and was not 
downregulated following stimulation (Figure 4.7B). Expression of the CD69 
activation marker whose expression rapidly increases following stimulation was 
likewise not affected by overexpression of LCPTP (Figure 4.7C). In contrast, CD25 
was not upregulated in cells overexpressing either wild-type, the substrate-trap or null 
mutant form of LCPTP. In the cmyc control cell lines, the expression of CD25 was 
upregulated (Figure 4.7D). The expression pattern of CD25 in the different cell lines 
following CD3/CD28 ligation correlated with the production of IL-2.
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Figure 4.7. Effect of LCPTP on surface marker expression in unstimulated and 
anti-CD3/CD28 stimulated cells.
Flow cytometric analysis of surface marker expression of stable cell lines A. CD3.
B. CD28. C. CD69. D. CD25. A and B: non activated sample (light blue), 24 hrs 
post-stim ulation (red), 48 hrs post-stim ulation (green), 72 hrs post-stimulation 
(purple), 96 hrs post-stimulation (dark blue). C and D: non activated sample (red), 
96 hrs post-stim ulation (dark blue). Data are representative of 3 separate 
experiments.
4.2.8. Overexpression of LCPTP induces integrin dependent cell 
aggregation.
We observed during cell culture of cmyc-LCPTP stable cell lines, an increase 
in cell aggregation. Control cmyc stable cell lines grow in single cell suspension 
(Figure 4.8A). In contrast, the cmyc-LCPTP wild-type, the cmyc-LCPTP substrate- 
trap and null mutant stable cell lines grow in clumps. The aggregation was integrin 
dependent demonstrated by adding an anti-CD18 antibody to the cultures (Figure 
4.8B). It was also noted that anti-CD28 antibody coated onto the plate, partially
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disaggregated the clumps while, when added in solution had no effect (Figure 
4.8B). Anti-CD3 antibody coated onto wells had no effect on aggregation. The effect 
was divalent cation dependent, demonstrated by adding the chelating agent EDTA to 
cultures, which resulted in de-aggregation (Figure 4.8B).
A B
4X WT2 4X
WT10 W T12__
4.8. Overexpression of LCPTP induces integrin dependent cell aggregation.
Photomicroscopy of stable cell lines. A. cm ycl, cmyc3, WT2, WT9, WT10, WT12, 
Trap and Null mutant cell lines (x4 magnification). B. WT2 stable cell line (x4 
magnification) with anti-CD28 coated on plate or added in solution, or anti-CD 18 
added in solution, or EDTA added in the medium.
4.2.9 Overexpressed LCPTP has no effect on surface expression of adhesion 
molecules or Fas/Fas ligand
Following the observation that overexpressing LCPTP in Jurkats has an effect 
on integrin-mediated aggregation, demonstrated by the ability of anti-CD 18 antibody 
to inhibit homotypic cell adhesion, it was of interest to determine whether this was 
due to upregulation of adhesion molecules relative to control cells. In addition, one 
possible explanation for the reduction in growth inhibition seen when cells 
overexpressing LCPTP were stimulated with anti-CD3/CD28 could be changes in Fas 
(CD95)/Fas ligand (CD 178) expression relative to control cells. The expression of 
CD2 (LFA-2), C D lla  (LFA-1 alpha chain), CD62L (L-selectin), CD152 (CTLA-4),
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CD 154 (ICAM) and Fas and FasL were analysed by flow cytometry (Table 4.1). 
All cell lines expressed CD2, C D lla , CD62L, CD152 and CD154 at comparable 
levels, in activated or unactivated samples. The level of expression did not change 
following 24 hours stimulation with anti-CD3/CD28. Fas and Fas ligand were not 
expressed on any of the cell lines. The expression of adhesion molecules and Fas and 
Fas ligand in the different cell lines is summarised in Table 4.1.
Cell Markers '
lines CD2 C D lla CD18 CD62L CD 152 CD 154 Fas FasL
cmycl 253 364 448 327 55 90 77 85
cmyc3 231 342 475 328 64 83 71 75
WT2 266 349 432 309 87 75 59 64
WT9 283 310 452 325 76 81 63 69
WT10 265 327 437 353 85 76 65 71
WT12 264 328 436 364 81 77 63 74
Trap 258 338 440 329 90 65 84 68
Null 273 359 419 374 63 81 75 72
Table 4.1. Effect of overexpressing LCPTP on adhesion molecules and Fas and Fas 
ligand.
The table shows the median fluorescence intensity of selected adhesion molecules and 
Fas and Fas ligand on cell lines.
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4.3 Discussion
LCPTP is one of the few tyrosine phosphatases, which is expressed 
exclusively in hematopoietic cells. It appears to have a restricted number of 
substrates limited to the MAP kinase family members (Brodeur et al., 2002). Most 
studies done previously have involved transiently overexpressing the phosphatase, 
either alone or with the MAP kinase substrate. We have overexpressed LCPTP in 
Jurkat T cells and generated stable cell lines in order to look at the functional 
consequences of LCPTP activity in both unstimulated and anti-CD3/anti-CD28 
stimulated cells. Initial attemps to make GFP tagged LCPTP constructs (WT, 
substrate-trap and Null mutant) and make stable cell lines overexpressing these 
proteins were not successful. We obtained several cell lines overexpressing LCPTP 
but failed to produce any cells expressing GFP alone. After two to three weeks in 
culture, clones expressing LCPTP tagged to GFP stopped dividing and died. There 
are two possible explanations: either LCPTP overexpression inhibits cell growth, or, 
the presence of GFP is toxic to the cells and when tagged to LCPTP, the construct 
was less toxic than GFP alone, but ultimately, cell survival was affected and longterm 
survival of clones was not possible (Stratagene, Drs Nigel Sharp and Madeleine 
Carreau, personal communication, (Bell et al., 2001)).
In order to ascertain whether it was the GFP tag or the LCPTP protein itself 
which was affecting longterm cell survival, efforts were made to generate alternative 
c-myc tagged constructs for transfection studies. These included c-myc alone as a 
control, c-myc-LCPTP wild-type and two mutant forms of LCPTP, both lacking 
phosphatase activity: the c-myc-LCPTP substrate trap protein, as the name implies, 
binds irreversibly to its substrate; in contrast, the c-myc-LCPTP null mutant binds 
reversibly to its substrate. A number of independent clones were obtained expressing 
the cmyc-LCPTP wild-type recombinant protein but despite repeated attempts, only 
one surviving clone was obtained for the substrate-trap recombinant protein. The 
clone obtained expressed the substrate-trap form of LCPTP at equivalent levels to the 
endogenous protein and so it is possible that the reason this clone survived was that 
the levels were sufficiently low enabling signalling via the endogenous LCPTP, or 
sufficiently low that some ERK was still free. Overexpression of the LCPTP 
substrate-trap could block all downstream signalling from its substrate MAP kinases
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and effectively stop MAP kinase dependent cell proliferation (Dumont et al., 1998); 
(DeSilva et al., 1998). Although LCPTP phosphatase is overexpressed in cells, its 
activity does not appear to affect cell cycle progression, as judged by the observation 
that the growth of cmyc-LCPTP WT, Trap and Null mutant cells is similar to the 
growth of cmyc control cell lines. Thus, LCPTP overexpression in Jurkat T cells is 
not detrimental to cell survival. This points to GFP being toxic to cell growth as the 
explanation for why it was not possible to establish cell lines overexpressing GFP 
tagged LCPTP proteins.
Cell lines overexpressing cmyc-LCPTP wild-type protein have been shown to 
reduce the level of MAPK phosphorylation after stimulation with anti-CD3/anti- 
CD28 antibodies compared to control cell lines expressing the cmyc tag alone. This 
provides evidence that LCPTP is active in cells in which it is overexpressed. As 
would be predicted, the phosphorylation of the MAPK family members was increased 
in the presence of the cmyc-LCPTP substrate-trap. LCPTP substrate trap binds the 
phosphorylated forms of ERK1 and ERK2 but does not remove the phosphate and 
thus the tyrosine phosphorylated forms of ERK1 and ERK2 accumulate in cells. The 
interaction of the null mutant is reversible and so it can bind to its substrate but will 
disassociate without dephosphorylating its target. There are two possible 
explanations why an increase in ERK phosphorylation is seen when the null mutant is 
overexpressed in cells. Firstly, LCPTP contains a kinase interaction motif (KIM). 
KIMs were first identified in the phosphotyrosine phosphatases, PTP-SL and STEP, 
which are involved in regulating MAP kinase activity (Pulido et al., 1998). Previous 
studies looking at interactions of overexpressed LCPTP with MAP kinases proposed a 
model in which LCPTP interacted constitutively with its protein substrates (Oh-hora 
et al., 1999); (Saxena et al., 1999). If this was the case, then the null mutant could 
bind to MAP kinases irreversibly via the KIM motif and sequester the MAP kinase 
away from endogenous LCPTP activity. We do not believe this to be the case, as we 
were not able to show a constitutive interaction of endogenous LCPTP with MAP 
kinases and concluded that LCPTP forms transient associations with its substrates via 
its phosphatase domain (Brodeur et al., 2002). A second explanation why 
overexpression of the null mutant leads to an increase in MAP kinase phosphorylation 
is that the protein is overexpressed compared to the endogenous LCPTP and will
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therefore compete with the endogenous LCPTP for its substrate. The competition 
prevents active LCPTP from encountering its substrate and the balance of MAP 
kinase phosphorylation is shifted.
Jurkat T cells do not require IL-2 for proliferation although they are capable of 
producing IL-2 following anti-CD3 and anti-CD28 stimulation. Previous studies have 
shown that both LCPTP mRNA and protein were increased after TCR or IL-2 
stimulation (Adachi et al., 1994). Also, transiently overexpressed LCPTP had a 
strong inhibitory effect on the transcriptional activation of the luciferase gene driven 
by the NFAT/AP-1 promotor region derived from the IL-2 gene (Saxena et al., 1998). 
This suggested that LCPTP could be involved in negatively regulating IL-2 
production. We have shown in the present study that there is a significant reduction in 
IL-2 production following stimulation of cells expressing either the wild-type or the 
substrate-trap form of LCPTP. There is also an inhibitory effect mediated by 
overexpressing the null mutant form of LCPTP. This data supports previous studies in 
Jurkat T cells in which a dominant negative form of ERK1 was overexpressed 
resulting in a reduction in TCR stimulated IL-2 production (Li et al., 1999a). Thus, a 
reduction in MAPK activity in Jurkat cells has a direct effect on the production of 
interleukin-2. Although a visible effect is seen on the MAPK phosphorylation, no 
change is observed in the general tyrosine phosphorylation pattern in activated cell 
lines.
When we initiated our studies to elucidate the functional effects of LCPTP 
activity in cells, the plan was to control experiments by comparing the differences 
seen when overexpressing wild-type protein, compared to mutant forms of LCPTP 
lacking phosphatase activity. The results were unexpected in that overexpressing the 
wild-type and both the substrate trap and the null mutant LCPTP proteins resulted in 
inhibition of IL-2 production. However, this can be explained by considering how 
signalling via the MAP kinases works. Upon phosphorylation by MAP kinase 
kinases (MAPKK), the MAP kinases translocate to the nucleus and phosphorylate 
transcription factors, which initiate gene transcription (DeSilva et al., 1998). The 
wild-type protein prevents activation of the MAP kinase by keeping it in an inactive 
state by dephosphorylation of the regulatory tyrosine residues. With the substrate-
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trap protein, MAP kinase can be phosphorylated, but is then trapped irreversibly by 
the mutant LCPTP protein in the cytoplasm, preventing the translocation of the active 
MAP kinase to the nucleus. This in turn, prevents the phosphorylation and activation 
of the transcription factors necessary for inducing IL-2 gene transcription. A similar 
explanation can be proposed for the null mutant having the same effect on reducing 
IL-2 production compared to the wild-type and the substrate-trap LCPTP proteins. 
There was an increase in MAP kinase activity in cells overexpressing the mutant 
protein, but the active kinase could be hindered from translocating to the nucleus 
because of continuous transient associations with the overexpressed null mutant. 
There is a suggestion that this could indeed be the case by the relative inhibition seen 
with the null mutant compared to wild-type protein. There is less inhibition seen with 
the null mutant, which can be explained by some of the active MAP kinase being able 
to translocate to the nucleus and fulfil its signalling functions (see Figure 4.8).
Depending on the activation state of T cells and external factors such as the 
presence of costimulation, cytokines, etc., TCR stimulation can induce cells to 
proliferate, become anergic or enter into apoptosis. Jurkat T cells when activated with 
antibodies to the invariant CD3 chain of the TCR complex and an antibody, which 
ligates the CD28 costimulatory molecule, undergo growth inhibition (Makover et al., 
1991). This growth inhibition in Jurkat T cells has been shown to be due to a 
reduction in expression of cyclin D3 resulting in cells arresting in the G1 phase of the 
cell cycle (Boonen et al., 1999). ERK activity is required for activation of cyclin D3 
and cyclin D3 activity can be blocked using a MAP kinase inhibitor (Dolci et al., 
2001). Since ERK activity is reduced by overexpressed LCPTP, one would predict 
that overexpressing wild-type LCPTP protein in cells would increase the growth 
inhibition effect mediated by CD3/CD28 ligation. Contrary to what was expected, 
overexpressing both wild-type and substrate-trap forms of LCPTP appeared to protect 
against CD3/CD28 stimulated growth inhibition. The reason for this observation 
remains unclear.
MAP kinases are involved in mediating signals triggered by diverse stimuli, 
including cytokines, growth factors and environmental stress leading to growth, 
differentiation and cell death (Rincon et al., 2000). The functional effects seen when
105
CHAPTER FOUR
LCPTP is overexpressed in Jurkat T cells, could be due to any number of 
explanations, all of which require further investigation. One explanation for a more 
sustained growth in cell lines overexpressing LCPTP following anti-CD3/anti-CD28 
stimulation could be that something other than cyclin D3, signalling downstream from 
LCPTP and MAP kinases is involved in regulating cell cycle progression. The LCPTP 
gene is often duplicated in cases of myeloid leukemia, which results in changes in 
LCPTP activity, which might contribute to unregulated growth and establishment of 
clonal dominance (Zanke et al., 1994). We also considered whether a change in 
expression of Fas and its ligand on the surface of cells could contribute to prolonged 
survival, but flow cytometric analysis showed there were no differences in surface 
expression following activation for Fas, FasL or other extracellular markers looked at.
One of the downstream functional effects of MAPK activation, is the 
upregulation of the early activation marker CD69 on the cell surface (Villalba et al.,
2000). In our studies, we would have expected to see some effect on the expression 
of CD69 following cell activation in the presence of overexpressed LCPTP. The 
expression of CD69 on the surface of cells is the same in all cell lines following 
CD3/CD28 stimulation. This suggests that in Jurkat T cells, expression of CD69 is 
not influenced by LCPTP dephosphorylating the MAP kinases. Iwashima and 
collaborators have identified an adapter protein, She, which like LCPTP, influences 
the MAPK pathway but does not affect CD69 expression. They found that She is 
essential for IL-2 production in J.SL1 T cells, but is dispensable for cell surface 
expression of CD69 and CD25 (Iwashima et al., 2002). In contrast, inducible 
expression of another tyrosine phosphatase, CD 148, in Jurkats, has been shown to 
inhibit TCR induced ERK phosphorylation and CD69 upregulation (Baker et al.,
2001).
In contrast to CD3, CD28 and CD69, we saw changes in the expression of the 
IL-2 receptor, CD25. CD25 is upregulated on the surface of activated T cells in 
response to TCR/CD28 stimulation and is maintained on the cell surface in the 
presence of IL-2 (Reem et al., 1985); (Ashwell et al., 1986); (Kabouridis and 
Tsoukas, 1990); (Cerdan et al., 1995). Expression of CD25 also controls T cell 
proliferation (Reem et al., 1985); (Cerdan et al., 1995). CD25 was upregulated on the
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surface of cells expressing the cmyc control protein, but failed to be upregulated 
following cell activation in the presence of the overexpressed wild-type, trap and null 
mutant LCPTP proteins. This data correlated with the reduction in the production of 
IL-2 from the cells and suggests that unlike CD69, expression of CD25 in Jurkat cells 
is dependent on MAP kinase activity.
One final observation regarding the functional consequences of 
overexpressing LCPTP in Jurkat T cells was the tendency of cells to aggregate in 
culture. The increased homotypic aggregation seen when overexpressing LCPTP was 
integrin mediated, demonstrated by the fact that an antibody to CD18, the common 
beta chain of LFA-1, inhibited cell clumping. Addition of EDTA to cultures also 
inhibited cell aggregation, indicating that the effect was divalent cation dependent. 
This data supports previous studies in which overexpression of LCPTP altered 
fibroblast morphology. Transfection of LCPTP into fibroblasts (NIH 3T3) enabled 
cells to form colonies in soft agar (Zanke et al., 1994). The increased cell aggregation 
was not due to changes in LFA-1 or ICAM expression although it could reflect 
changes in integrin affinity. Thus LCPTP could increase binding integrin potential, 
via a MAPK independent pathway since downstream signalling of MAP kinase 
augments the affinity of integrins (O'Rourke et al., 1998).
There is still much to be learnt about the role of LCPTP in T cells. One 
obvious question for LCPTP is how and when its activity is regulated. We observed 
that the cell aggregation effect could be inhibited by plate bound anti-CD28 but not 
by plate bound anti-CD3. Anti-CD28 in solution was less effective at inhibiting the 
cell clumping. Taken together, these results suggest that LCPTP activity could in part 
be regulated by signalling via CD28 and requires crosslinking, which is mimicked by 
binding the antibody to plastic. CD28 is widely recognised as being an important 
costimulatory molecule for T cell activation and IL-2 production (June et al., 1990); 
(Schwartz, 1992); (Linsley and Ledbetter, 1993). It could be envisaged that CD28 
signalling is important for ‘switching off’ negative signalling effects. This has been 
reported to be the case for another T cell phosphatase, Lyp. Lyp targets Cbl-b, a 
protein involved in the negative regulation of T cell signalling. Upon CD28 ligation, 
Lyp maintains Cbl-b in a dephosphorylated state and allows activation of signalling
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pathways to proceed unimpeded which lead to IL-2 gene transcription (Cohen et al.,
1999)2.
Studies have been initiated to determine how relevant the observations made 
in Jurkats are to what happens when LCPTP is overexpressed in primary T cells, these 
are described in the next chapter.
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2 The work described in this chapter has been submitted to Journal of Immunology.
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Figure 4.9 Model to show the effect of A) endogenous LCPTP, B) overexpression 
of LCPTP wild-type and C) overexpression of substrate-trap or null mutant 
LCPTP in Jurkat T cells, on MAP kinase translocation into the nucleus.
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CHAPTER FIVE: RESULTS 
Effect of overexpressing LCPTP in primary T cells
5.1 Introduction
In the previous two chapters (Chapters 3 and 4) Jurkat T cells have been used 
as a model to characterise the role of LCPTP in T cell signalling pathways. Jurkats 
have the benefits that they can be grown in large numbers and are relatively easy to 
transfect. However, there are some discrepancies between leukemic cell lines, such as 
Jurkat cells and nontransformed T cells, or primary T cells. One of the reasons why 
Jurkat T cells may behave differently to primary T cells is that Jurkat T cell lines do 
not express the PTEN or SHIP protein phosphatases (Shan et al., 2000); (Astoul et al., 
2001) causing an imbalance in the PI3K pathway. This results in an abnormal and 
constitutive localisation of the tyrosine kinase, ITK, at the cell membrane and a 
deregulation of actin metabolism. Thus these factors should be considered when 
studying the TCR pathway using transformed cells and any conclusions drawn may 
differ in primary T cells. In order to address this, a relatively new strategy was 
adopted which facilitates transfection of primary T cells. The technique employed to 
overexpress LCPTP in CD4+ T cells was to infect primary T cells using adenovirus 
for gene delivery.
Adenoviruses replicate in the host nucleus using their enzymes to synthesise 
DNA and mRNA. Adenoviruses are used in research to study mRNA synthesis and 
regulation, DNA replication and they are also used in cellular transformation 
(Feldman et al., 1997). The adenovirus used was engineered for safe use in the 
laboratory by depleting both the El 1 gene essential for viral replication and the E3 
gene, which is implicated in the evasion of the hosts immune response to the virus 
(Richards et al., 2000). The adenoviruses need a membrane receptor to attach and 
enter cells. This receptor is called CAR which stands for Coxsackie-adenovirus 
receptor (Bergelson et al., 1998). All human cells possess the receptor for adenovirus 
entry except skin fibroblasts, alveolar macrophages, smooth muscle cells and 
lymphocytes. James DeGregori’s team engineered a transgenic mouse expressing the 
human CAR receptor on all cells. This allows the infection of primary T cells with 
adenovirus constructs expressing the gene of interest and enables the observation of 
the effects of overexpresssing the protein in cells. Unlike other systems used for
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overexpressing proteins of interest in primary cells (eg. retrovirus), the adenoviral 
delivery system does not depend on cells being in cycle in order to infect and 
integrate into the host DNA. The adenovirus does not integrate into the host DNA. 
This overcomes another problem often encountered during transfection studies 
because there is no random integration of the transfected protein into the host cell’s 
genome which could potentially leading to mutations in proteins key to signalling 
pathways of interest in the functional studies performed (Leon et al., 1998).
Utilising the adenoviral technology, studies have been done not only looking 
at effects of LCPTP on murine naive T cells, but also on antigen differentiated Thl 
and Th2 cells. These studies have made use of the double transgenic CAR-1- 
DOl 1.10 mice. In addition to the CAR receptor, all the T cells in the mice have been 
engineered to express a T cell receptor specific for an a ovalbumin peptide and can 
therefore be activated in vitro in the presence of APCs and peptide. Naive CD4+ T 
cells were purified from CAR-1-D011.10 and either used directly, or differentiated 
into Thl and Th2 subsets using antigen and the appropriate cytokines, and infected 
with adenovirus containing LCPTP wild-type or substrate-trap proteins. The effect of 
overexpressing LCPTP in primary T cells was monitored by following the responses 
of cells to restimulation with anti-CD3 and anti-CD28 antibodies and measuring the 
effect of the phosphatase on MAP kinase activation, cytokine production and cell 
proliferation.
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5.2 Results
5.2.1 Cloning of LCPTP into adenovirus vector and transient transfection.
In order to transfect LCPTP into primary T cells, the phosphatase had to be 
cloned into the Admid system for generation of recombinant viruses (Richards et al., 
2000). The first step involved cloning LCPTP into pCR259 vector. The genes cloned 
were LCPTP wild-type, substrate-trap and LCPTP wild-type cloned in backwards to 
produce anti-sense. Once cloned, the plasmid expression potential was verified by 
transiently transfecting Jurkat T cells and probing for LCPTP protein. LCPTP wild- 
type and substrate-trap were both highly expressed in Jurkat T cells. In contrast, there 
was no overexpression of proteins seen in cells overexpressing LCPTP anti-sense 
protein.
WT Tran anti-sense
-L C P T P
1 2 3
Figure 5.1 Transient transfection of pCR259-LCPTP wild-type, substrate-trap 
and anti-sense into Jurkat T cells.
Western blot of crude lysate of 5 x 105 cells probed with anti-LCPTP. 1) pCR259- 
LCPTP wild-type; 2) pCR259-LCPTP substrate-trap; 3) pCR259-LCPTP anti-sense. 
Data are representative of two separate experiments.
5.2.2 Concentration of viruses by caesium chloride gradient
In order to achieve efficient infection of T cells, it was necessary to obtain 
concentrated recombinant viral stocks. HEK cells were infected with virus and 
supernatants from cells collected. The virus was concentrated from culture 
supernatants using caesium chloride gradients. The first gradient was a step gradient 
formed with 1.2 and 1.4 M caesium chloride solutions and the second gradient was a
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continuous gradient made with 1.2 and 1.4 M caesium chloride stock solutions. The 
gradients allow the separation of defective virus particles from the infectious viruses 
and concentrate the virus for infection of primary T cells. Figure 5.2 illustrates 
examples of each gradient and the separation of viruses.
idiem
— Dtfwttvt particles
-  bfcctiovs virusts -
( oniinuou-s gradient
Figure 5.2. Photograph showing concentration of viruses using caesium chloride 
gradients.
A. Step gradient of 1.2 and 1.4 M caesium chloride. B. Continuous gradient of 
caesium chloride. Infectious viruses and defective particles are shown on the picture.
5.2.3 Thl/Th2 differentiation from primary CAR-1-D011.10 T cells
Primary T cells were isolated from mouse spleens, and differentiated into Thl 
and Th2 cells using a cocktail of antibodies and appropriate cytokines and APCs 
presenting antigen, in the form of ovalbumin peptide. Intracellular cytokine staining 
was performed in order to characterise the phenotypes of the T h l and Th2 cell 
populations generated. The CAR-1-D011.10 mice have been bred onto a BALB/c 
background. BALB/c mice T cells have a natural bias to differentiate towards a Th2 
phenotype. The primary cells when pushed towards a Th2 phenotype produced IL-4 
and no IFN-y. In contrast, primary cells stimulated under T h l differentiating 
conditions produced IFN-y in addition to IL-4 (Ouyang et al., 2000); (Lee et al.,
2000); (Ho et al., 1996); (Zheng and Flavell, 1997); (Feber, 1999). Figure 5.3 
illustrates example of T h l and Th2 phenotypes, unstimutated and stimulated with 
anti-CD3 and anti-CD28
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Figure 5.3. Thl/Th2 differentiation from primary T cells taken from CAR-1- 
D011.10 transgenic BALB/C mice.
Flow cytometry measurements showing intracellular staining of resting and activated 
T h l and Th2 cells differentiated from primary CAR-1-D011.10 T cells. Cells are 
double stained with FITC conjugated antibody to IFN-y and PE conjugated antibody 
to IL-4.
5.2.4 Optimisation of multiplicity of infection (m.o.i.) for overexpressing 
LCPTP in mouse primary T cells.
Conditions were evaluated in order to achieve overexpression of LCPTP in 
primary T cells and maintain a reasonable cell survival rate after infection. Different 
amounts of virus were added to equivalent cell numbers and cell lysates were probed 
for the presence of LCPTP. In addition, cell survival rate was monitored by counting 
viable cells following staining with Trypan blue. Figure 5.4A shows the increase in 
LCPTP protein expression in T h l cells after infection with different m.o.i. of 
adenovirus containing wild-type LCPTP. 5 viruses per cell was sufficient to detect an 
increase in expression of LCPTP compared to the non-infected cells. Figure 5.4B 
shows the survival rate of T h l and Th2 cells after infection with different m.o.i. of 
adenovirus containing either the wild-type LCPTP, the mutant substrate-trap form of 
LCPTP and the Th2 transcription factor Gata3 compared to non-infected cells (Zheng
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and Flavell, 1997). The Gata3 adenoviral construct, was used as a positive control 
which had been shown previously in the laboratory to positively affect Th2 cytokine 
production (Nigel Sharp, personal communication). Similar survival was apparent 
between T h l and Th2 cells infected with the same virus. In cells infected with 
LCPTP wild-type or substrate-trap protein there was a decrease in cell survival 
compared to infection with Gata3 protein. This decrease in survival correlated with 
the ability of cells to aggregate and form clumps in culture. T h l and Th2 cells 
infected with LCPTP wild-type or substrate-trap protein formed clumps in the 
medium, as early as one hour after infection. This is shown in photomicrographs (x4 
magnification) in Figure 5.4C. Gata3 infected cells did not form clumps and appeared 
similar to the uninfected control cells.
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Figure 5.4. Effect of the multiplicity of infection on the expression of LCPTP
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protein and growth characteristics of primary cells.
A. Western blot of cell lysates 24 hours after infection, probed for LCPTP. Thl cells 
infected with different m.o.i. of LCPTP wild-type virus: 0, 5, 10, and 50. B. Survival 
rate of Thl and Th2 cells at 24 hours following virus infection compared to non- 
infected cells. Cells were counted and data are given as a percentage of the viable 
uninfected control cell population. LCPTP wild-type (red); LCPTP substrate-trap 
(blue); Gata3 (green); solid line = T hl cells, broken line = Th2 cells. C. 
Photomicrography (x4 magnification) of Thl and Th2 cells either uninfected or 
infected with LCPTP wild-type, LCPTP substrate-trap and Gata3 viruses at m.o.i. of 
5, 10 and 50. Data are representative of 2 separate experiments.
5.2.5 LCPTP wild-type and substrate-trap overexpression in T h l and Th2 
cells.
In order to have a significant amount of LCPTP expressed in cells and
maintain a sufficient survival rate, a m.o.i. of 10 was selected as optimal for further
experiments. Figure 5.5 shows a Western blot probed with LCPTP antibody from cell
lysates of Thl and Th2 cells infected with the LCPTP viruses at a m.o.i. of 10. The
endogenous level of LCPTP in control uninfected Thl and Th2 cells is shown in lanes
1 and 4 respectively. In comparison, there is an increase in the expression of LCPTP
seen in cells infected with LCPTP wild-type (lanes 2 and 5) and substrate-trap
proteins (lanes 3 and 6). Thl________ Th2
MWjJttOctl WT Trapctl WT Tran
9 6 “
6 4 “
5 0 “
3 6 -
3 0 “
1 6 -  
6 -
1 2  3 4 5 6
Figure 5.5. LCPTP wild-type and substrate-trap overexpression in Thl and Th2
cells.
Western blot probed with LCPTP antibody. Uninfected Thl and Th2 cells = control 
(ctl) and Thl or Th2 cells infected with a m.o.i. of 10 for LCPTP wild-type and
LCPTP
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substrate-trap viruses. Data are representative of two separate experiments
5.2.6 LCPTP overexpression affects MAPK phosphorylation in Thl and Th2 
cells.
In order to see if the effects seen in stable ceil lines overexpressing LCPTP 
also occur in primary cell lines, Thl and Th2 cells infected with LCPTP wild-type 
and substrate-trap were activated with anti-CD3 antibody, lysed and probed with a 
phospho-MAPK antibody. The endogenous level of MAP kinase phosphorylation in 
Thl and Th2 cell lysates (Figure 5.6 lanes 1 and 5) was reduced when LCPTP wild- 
type is overexpressed in cells (lanes 2 and 6). No difference was observed when the 
substrate-trap mutant protein was overexpressed (lanes 3 and 7) which is contrary to 
the results observed in stable Jurkat T cell lines (Figure 4.3). The presence of 
overexpressed Gata3, as a control for cells infected with a virus gives a slight increase 
in MAP kinase phosphorylation (lanes 4 and 8).
T hl Th2
MW tkDa) ctl WT TrapGata3 ctl WT TrapGata3
6 4 “
5 0 -
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Figure 5.6. LCPTP overexpression affects MAPK phosphorylation in T hl and 
Th2 cells.
Western blot probed with a phospho MAPK specific antibody. Cell lysate of anti- 
CD3 activated cells: Thl and Th2, uninfected and infected with LCPTP wild-type, 
substrate-trap and Gata3.
5.2.7 LCPTP affects cytokine production in naive, Thl and Th2 cells.
The stable Jurkat T cell lines o v e rex p re ss in g  L C PT P wild-type,
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substrate-trap and null phosphatase mutant had a reduced level of IL-2 production 
following anti-CD3 and anti-CD28 activation. This decrease in cytokine production 
correlated with a decrease in MAP kinase phosphorylation in the LCPTP wild-type 
overexpressing cell line. In order to see if the overexpression of LCPTP in primary T 
cells has the same effect, cytokine production following TCR and CD28 activation 
was monitored. Figure 5.7 shows the cytokine production measured at 24, 48 and 72 
hours for IL-2, IL-4, IL-5, IL-13 and IFN-y. In the case of IL-2, the overexpression of 
both LCPTP wild-type and substrate-trap, in naive and both Thl and Th2 cells, 
inhibited the production of IL-2 compared to the control uninfected cells (Figure 5.7 
A, B and C). IL-2 production was also reduced in cells overexpressing Gata3. This 
result confirmed previous observations on the functional consequences of 
overexpressing Gata3 in primary murine cells (personal communication, Dr Andy 
Blanchard). As would be expected, the production of IL-2 is much lower in Th2 cells 
compared to Thl cells (Ouyang et al., 2000); (Lee et al., 2000); (Ho et al., 1996); 
(Zheng and Flavell, 1997); (Feber, 1999).
The production of IL-4, IL-5 and IL-13 is characteristic of Th2 cells and well 
differentiated Thl cells do not produce these cytokines. The CAR-1-D011.10 
transgenic so called ‘T h l” cells produced a small quantity of IL-4, IL-5 and IL-13 
due to the fact that the population is not homogeneous for Thl cytokine secreting 
cells (see Figure 5.5). Overexpressed LCPTP had no effect on the production of IL-4 
(Figure 5.7 D) and IL-5 (Figure 5.7 F) but lead to a decrease in IL-13 production from 
Thl cell cultures (see discussion) (Figure 5.7 H). In Th2 cells, the presence of 
LCPTP wild-type had a small effect on the production of IL-4, IL-5 and IL-13 and a 
more pronounced effect was seen with overexpression of LCPTP substrate-trap 
protein (Figure 5.7 E, G and I). The presence of Gata3, an activator of transcription 
of Th2 cytokines, increased the production of IL-4, IL-5 and IL-13 from Th2 cells 
(Figure 5.7 E, G and I).
The production of IFN-y is regarded as specific to Thl cells (Mosmann et al., 
1986); (O'Garra, 1998) and no IFN-y production was detected from cells 
differentiated towards a Th2 phenotype (Figure 5.7 K). The overexpression of 
LCPTP wild-type, substrate-trap or Gata3 protein decreased the production of IFN-y
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from T hl cells (Figure 5.7 J).
A IL-2 production by naive cells
control act WT act Trap act Gata3 act
L-2 production from T hl cells L-2 production from Th2 cells
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24  hrs
I I I I '  ’ I I I
contro l W T  act T rap  act G ata3  act contro l W T  act T rap  act G ata3  act
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D IL-4 production from T hl cells £  IL-4 production from Th2 cells
control W T  act T rap  act G ata3 act
P  IL-5 production from T hl cells G  IL-5 production from Th2 cells
I I --------------  I
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H IL-13 production from T hl cells I IL-13 production from Th2 cells
control WT act Trap act Gata3 actcontrol WT act Trap act Gata3 act
J  IFN-y production from Thl cells K  IFN-y production from Th2 cells
24 hrs
control WT act Trap act Gata3 actcontrol WT act Trap act Gata3act
Figure 5.7. Effect of LCPTP overexpression on cytokine production from naive, 
Thl and Th2 cells.
T hl and Th2 cells, uninfected and infected with adenovirus-LCPTP wild-type, 
substrate-trap and adenovirus-Gata3 were activated with anti-CD3 and anti-CD28 
antibodies. Supernatants were taken and analysed by ELISA for the presence of IL-2 
(graphs A and B), IL-4 (graphs C and D), IL-5 (graphs E and F), IL-13 (graphs G and 
H) and IFN-y (graphs I and J) cytokines. Cytokine measurements were done over 
three time points: 24 hours (light blue bars), 48 hours (dark blue bars) and 72 hours 
(green bars). Data are representative of three separate experiments and all error bars 
are within 5 percent range.
5.2.8 LCPTP overexpression alters the proliferation capacity of naive, T h l 
and Th2 cells
As a consequence of T cell receptor and CD28 ligation, primary rested T cells 
undergo proliferation. In contrast, the Jurkat T cell line responded to anti-CD3 and 
anti-CD28 ligation by undergoing growth inhibition. LCPTP overexpression in 
Jurkats partially abrogated the CD3/CD28 mediated growth inhibition (Figure 4.6). It 
was therefore of interest to determine the effect of overexpressing LCPTP on
120
CHAPTER FIVE
CD3/CD28 stimulated growth in primary T cells differentiated into T h l and Th2 
cells. Cell proliferation was monitored by measuring 3H-thymidine incorporation 
(cpm) into cells over a time course up to 96 hours following stimulation with anti- 
CD3 and anti-CD28 antibodies. Results show the cell proliferation in unstimulated or 
CD3/CD28 stimulated cells in uninfected cells and cells infected with adenovirus- 
LCPTP wild-type, substrate-trap and Gata3 proteins (Figure 5.8). At 24 hours post­
activation, the differences between the uninfected cells and the infected cells are 
minimal except for a higher basal proliferation in unstimulated Th2 cells (Figure 
5.8D). The proliferation seen at 48 hours shows a higher basal proliferation for both 
T hl and Th2 cells and consequently a higher proliferation following TCR and CD28 
stimulation for T h l cells infected with LCPTP (Figure 5.8E and I). The proliferation 
of Th2 cells was enhanced in cells infected with LCPTP compared to the unifected 
cells although this difference was small relative to the proliferation of unactivated 
cells (Figure 5.8E and J). The proliferation of activated naive cells at 48 and 72 hours 
was reduced compared to the proliferation of uninfected cells (Figure 5.8B, C and H).
The proliferation at 72 and 96 hours for T h l and Th2 cells was similar with a higher 
proliferation rate for cells infected with LCPTP compared to uninfected cells and cells 
infected with Gata3 (Figure 5.8F, G, I and J).
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Figure 5.8. Effect of overexpressing LCPTP on CD3/CD28 stimulated 
proliferation in naive, T hl and Th2 cells.
Incorporation of 3H-thymidine expressed as counts per minute (cpm) in T h l and Th2 
cells, either unstimulated or stimulated with anti-CD3 and anti-CD28 antibodies. 
Cells were either uninfected or infected with adenovirus LCPTP wild-type, substrate- 
trap and Gata3 proteins. Proliferation was measured at different time points ranging 
from 24 to 96 hours. Unstimulated cells = purple bars; CD3/CD28 stimulated cells = 
green bars. For graphs H, I, J, LCPTP wild-type infected cells: = red line, LCPTP 
substrate-trap infected cells = orange line, Gata3 infected cells = green line, uninfected 
cells = blue line. This is representative of 3 independent experiments and error bars 
are all within a 5 percent range.
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5.3 Discussion
In Chapter 4 stable transfectants were made in the Jurkat T cell line 
overexpressing the wild-type, substrate-trap and null mutant forms of LCPTP 
phosphatase. The conclusions on the phenotype of the Jurkat transfected cell lines 
were that LCPTP affects the rate of MAP kinase phosphorylation, the production of 
IL-2 following TCR and CD28 stimulation and finally the growth inhibition rate of 
Jurkat T cells following the same TCR and CD28 stimulation. These results provide 
important data towards the aim of characterising the function of LCPTP protein in a 
leukemic cell line. The question is: Does LCPTP produce the same functional effect 
in primary T cells? To answer this question, transient infections of primary CD4+ T 
cells using adenovirus containing either LCPTP wild-type or substrate-trap proteins 
were carried out and experiments performed to determine whether the data obtained 
in Jurkats could be reproduced in primary T cells.
Unlike Jurkats, primary T cells are not easily transfected with foreign proteins 
using conventional techniques. To overcome this problem, it was decided to utilise a 
method dependent on viral infection to deliver LCPTP into cells. The CAR-1- 
DOl 1.10 transgenic mice, which express the adenoviral receptor, CAR, on the surface 
of T cells were used to maximise the chances of delivering LCPTP into primary cells. 
The expression of CAR on the surface of cells does not necessarily appear to be a 
prerequisite to achieve infection. This was highlighted in a recent report by a Finnish 
team who were able to infect primary T cells with recombinant adenovirus vector 
without the CAR receptor on the T cell surface (Chen et al., 2002). With a m.o.i. of 
1000 up to 5000 viruses per cell, they were able to achieve nearly hundred per cent 
infection efficiency. The large number of viruses used per cell did not seem to affect 
the infected T cells capacities to produce IFN-y for Thl cells or IL-4 for Th2 cells 
(Chen et al., 2002). This has important implications for the studies discussed in this 
chapter because it shows that the adenovirus does not harm the cells and that they are 
able to react normally to TCR and CD28 stimulation. Expression of CAR-1 receptor 
on the surface of T cells, enable studies to be performed to evaluate the effect of 
overexpressing LCPTP using only 10 infective virus particles/cell. The fact that no 
effects were seen on cytokine production using one hundred times the number of 
viruses, gives one confidence that effects seen overexpressing LCPTP protein in
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murine T cells were due to the presence of the phosphatase and not due to the 
adenovirus components.
The first hurdle to overcome was to produce adenovirus containing LCPTP 
phosphatase and to be able to express the phosphatase in cells. The primary step for 
the production of an altered adenovirus was to clone the gene of interest into a vector 
(pCR259), to make a recombinant plasmid which included the adenovirus genome 
(pCR249) (Richards et al., 2000). Transient transfections of pCR259 containing 
LCPTP wild-type or substrate-trap proteins overexpressed the phosphatase, indicating 
that the gene was in the correct reading frame in the vector and ready to be 
recombined into the viral genome. The concentration of the virus by caesium 
chloride gradient, shown in Figure 5.2, was essential for further studies infecting 
primary T cells because to achieve infection, the virus had to be combined with cells 
in a minimal volume (Dr Nigel Sharp personal communication).
Experiments were done infecting primary T cells with adenovirus constructs 
including two different forms of LCPTP, namely wild-type and substrate-trap. An 
anti-sense LCPTP construct was also made to act as a negative control. However, due 
to problems encountered during scale up, only limited amounts of the anti-sense 
containing virus were obtained. This was used to demonstrate that the overexpression 
of LCPTP seen in cells infected with wild-type or substrate-trap LCPTP protein was 
specific and not due to changes induced by viral proteins. All subsequent 
experiments were performed using an adenovirus construct containing the Gata3 gene 
instead of the anti-sense LCPTP in order to have a positive control for the adenovirus 
infection technique. Gata3 is a Th2 transcription factor and its effects in primary Thl 
and Th2 cells have been studied previously in the department (Zheng and Flavell, 
1997); (Zhang et al., 1997); (Drs Andrew Blanchard and Nigel Sharp, personal 
communication). Infection of primary T cells with adenovirus proved not to be a 
trivial technique. It was found that as the multiplicity of infection with LCPTP viral 
constructs increased, there was an inverse correlation with cell survival. In Jurkat T 
cells, we observed that overexpression of LCPTP wild-type did not disturb the growth 
potential of unactivated cells but overexpression of LCPTP substrate-trap appeared to 
be detrimental to cell growth. In primary Thl and Th2 cells, the overexpression of
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both wild-type and substrate-trap forms of LCPTP protein affected cell survival. 
Increasing the multiplicity of infection with LCPTP constructs, correlated with an 
increase in cell aggregation in cultures. In contrast to infection of cells with LCPTP, 
the growth of Thl and Th2 cells overexpressing the Gata3 construct was less affected 
in terms of aggregates and cell death. This suggested that the effects seen on cell 
growth in cells overexpressing the LCPTP constructs were in some way linked to the 
increased level of phosphatase protein present. Due to time limitations, no further 
experiments were conducted in order to clarify this increase in cell toxicity. Instead, 
efforts were concentrated in obtaining functional data with the cells overexpressing 
the different forms of LCPTP protein.
The infection of cells with as few as five viruses per cell was enough to see an 
augmentation in LCPTP concentration in total protein extracts above the endogenous 
levels present. An m.o.i. of 10 viruses/cell was determined to be a reasonable 
compromise on being able to demonstrate overexpression and maintain enough viable 
cells in order to proceed with further functional studies. This is considerably less then 
the 1000 viruses per cell, used by Chen et al. (2002) (Chen et al., 2002). In order to 
determine whether LCPTP infection was equally efficient in Thl and Th2 cells, 
western blots were performed on total protein extracts from cells, probed for the 
presence of LCPTP. Figure 5.5 shows that both cell types overexpressed LCPTP 
compared to the endogenous level seen in the non-infected cells. This result 
demonstrated clearly that we had achieved the aim of transiently overexpressing both 
LCPTP wild-type and substrate-trap proteins into primary Thl and Th2 cells.
We reported that the phosphorylation of MAP kinase members ERK1 and 
EKR2 was reduced in the presence of overexpressed LCPTP in Jurkat T cells, 
following TCR and CD28 activation. The same experiment was done in 
differentiated Thl and Th2 cells. As expected, the overexpression of LCPTP wild- 
type reduced the amount of phosphorylated MAP kinase members. Contrary to the 
result obtained in Jurkat T cells, the overexpression of LCPTP substrate-trap did not 
increase the level of MAP kinase phosphorylation which remained equivalent to that 
seen in the uninfected control. A possible explanation for this is that the substrate- 
trap phosphatase is not able to trap the MAP kinase thus maintaining it in a
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phosphorylated form. However, the gene cloned into the adenoviral vector was 
sequenced and does contain the designated mutations. An alternative explanation, is 
that there is a difference in the ratio of the substrates in Thl and Th2 cells compared 
to Jurkats. Some phosphorylated MAP kinase protein could be trapped by the mutant 
LCPTP protein, but enough remains free in the cytoplasm to become phosphorylated. 
A third explanation, is that the LCPTP used for the adenoviral construct is human. It 
is possible that although transfecting wild-type LCPTP into murine cells, clearly has 
an effect, that there are differences between the way human LCPTP interacts with 
human and mouse MAP kinases. These differences become apparent when 
transfecting murine cells with the substrate-trap LCPTP protein. The presence of 
overexpressed Gata3 increased the MAP kinase phosphorylation supporting the 
theory that the reduction of MAPK phosphorylation observed in cells overexpressing 
LCPTP wild-type is due to the presence of the phosphatase and not due to an 
adenovirus component. An unexpected observation was the increase seen in MAP 
kinase phosphorylation in cells overexpressing Gata3. A possible explanation is 
based on the fact that it is known that MAP kinases phosphorylate Gata3, which 
induces the release of Th2 cytokines, including IL-4. IL-4 acts in an autocrine loop 
binding back onto receptors and activating MAP kinase signalling pathways (Chen et 
al., 2000); (Day et al., 2002); (Moore et al., 2002). There was an apparent greater 
increase in MAP kinase phosphorylation in Th2 cells overexpressing Gata3 compared 
to Thl cells relative to respective controls. The above explanation would fit with the 
observation that the “T h l” population was shown to include some IL-4 secreting cells 
in addition to ones secreting IFN-y.
The overexpression of LCPTP wild-type and substrate-trap proteins in naive 
and both Thl and Th2 cells reduced the production of specific cytokines (Figure 5.7). 
As previously shown in Jurkat T cells, overexpression of LCPTP in primary T cells 
resulted in a reduction in the production of IL-2 following stimulation with anti- 
CD3/CD28 antibodies. In addition, overexpression of LCPTP protein in primary T 
cells also reduced the production of IL-4, IL-5 and IL-13 in Th2 cells and IFN-y in 
Thl. This reduction was not due to increase in cell death since the same number of 
viable cells were taken to measure the cytokine production. This is in contrast to 
overexpressing Gata3 which lead to an increase in the production of IL-4, IL-5 and
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IL-13 cytokines in Th2 cells. One could expect an increase in the production of Th2 
cytokines in Thl cells transfected with Gata3 protein as reported by Lee et al. (Lee et 
al., 2000). The fact that overexpressed Gata3 in Thl cells does not raise the amount 
of Th2 cytokines in our experiments, may suggest the need of a post-translational 
modification on Gata3 in order to bind to the promotor regions of the Th2 cytokine 
genes as proposed by Yamagata et al. and Cousins et al. (Yamagata et al., 2000); 
(Cousins et al., 2002). The reduction of Th2 cytokines by overexpressing LCPTP is 
unexpected because it has previously been shown that the ERK inhibitor PD98059, 
inhibits the MEK and ERK signalling pathways and this leads to enhanced production 
of Th2 cytokines (IL-4, IL-5, IL-13) following cell activation with a combination of 
PMA/anti-CD3 or by anti-CD3/CD28 antibodies (Dumont et al., 1998). The 
differences could indicate that PD98059 hits other targets in addition to ERK. Badou 
et al. showed that the MAPK signalling pathway can be dispensable for the 
production of IL-4. In contrast, IFN-y synthesis is dependent on both the calcium 
response and the MAPK activation (Badou et al., 2001). Reported increases in IL-4 
synthesis could merely reflect a bias in cultures following Th2 cytokines in the 
absence of regulating Thl cytokines. There is controversy in the literature regarding 
the role of the different MAP kinase signalling pathways in secretion of the different 
cytokines. For instance, in one study it was shown that IL-2, IL-4 and IFN-y 
production was reduced when p38 activity was inhibited (Zhang et al., 1999). In 
contrast, another study reported that blocking p38 activity in Thl cells affected IFN-y 
production but not Th2 cytokine production (Rincon et al., 1998). From our results, it 
is concluded that the reduction in MAPK activity in naive, primary Thl and Th2 cells 
has a direct effect on the production of IL-2 in both naive and Thl cells, on the 
production of IFN-y in Thl cells and, on the production of IL-4, IL-5 and IL-13 in 
Th2 cells.
In Jurkat T cells overexpressing LCPTP protein, the growth inhibition seen 
following TCR and CD28 stimulation was reduced. In primary Thl and Th2 cells, 
there was an increase in basal proliferation following recent stimulation in cells 
overexpressing LCPTP wild-type or substrate-trap proteins. Thus LCPTP appears to 
have a role in regulating cell cycle progression. A plausible explanation for the 
higher basal proliferation is provided by the study of Zanke (1994), where he
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demonstrated that when the LCPTP gene was present in cells in a multiple copy 
number, the growth of cells became unregulated and establishment of clonal 
dominance was also seen (Zanke et al., 1994). Zanke’s studies and the results in the 
Jurkats and primary murine naive, Thl and Th2 cells where LCPTP apparently 
favours cell growth under certain conditions suggests that a disregulation in LCPTP 
activity renders it to have the potential to become an oncogene. The fact that the 
difference in the proliferation rate between the control uninfected cells and the 
infected cells became less obvious could be explained by the transient nature of 
adenovirus infection, losing copies of the virus from mother to daughter cells.
In conclusion, the phenotypes observed in transformed cell lines where 
LCPTP affects the rate of MAP kinase phosphorylation, the production of IL-2 
following TCR and CD28 stimulation and finally the rate of growth inhibition 
following cell activation can be extrapolated to primary CD4+ T cells where an 
overexpression of LCPTP also affects MAP kinase phosphorylation, cytokine 
production and proliferation3.
3 Part of the work described in this chapter will be submitted to Journal of 
Immunology.
CHAPTER SIX: GENERAL DISCUSSION
The role of phosphatases in T cell signalling has been the focus of many 
investigations in recent years. The present work contributes to further the knowledge 
and understanding on LCPTP, a hematopoietic restricted phosphatase. Previously, 
several studies have looked at the biochemical function of LCPTP, but few have 
investigated the biological function of LCPTP. The characterisation of the role of 
LCPTP in T cell signalling was expanded with a number of approaches. Firstly, we 
looked at protein interactions of endogenous LCPTP in Jurkat T cells and peripheral 
CD4+ T cells (Chapter 3). Secondly, the functional consequences of overexpressing 
stable LCPTP wild-type, substrate-trap and null mutant proteins in Jurkat cells were 
investigated (Chapter 4). The final results chapter describes the consequences of 
overexpressing LCPTP in primary naive, Thl and Th2 murine T cells infected with 
wild-type or substrate-trap LCPTP protein (Chapter 5).
6.1 L C P T P -T he Present
6.1.1 The function of LCPTP in cells
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Figure 6.1: Model for LCPTP (HePTP) in T cells signalling
Figure from Saxena et al., 1999. “A. In the absence of external stimuli, the classical 
pathway of MAP kinase activation (originating at a receptor, R l) through Ras, Raf 
and Mek has a low basal activity, which is counteracted by HePTP. B. Stimulation 
of receptors (R2) that couple to adenylate cyclase (AC) turn on the new pathway that 
involves phosphorylation of HePTP at Ser 23 by PKA, leading to dissociation of ERK 
from HePTP. This release from inhibition results in MAP-kinase activation and 
s u b s e q u e n t  c - f o s  i n d u c t i o n . ” ( S a x e n a  e t  a l . ,  1999) .
130
CHAPTER SIX
Resting T ccfl
T cell activation
Kinases
Ad a pi on
ME*
TruuMtt
•ssoeinitio* 
to  ZtLUBtUS 
a  U s a l  ERK 
ik w jk o ry t to t io *
■2/Protil
Figure 6.2: Model for LCPTP role in early T cells signalling
A. In resting cells, the TCR pathway is not engaged. LCPTP maintains a basal 
phosphorylation level of MAPK family members through transient associations. In 
controlling MAPK phosphorylation, LCPTP prevents unregulated cell proliferation.
B. In cells activated by both TCR and CD28 signals, LCPTP is removed from the 
MAPK family members which allows full MAPK phosphorylation leading to IL-2 
production and proliferation.
T cells have evolved to undergo proliferation and clonal expansion on 
recognition of specific peptide and appropriate costimulatory and accessory signals. 
Only a very small percentage of T cells possess a TCR capable of binding to a given 
peptide with subsequent initiation of signalling pathways which drive cell 
proliferation. It is important that the whole T cell repertoire is not activated 
simultaneously as the consequences of every single T cell undergoing clonal 
expansion would lead to a severe effect on haematopoietic cell homeostasis. To 
guard against such an event, there must be tight regulation at multiple steps in 
signalling pathways to prevent inadvertent triggering of cell proliferation. On such
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step is the regulation of the MAP kinase family members and a candidate protein for 
achieving this is LCPTP. We have shown that LCPTP forms transient associations 
with ERK1 and ERK2 and that overexpressing LCPTP in cells reduces MAPK 
phosphorylation. Thus LCPTP stops MAPK family members translocating into the 
nucleus and prevents unregulated proliferation. This role of LCPTP is suggested by 
the fact that overexpressing LCPTP leads to the phosphatase interacting with ERK1 
and ERK2 in both unstimulated and stimulated cells. Data published by Pettiford and 
Herbst (2003) confirm this role. After transfecting HePTP anti-sense into K562 cells, 
they observed enhanced nuclear translocation of ERK, ultimately leading to 
uncontrolled differentiation and proliferation (Pettiford and Herbst, 2003).
Studies by Zhong et al. (2000) also support a role for LCPTP in termination of 
MAPK signalling. Specific monoclonal phospho-antibodies were used to demonstrate 
that the dephosphorylation of ERK operates differentially dependent on its 
localisation either in the nucleus, or in the cytoplasm. Switching off signalling via 
MAP kinases involves dephosphorylation in the nucleus by a Ser/Thr phosphatase and 
a tyrosine phosphatase while the completion and maintenance of its inactivation is 
carried out by a PTP in the cytoplasm. LCPTP mRNA has been shown to increase 
several fold following T cell stimulation (Zanke et al., 1992) although protein levels 
increased only moderately compared to resting cells. It is possible that upon 
termination of signalling, stabilisation of mRNA leading to increased LCPTP protein 
expression then allows LCPTP to fulfil a role in returning to and maintaining MAP 
kinases in an inactive state. The T cell returns to a rested state.
6.1.2 Regulation of LCPTP
It would be predicted that upon recognition of antigenic peptide by a T cell 
bearing the appropriate TCR and costimulatory and accessory signals, the activity of 
LCPTP changes. We do not have sufficient data from our studies to determine 
exactly how and when LCPTP itself is regulated, although we do have data 
suggesting that this could be mediated in part via CD28 ligation. Alterations in 
LCPTP activity would mean that the balance of phosphatase and kinase activities 
regulating MAP kinase activity is shifted in favour of kinases. Upstream kinases 
phosphorylate and activate MAP kinases leading to nuclear translocation and
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downstream activation of transcription factors. Munoz et al. (2003) suggested in a 
recent publication that intracellular redox conditions can play a role in the modulation 
of the activity and subcellular location of the MAPK family members by regulating 
the association of phosphatases including LCPTP with their substrates (Munoz et al., 
2003). Interestingly, a synergism between CD28 costimulation and changes in 
intracellular redox conditions has been shown to enhance transcription from the IL-2 
promotor (Hehner et al., 2000).
Other clues as to how and when LCPTP is regulated, include studies by Wang 
et al. (2003) who identified a complex containing the two phosphatases, PP2A and 
LCPTP, working cooperatively on phosphorylated forms of ERK1 and ERK2 in a 
cholesterol-regulated way (Wang et al., 2003b). They observed a higher proportion 
of the phosphorylated form of MAPK family members in lipid rafts when cells were 
stressed by acute cholesterol depletion. This was as a consequence of the disassembly 
of the PP2A and LCPTP complex. This data supports the fact that LCPTP is present 
in cells to control the basal phosphorylation level of MAPK family members and 
when the cell is stimulated, the phosphatases are removed from the MAPK area in 
order to promote signalling.
There are a large number of phosphatases in addition to LCPTP which have 
MAP kinase family members as substrate. Homologs of human LCPTP have been 
found in rat, mouse and also in the budding yeast Saccharomyces cerevisiae (Ptp2 and 
Ptp3). Both Ptp2 and Ptp3 are global regulators of MAPK signalling in yeast. Ptp2 is 
a nuclear protein and Ptp3 is a cytoplasmic protein (Mattison and Ota, 2000). The 
existence of homologs in a primitive eukaryote may suggest a highly important 
function for LCPTP, since it has been conserved through evolution. Resting T cells 
express only two phosphatases which have been shown to specifically 
dephosphorylate MAP kinase family members, namely LCPTP and VH1-related 
phosphatase. The other phosphatases which have the same substrate specificity need 
to be transcribed following TCR stimulation (Mustelin et al., 2002); (Alonso et al., 
2003). VH1-related phosphatase is under the regulation of ZAP-70, which 
phosphorylates VH1, and thereby, inactivates VH1 (Alonso et al., 2003). An 
unpublished result from our group demonstrated a potential interaction between
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LCPTP protein and TCR zeta protein. It is possible that like VH1, LCPTP is 
regulated by a TCR proximal kinase, or even by TCR zeta itself. Studies were 
performed to look for increases in LCPTP tyrosine phosphorylation following TCR 
ligation to see if any change could be detected analogous to the increase in LCPTP 
tyrosine phosphorylation seen in rat mast cells following ligation of surface IgE 
receptors (Swieter et al., 1995). No changes in LCPTP tyrosine phosphorylation were 
detected which could reflect differences between regulation of LCPTP in rat mast 
cells and human T cells (data not shown). This aspect of regulation of LCPTP in T 
cells requires further investigation.
The first model of the role of LCPTP in T cell signalling, proposed by Saxena 
and collaborators, placed LCPTP directly downstream of the cAMP pathway linking 
the TCR and cAMP pathways (Figure 6.1). This model depends on the activation of 
the cAMP pathway in order to inactivate LCPTP. In the cell systems our studies were 
performed in, we have shown that the amount of cAMP in cells is usually low and 
thus LCPTP inactivation is unlikely to be caused by the accumulation of cAMP since 
the TCR signal is known to be associated with a decrease of the cAMP pathway 
(Tamir et al., 1996); (Ramstad et al., 2000). On the basis of the present study and 
previous reports in the literature, a possible model for the role LCPTP plays in T cell 
signalling and activation is presented (Figure 6.2).
We have shown that the functional consequences of overexpressing LCPTP in 
cells, include inhibition of TCR stimulated IL-2 production and T cell proliferation 
which would fit with LCPTP playing a negative role in MAP kinase activation.
6.2 LCPTP-The future
There is still much to learnt about LCPTP -  How and when it is regulated, 
possible as yet unidentified substrates, the full extent of its role in T cell signalling 
and activation.
An LCPTP knockout mouse has been generated with no associated phenotype 
except for a comment about raised ERK phosphorylation in spleen cells (Gronda et 
al., 2001). This implies that LCPTP plays a redundant role in regulating MAP kinase
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phosphorylation. However, the problem with knocking out a gene in mice, is that it 
can cause an imbalance in the expression of other proteins (Okkenhaug and 
Vanhaesebroeck, 2001). For example, in cells from PI-3 kinase p85a knockout mice, 
p85|3 expression were upregulated and pi 10a, pi 10(3 and pi 106 was downregulated 
(Fruman et al., 1999); (Suzuki et al., 1999); (Lu-Kuo et al., 2000). In the LCPTP 
knockout, the expression of other proteins regulating MAP kinase activity, such as 
VH1 was not examined. In attempting to define a biological function for a protein in 
vivo, a more physiological approach might be to replace the endogenous protein with 
equivalent levels of a defective protein. Okkenhaug et al. have taken this approach 
for examining the role of pi 106 in TCR signalling, by generating a point mutation in 
the pi 106 gene (Okkenhaug et al., 2002). Expression of pi 106 and the other Pl-3 
kinase subunits was equivalent to wildtype mice. Studies were performed looking at 
the effects of a mutant enzyme without gross changes on other Pl-3 kinase subunits. 
Another example for cautionary interpretation of data obtained from in vivo 
experiments, is studies which differences have been observed between knock-out cells 
and cells expressing a dominant negative form of protein. Lck provides an example. 
Studies in Lck-/- cells showed an inability to mobilise calcium after TCR stimulation, 
whereas cells expressing the dominant negative form of the protein respond normally 
(Trobridge and Levin, 2001). Thus, elimination of a particular protein can push 
another protein to take up another role and replace the function of the eliminated 
protein, resulting in a poor phenotype from the knock-out mouse. On the other hand, 
overexpression of a dominant negative protein can create effects outside the normal 
physiological function of the protein (Trobridge and Levin, 2001). The use of a null 
mutant LCPTP phosphatase, as a replacement for endogenous LCPTP in the mouse, 
could lead to a more extended phenotype than seen in the LCPTP knock-out mouse 
published. We observed that overexpression of the null LCPTP phosphatase in 
Jurkat T cells, reduced the production of IL-2 nearly as much as the wild-type protein. 
This suggests that LCPTP might have functions in cells independent of its 
phosphatase activity and the expression of a negative mutant could reveal those 
functions.
Other approaches which could be used to study the roles of signalling proteins 
in cells, include the use of RNA anti-sense technology, where a mRNA encoding for
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the anti-sense protein is transfected into cells leading to an association between the 
sense and anti-sense mRNA and a block in protein translation (Bettaieb et al., 2003); 
(Troussard et al., 2003); (Wang et al., 2003a). Alternatively, RNA interference on 
LCPTP in hematopoietic cells could be performed (Elbashir et al., 2001). Another 
way to create a knock-out of LCPTP in differentiated cells would be to use antibody 
against LCPTP protein transfected into cells, making complexes with the protein, and 
abolishing its function, as has been done with PKC theta (Szamel et al., 1998). An 
alternative approach is to create a conditional knock-out by flanking the LCPTP gene 
containing the antibiotic resistance with sequence targeting the expression of the 
protein to a specific type of cell or organ which would allow the effects of the knock­
out to be studied in restricted cell types/tissue (Metzger and Chambon, 2001); (Xu et 
al., 2001); (Troussard et al., 2003). Inducible knockouts have been useful in cases 
where knocking out a protein has proved to be embryonically lethal, or where 
expression of a protein is key for cell development. An example is provided again by 
studies on Lck. In the absence of Lck, T cells fail to mature. By creating an inducible 
knockout, Zamoyska et al., (2000) were able to study the effects of Lck on mature T 
cell function, by switching off gene expression post thymic development (Seddon et 
al., 2000).
The only identified substrates of LCPTP to date, are members of the MAP 
kinase family. It is possible that additional substrates await identification, and almost 
certainly, there are other proteins with which LCPTP interacts within signalling 
complexes, controlling and regulating LCPTP activity. Proteomics technology has 
advanced considerably in recent years, enabling detection and identification of 
members of signalling complexes from ever decreasing cell numbers. Whereas in our 
studies, cell numbers restricted us to using cell lines for proteomic work, progress 
should facilitate the use of primary cells (Nyman et al., 2001). Likewise, advances in 
protein microarray technology will enable detailed studies in the future, looking at 
tissue distribution/expression levels of proteins, protein-protein interactions and 
enzyme-substrate interactions which could give further clues as to what stages in T 
cell activation/differentiation, LCPTP is involved (Kumble, 2003).
Many diseases are thought to be due to an inbalance in the immune system,
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including autoimmune diseases, such as rheumatoid arthritis and juvenile diabetes, as 
well as asthma. Understanding how proteins function in cells can provide targets 
which could attenuate the reactivity of cells and help reduce the effect of disease. As 
demonstrated in this study, the overexpression of LCPTP in primary cells reduces the 
production of IL-2 and effector cytokines, contributing to lower the level of T ceil 
reaction to an antigen. Anergy is a situation where cells fail to proliferate upon 
restimulation because they cannot produce IL-2 (DeSilva et al., 1991); (Beverly et al., 
1992). In situations where there is inappropriate T cell activation, overexpression of 
LCPTP could promote a state of anergy in cells because they produce much less IL-2 
than normal cells following TCR and CD28 stimulation. Li et al. found reduced 
ERK and JNK kinase activities in anergic cells (Li et al., 1996). They proposed that 
the reduced ERK function could result from a defective phosphorylation by an 
upstream kinase or from an increase activity of a kinase specific phosphatase namely 
PAC. LCPTP protein could also be implicated in this process.
In conclusion, we propose that LCPTP is a regulator of MAP kinase 
phosphorylation at the basal level, adjusting the balance between overreaction and 
anergy and further studies understanding the biology of LCPTP could present it as a 
future therapeutic target.
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